JP2018076285A - Pharmaceuticals containing bicyclic imidazolo derivatives - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide pharmaceuticals containing a compound useful as an inhibitor of phosphodiesterase 1 (PDE1), and a method of using the compound.SOLUTION: The invention provides pharmaceuticals containing a compound represented by the formula in the figure, and a method of using the compound. (Ris H, a substituted/unsubstituted C1-6 alkyl group or the like; Ris a substituted/unsubstituted C1-6 alkyl group or the like; Ris H, halogen, or the like; Ris H, halogen, a C1-6 alkyl group, or the like; X is O or S; W is a covalent bond, -C≡C-, -CH=CH-, -O- or -N(R5)-; and R5 is H or a C1-6 alkyl group.)SELECTED DRAWING: None

Description

  The present invention relates to a medicament comprising a bicyclic imidazolo derivative compound that may be useful as an inhibitor of the phosphodiesterase 1 (PDE1) enzyme.

  The prevalence of neurological and psychiatric disorders is increasing worldwide. Up to 1 billion people suffer from debilitating neurological conditions such as Alzheimer's disease and Parkinson's disease, and about 7 million people die each year. “Neuropathies: Public health issues” World Health Organization 2006. Neurological and psychiatric disorders are common in all countries, regardless of age, gender, education or income. However, as many neurological disorders are associated with aging, the effects of these disorders become more apparent as people around the world age.

  Despite being able to treat some of these diseases, front-line treatments (such as L-DOPA for Parkinson's disease) are often burdened by undesirable side effects or can be ineffective . For example, there are currently no approved treatments for cognitive impairment in schizophrenia, despite high unmet medical needs.

  The challenges for neurological and psychiatric disorders are continuing and increasing, and there are currently no safe and effective drugs to treat them, to treat these symptoms and their underlying causes The overwhelming need for new drugs is underscored.

で示される構造を有し、又はその製薬学的に許容される塩である（ここに、各変数は本明細書に定義及び記載されるとおりである）。 It has now been found that the compounds disclosed herein and pharmaceuticals or pharmaceutical compositions containing them can be effective as inhibitors of the phosphodiesterase 1 (PDE1) enzyme. Such compounds have the general formula I:

Or a pharmaceutically acceptable salt thereof (wherein each variable is as defined and described herein).

  The compounds disclosed herein and medicaments or pharmaceutical compositions containing them may be useful for treating various diseases, disorders or conditions associated with modulation of the PDE1 enzyme. Such diseases, disorders or conditions include those described herein.

  The compounds disclosed herein and pharmaceuticals or pharmaceutical compositions containing them also can be used to study PDE1 enzymes in biological and pathological phenomena, to study intracellular signaling pathways that occur in PDE1-expressing tissues, and in vitro Or it may be useful for comparative assessment of neuronal activity of novel PDE1 inhibitors or other modulators in vivo.

FIG. 1 shows the discrimination index of Example 1 in Test Example 5. ## means P is <0.01 compared to the vehicle + vehicle treatment group in the unmatched t-test. ** means that P is <0.01 compared to the PCP + vehicle treatment group in Dunnett's test. The standard error of the average value is n = 14-17. FIG. 2 shows the discrimination index of Example 115 in Test Example 5. ## means P is <0.01 compared to the vehicle + vehicle treatment group in the unmatched t-test. * Means that P is <0.05 compared to the PCP + vehicle treatment group in Dunnett's test. ** means that P is <0.01 compared to the PCP + vehicle treatment group in Dunnett's test. The standard error of the average value is n = 11-15. FIG. 3 shows the discrimination index of Example 149 in Test Example 5. ## means P is <0.01 compared to the vehicle + vehicle treatment group in the unmatched t-test. ** means that P is <0.01 compared to the PCP + vehicle treatment group in Dunnett's test. The standard error of the average value is n = 10-14. FIG. 4 shows the discrimination index of Example 245 in Test Example 5. ## means P is <0.01 compared to the vehicle + vehicle treatment group in the unmatched t-test. ** means that P is <0.01 compared to the PCP + vehicle treatment group in Dunnett's test. The standard error of the average value is n = 11-14. FIG. 5 shows the discrimination index of Example 288 in Test Example 5. ## means P is <0.01 compared to the vehicle + vehicle treatment group in the unmatched t-test. ** means that P is <0.01 compared to the PCP + vehicle treatment group in Dunnett's test. The standard error of the average value is n = 7-11.

の化合物又はその製薬学的に許容される塩を有効成分とする医薬を含む：
［式中、
Ｒ^１は
（ｉ）水素、
（ｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
（ｃ）ヒドロキシル、
（ｄ）フェノキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）アミノ（ここに、該基は適宜、同一又は異なる１〜２のＣ_１−６アルキル、Ｃ_３−８シクロアルキル又はフェニル（ここに、フェニルは適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、Ｃ_１−６アルコキシ又はトリフルオロメチルで置換されていてもよい）で置換されていてもよい））、及び
（ｉｉｉ）Ｃ_３−１０シクロアルキル；フェニル；５〜６員単環性ヘテロアリール；４〜８員飽和又は部分的に不飽和の単環性ヘテロ環；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和の単環性ヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）；及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
ＸはＯ又はＳであり；
Ｗは共有結合、−Ｃ≡Ｃ−、−ＣＨ＝ＣＨ−、−Ｏ−又は−Ｎ（Ｒ^５）−であり；
Ｒ^５は水素又はＣ_１−６アルキルであり；
Ｒ^２は
（ｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
（ｃ）ヒドロキシル、
（ｄ）フェノキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）アミノ（ここに、該基は適宜、同一又は異なる１〜２のＣ_１−６アルキル、Ｃ_３−８シクロアルキル又はフェニル（ここに、フェニルは適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、Ｃ_１−６アルコキシ又はトリフルオロメチルで置換されていてもよい）で置換されていてもよい））、及び
（ｉｉ）Ｃ_３−１０シクロアルキル；フェニル；５〜６員ヘテロアリール；４〜８員飽和又は部分的に不飽和のヘテロ環；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和のヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
あるいは、Ｒ^２及びＲ^５は、それらが結合している窒素原子と一緒になって、４〜８員飽和又は部分的に不飽和の単環性ヘテロ環を形成してもよく；ここに、該環は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ、ヒドロキシ又はアミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｅ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｆ）５〜６員単環性ヘテロアリールオキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）Ｃ_１−６アルキルカルボニル（ここに、アルキルは適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はアミノ（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
Ｒ^３は
（ｉ）水素、
（ｉｉ）ハロゲン、
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）ヒドロキシ、及び
（ｄ）オキソ）、又は
（ｉｖ）Ｃ_３−８シクロアルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）オキソ）、
（ｖ）Ｃ_２−６アルケニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲンで置換されていてもよい）、
（ｖｉ）Ｃ_３−８シクロアルケニル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）オキソ）、及び
（ｖｉｉ）４〜８員飽和又は部分的に不飽和の単環性ヘテロ環（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）シアノ）
から選択され；
Ｒ^４は
（ｉ）水素、
（ｉｉ）ハロゲン、
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、又は
（ｉｖ）シアノ
から選択され；
但し、Ｒ^１が水素である場合、Ｗは−Ｏ−又は−Ｎ（Ｒ^５）−であり、Ｒ^４は水素である］。 1. General description of the compounds according to the invention:
In certain embodiments, the present invention provides compounds of formula I:

Or a pharmaceutically acceptable salt thereof as an active ingredient:
[Where:
R ¹ is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (iii) C _3-10 cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl; 4-8 membered saturated or partially unsaturated monocyclic heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6 membered monocyclic heteroaryl-C _1-4 Al Le; or 4-8 membered saturated or partially selected from monocyclic heterocycle -C _1-4 alkyl unsaturated;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
X is O or S;
W is a covalent bond, —C≡C—, —CH═CH—, —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is (i) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (ii) C _3-10 cycloalkyl; phenyl; 5-6 membered heteroaryl; 4-8 Membered saturated or partially unsaturated heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered heteroaryl-C _1-4 alkyl; or 4-8 Tiredness Or partially selected from heterocyclic -C _1-4 alkyl unsaturated;
Here, each group in the above (ii) may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ), And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxy or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). May be);
R ³ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) hydroxy, and (d) oxo), or (iv) C _3-8 cycloalkyl, wherein the group is optionally substituted with the same or different 1-4 groups selected from: Also good:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo),
(V) C _2-6 alkenyl (wherein the group may be optionally substituted with the same or different 1 to 4 halogens),
(Vi) C _3-8 cycloalkenyl (wherein the group is optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo), and (vii) a 4-8 membered saturated or partially unsaturated monocyclic heterocycle, wherein the groups are suitably selected from: Optionally substituted with 1 to 4 different groups:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) cyano)
Selected from;
R ⁴ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens), or (iv) selected from cyano;
However, when R ¹ is hydrogen, W is —O— or —N (R ⁵ ) —, and R ⁴ is hydrogen].

2. Compounds and definitions:
Compounds according to the present invention include those generally described above and are further illustrated by the classes, subclasses and species disclosed herein. In this specification, the following definitions shall apply unless otherwise indicated. For the purposes of the present invention, chemical elements are identified according to the Periodic Table of Elements, CAS version, Chemistry and Physics Handbook 75th Edition. Furthermore, the general principles of organic chemistry are “Organic Chemistry” Thomas Sorel, University Science Books, Sausalito: 1999 and “Advanced Organic Chemistry of March” 5th Edition: Smith. M.M. B. And March. J. et al. John Wiley & Sons, New York: 2001, the contents of which are incorporated herein by reference in their entirety.

The term “C _1-6 alkyl” is used alone or as part of a larger moiety, eg, “C _1-6 alkylcarbonyl”, and is a straight or branched alkyl group having 1 to 6 carbon atoms. Say. Typical groups for this group are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

The term “C _2-6 alkenyl” refers to a straight or branched alkenyl having 2 to 6 carbon atoms and at least one carbon-carbon double bond. Typical groups for this group are ethenyl, propenyl, butenyl, 3-methyl-1-butenyl, pentenyl and hexenyl.

The term “C _1-6 alkoxy” refers to a straight or branched alkoxy group having from 1 to 6 carbon atoms. Typical groups for this group are methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butyloxy.

The term “C _3-10 cycloalkyl” refers to a 3-10 membered, preferably 5-6 membered cycloalkyl group. As used herein, the term “cycloalkyl” includes mono- or bicyclic hydrocarbon rings optionally fused to another cycloalkyl or aryl group. Typical groups for this group include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, indanyl and tetrahydronaphthyl.

The term “C _3-8 cycloalkenyl” refers to a 3- to 8-membered, preferably 5- to 6-membered cycloalkenyl group having at least one unsaturated bond between the carbon atoms constituting the ring. As used herein, the term “cycloalkenyl” includes mono- or bicyclic hydrocarbon rings optionally fused to another cycloalkenyl or aryl group. Typical groups for this group include, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and dihydronaphthyl.

  The term “halogen” means F, Cl, Br or I.

  The term “aryl” is used by itself or as part of a larger moiety as in “aryloxy”, wherein at least one ring in the ring system is an aromatic carbocycle and each ring is 3-7 rings A monocyclic or bicyclic ring system having a total of 5 to 14 ring members, including members. The term “aryl” may be used interchangeably with the term “aryl ring”. In some embodiments of the present invention, “aryl” includes, but is not limited to, aromatic carbocycles including, for example, phenyl, naphthyl, anthracyl, etc., which may be optionally substituted. Say.

  The term “heteroatom” means one or more oxygen, sulfur, nitrogen, phosphorus or silicon (any oxide form of nitrogen, sulfur, phosphorus, boron or silicon; quaternized form of any basic nitrogen) Or a heterocycle substitutable nitrogen, such as N (for 3,4-dihydro-2H-pyrrolyl and the like), NH (for pyrrolidinyl and the like) or NR + (for N-substituted pyrrolidinyl and the like)).

  The terms “heteroaryl” and “heteroar-” are used alone or as part of a larger moiety, eg “heteroaryloxy”, 5 to 10 ring atoms, preferably 5, 6, A group having 9 or 10 ring atoms; having 6, 10 or 14π electrons shared by the ring arrangement; and having 1 to 5 heteroatoms in addition to carbon atoms. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, Examples include prynyl, naphthyridinyl, and pteridinyl. As used herein, the terms “heteroaryl” and “heteroar-” also include groups in which an aromatic heterocycle is fused to one or more aryl, alicyclic, or heterocycles, where the aromatic A group is attached to any member of the heterocycle. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolidinyl, carbazolyl, acridinyl, acridinyl, And phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido [2,3-b] -1,4-oxazin-3 (4H) -one. A heteroaryl group may be monocyclic or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group” or “aromatic hetero”, any of which includes rings that are optionally substituted.

In the present specification, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and are saturated or A 5- to 7-membered monocyclic or 7 to 10-membered bicyclic heterocycle moiety that is partially unsaturated and has 1 or more, preferably 1 to 4 heteroatoms in addition to carbon atoms. The term “nitrogen” when used in reference to a ring atom of a heterocycle includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0 to 3 heteroatoms selected from oxygen, sulfur or nitrogen, nitrogen is N (in the case of 3,4-dihydro-2H-pyrrolyl etc.), NH (In the case of pyrrolidinyl and the like) or ⁺ NR (in the case of N-substituted pyrrolidinyl and the like).

  The heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any ring atom may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, pyrrolidinyl, piperidinyl, pyrrolinyl, oxazolidinyl, Examples include piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocycle” "Heterocyclic radical" is used interchangeably and refers to groups in which the heterocycle is fused with one or more aryl, heteroaryl, or alicyclic rings, such as indolinyl, 3H-indolyl, isoindolinyl, chromanyl, phenanthridine. And the like, a group attached to any member of the heterocycle, including thio, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl and the like. The heterocyclic group may be further substituted with one or more oxo groups as appropriate, and includes, for example, 1-oxo-2H-isoindolyl, 1,3-dioxoisoindolyl. The heterocyclic group may be a monocyclic or bicyclic group.

典型的なＣ_３−１０シクロアルキル−Ｃ_１−４アルキル基としては、シクロプロピルメチル、シクロブチルメチル、シクロペンチルメチル、シクロヘキシルメチル、シクロヘプチルメチル、シクロオクチルメチル、シクロヘキシルエチル、シクロヘキシルプロピル、シクロヘキシルブチル、及びアダマンチルメチルが挙げられる。 The term _{"C 3-10} cycloalkyl _{-C 1-4} alkyl" refers to a radical as defined above _{"C 3-10} cycloalkyl" is substituted on the _{"C 1-4} alkyl". Examples of “C _1-4 alkyl” include linear or branched C _1-4 alkyl and C _3-4 alkyl having a ring structure. Examples of linear or branched C _1-4 alkyl include methyl, ethyl, trimethyl, 1-methylmethyl, 1-ethylmethyl, 1-propylmethyl, 1-methylethylene, 2-methylethyl, 1-ethylethyl and the like. And methylene and ethylene are preferable. C _3-4 alkyl having a ring structure is an alkylene selected from the following formulae.

Typical C _3-10 cycloalkyl-C _1-4 alkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, And adamantylmethyl.

The term “phenyl-C _1-4 alkyl” refers to a group in which “phenyl” is substituted on “C _1-4 alkyl” as defined above. Exemplary phenyl-C _1-4 alkyl groups include benzyl, phenethyl, phenylpropyl, and phenylbutyl.

The term “heteroaryl-C _1-4 alkyl” refers to a group wherein “heteroaryl” as defined above is substituted on “C _1-4 alkyl” as defined above. Exemplary heteroaryl-C _1-4 alkyl groups include pyridylmethyl, pyrimidylmethyl, imidazolylmethyl, thiazolylmethyl, quinolylmethyl, pyridylethyl, and pyridylpropyl.

The term "heterocycle -C _1-4 alkyl" refers to a radical as defined above "heterocycle" is substituted on the "C _1-4 alkyl" as defined above. Exemplary heterocycle-C _1-4 alkyl groups include piperidylmethyl, pyrrolidylmethyl, morpholinylmethyl, tetrahydrofuranylmethyl, and tetrahydropyranylmethyl.

  The term “aminocarbonyl” refers to a group in which a hydrogen atom of a formyl group is substituted with an amino group.

  As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond between the atoms making up the ring. The term “partially unsaturated” includes rings having multiple sites of unsaturation, but does not include aryl or heteroaryl moieties as defined herein.

  As used herein, the term “pharmaceutically acceptable salt” is suitable for use in contact with human and lower animal tissues within the scope of reasonable medical judgment, and is excessively toxic, A salt that meets a reasonable benefit / risk ratio without irritation or allergic reaction. Pharmaceutically acceptable salts are generally well known in the art. For example, pharmaceutically acceptable salts are described in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19 by S. M. Berge et al., Which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds according to the invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts include salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid; acetic acid, oxalic acid, Obtained by salts with organic acids such as maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid; or other methods used in the art such as ion exchange. The pharmaceutically acceptable salts of the compounds of the present invention also include adipates, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyric acid. Salt, camphorsulfonate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glucone Acid salt, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate Acid salt, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmi Phosphate, pamoate, pectate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate Acid salts, p-toluenesulfonate, undecanoate, valerate, and the like are also included.

Suitable base-derived salts include alkali metal, alkaline earth metal, ammonium salts, and N ⁺ (C _1-4 alkyl) ₄ salts. Typical examples of such alkali or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, and the like. The pharmaceutically acceptable salts of the compounds of the present invention may also include, where appropriate, non-toxic ammonium, quaternary ammonium, and halides, hydroxides, carboxylates, sulfates, phosphates, Also included are amine cations formed using counter ions such as nitrates, lower alkyl sulfonates and aryl sulfonates.

Unless otherwise stated, structures shown herein are intended to include all isomers (eg, enantiomers, diastereomers, and geometric isomers (or conformers)) of such structures: R and S configurations for asymmetric centers, Z and E double bond isomers, and Z and E conformers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Further, unless otherwise specified, structures shown herein also include compounds that differ only in the presence of one or more isotopically labeled atoms. For example, compounds having this structure in which hydrogen is replaced with deuterium or tritium, or carbon is replaced with carbon labeled with ¹³ C or ¹⁴ C are within the scope of the present invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or therapeutic agents according to the present invention.

［式中、
Ｒ^１は
（ｉ）水素、
（ｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
（ｃ）ヒドロキシル、
（ｄ）フェノキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）アミノ（ここに、該基は適宜、同一又は異なる１〜２のＣ_１−６アルキル、Ｃ_３−８シクロアルキル又はフェニル（ここに、フェニルは適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、Ｃ_１−６アルコキシ又はトリフルオロメチルで置換されていてもよい）で置換されていてもよい））、及び
（ｉｉｉ）Ｃ_３−１０シクロアルキル；フェニル；５〜６員単環性ヘテロアリール；４〜８員飽和又は部分的に不飽和の単環性ヘテロ環；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和の単環性ヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）；及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
ＸはＯ又はＳであり；
Ｗは共有結合、−Ｃ≡Ｃ−、−ＣＨ＝ＣＨ−、−Ｏ−又は−Ｎ（Ｒ^５）−であり；
Ｒ^５は水素又はＣ_１−６アルキルであり；
Ｒ^２は
（ｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
（ｃ）ヒドロキシル、
（ｄ）フェノキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）アミノ（ここに、該基は適宜、同一又は異なる１〜２のＣ_１−６アルキル、Ｃ_３−８シクロアルキル又はフェニル（ここに、フェニルは適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、Ｃ_１−６アルコキシ又はトリフルオロメチルで置換されていてもよい）で置換されていてもよい））、及び
（ｉｉ）Ｃ_３−１０シクロアルキル；フェニル；５〜６員ヘテロアリール；４〜８員飽和又は部分的に不飽和のヘテロ環；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和のヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
あるいは、Ｒ^２及びＲ^５は、それらが結合している窒素原子と一緒になって、４〜８員飽和又は部分的に不飽和の単環性ヘテロ環を形成してもよく；ここに、該環は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ、ヒドロキシ又はアミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｅ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｆ）５〜６員単環性ヘテロアリールオキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）Ｃ_１−６アルキルカルボニル（ここに、アルキルは適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はアミノ（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
Ｒ^３は
（ｉ）水素、
（ｉｉ）ハロゲン、
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）ヒドロキシ、及び
（ｄ）オキソ）、又は
（ｉｖ）Ｃ_３−８シクロアルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）オキソ）、
（ｖ）Ｃ_２−６アルケニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲンで置換されていてもよい）、
（ｖｉ）Ｃ_３−８シクロアルケニル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）オキソ）、及び
（ｖｉｉ）４〜８員飽和又は部分的に不飽和の単環性ヘテロ環（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）シアノ）
から選択され；
Ｒ^４は
（ｉ）水素、
（ｉｉ）ハロゲン、
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、又は
（ｉｖ）シアノ
から選択され；
但し、Ｒ^１が水素である場合、Ｗは−Ｏ−又は−Ｎ（Ｒ^５）−であり、Ｒ^４は水素である］。 3. Description of exemplary embodiments:
In some embodiments, the present invention also includes a PDE1 inhibitor. In certain embodiments, the present invention includes a medicament comprising a compound of formula I or a pharmaceutically acceptable salt thereof as an active ingredient:

[Where:
R ¹ is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (iii) C _3-10 cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl; 4-8 membered saturated or partially unsaturated monocyclic heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6 membered monocyclic heteroaryl-C _1-4 Al Le; or 4-8 membered saturated or partially selected from monocyclic heterocycle -C _1-4 alkyl unsaturated;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
X is O or S;
W is a covalent bond, —C≡C—, —CH═CH—, —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is (i) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (ii) C _3-10 cycloalkyl; phenyl; 5-6 membered heteroaryl; 4-8 Membered saturated or partially unsaturated heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered heteroaryl-C _1-4 alkyl; or 4-8 Tiredness Or partially selected from heterocyclic -C _1-4 alkyl unsaturated;
Here, each group in the above (ii) may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ), And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxy or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). May be);
R ³ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) hydroxy, and (d) oxo), or (iv) C _3-8 cycloalkyl, wherein the group is optionally substituted with the same or different 1-4 groups selected from: Also good:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo),
(V) C _2-6 alkenyl (wherein the group may be optionally substituted with the same or different 1 to 4 halogens),
(Vi) C _3-8 cycloalkenyl (wherein the group is optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo), and (vii) a 4-8 membered saturated or partially unsaturated monocyclic heterocycle, wherein the groups are suitably selected from: Optionally substituted with 1 to 4 different groups:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) cyano)
Selected from;
R ⁴ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens), or (iv) selected from cyano;
However, when R ¹ is hydrogen, W is —O— or —N (R ⁵ ) —, and R ⁴ is hydrogen].

As defined generally above, R ¹ is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl), and (iii) C _3-10 cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl; 4 ˜8 membered saturated or partially unsaturated monocyclic heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6 membered monocyclic heteroaryl-C _{1 -4} alkyl ; Or 4-8 membered saturated or partially selected from monocyclic heterocycle -C _1-4 alkyl unsaturated;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). In some embodiments, R ¹ is C _5-6 cycloalkyl-C _1-4 alkyl, wherein the groups are optionally the same or different 1-4 halogen, C _1-6 alkyl or C _1-6 alkoxy. May be substituted). In some embodiments, R ¹ is phenyl-C _1-4 alkyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, C _1-6 alkyl or C _1-6 alkoxy). Is good). In some embodiments, R ¹ is C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1-3 halogens, C _1-6 alkoxy, or hydroxy). In some embodiments, R ¹ is hydrogen.

As generally defined above, W is a covalent bond, —O— or —N (R ⁵ ) —. In some embodiments, W is a covalent bond. In some embodiments, W is —O—. In some embodiments, W is —N (R ⁵ ) —.

As defined generally above, R ⁵ is hydrogen or C _1-6 alkyl. In some embodiments, R ⁵ is hydrogen. In some embodiments, R ⁵ is C _1-6 alkyl.

As defined generally above, R ² is (i) a C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from: :
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (ii) C _3-10 cycloalkyl; phenyl; 5-6 membered heteroaryl; 4-8 Membered saturated or partially unsaturated heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered heteroaryl-C _1-4 alkyl; or 4-8 Tiredness Or partially selected from heterocyclic -C _1-4 alkyl unsaturated;
Here, each group in the above (ii) may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). In some embodiments, R ² is C _3-10 cycloalkyl (wherein the groups are optionally the same or different 1-4 halogen, C _1-6 alkyl (where the groups are optionally the same or different). 1 to 3 halogens, optionally substituted with C _1-6 alkoxy or hydroxy) or C _1-6 alkoxy (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy) Or optionally substituted with hydroxy). In some embodiments, R ² is C _3-10 cycloalkyl-C _1-4 alkyl, wherein the groups are optionally the same or different 1-4 halogen, C _1-6 alkyl, wherein the group Are optionally the same or different 1 to 3 halogens, optionally substituted with C _1-6 alkoxy or hydroxy, or C _1-6 alkoxy (wherein the groups are optionally the same or different 1 to 3 halogens). , _Optionally substituted with C _1-6 alkoxy or hydroxy). In some embodiments, R ² is phenyl-C _1-4 alkyl, wherein the group is optionally substituted with the same or different 1-4 halogen, C _1-6 alkyl, or C _1-6 alkoxy. Is good). In some embodiments, R ² is a 5-6 membered monocyclic heteroaryl-C _1-4 alkyl (wherein the groups are optionally the same or different 1-4 halogen, C _1-6 alkyl or C _{1 Optionally} substituted with _-6 alkoxy). In some embodiments, R ² is C _1-6 alkyl (wherein the group is optionally substituted with 1-3 of the same or different halogen, C _1-6 alkoxy or hydroxy).

As defined generally above, R ³ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) hydroxy, and (d) oxo), or (iv) C _3-8 cycloalkyl, wherein the group is optionally substituted with the same or different 1-4 groups selected from: Also good:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo),
(V) C _2-6 alkenyl (wherein the group may be optionally substituted with the same or different 1 to 4 halogens),
(Vi) C _3-8 cycloalkenyl (wherein the group is optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo), and (vii) a 4-8 membered saturated or partially unsaturated monocyclic heterocycle, wherein the groups are suitably selected from: Optionally substituted with 1 to 4 different groups:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) cyano)
Selected from. In some embodiments, R ³ is hydrogen. In some embodiments, R ³ is halogen. In some embodiments, R ³ is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1-3 halogens, C _1-6 alkoxy, or hydroxy). In some embodiments, R ³ is C _3-8 cycloalkyl, wherein the group is optionally substituted with 1-3 of the same or different halogen, C _1-6 alkoxy, or hydroxy. . In some embodiments, R ³ is C _2-6 alkenyl, wherein the groups are optionally substituted with the same or different 1-4 halogens. In some embodiments, R ³ is C _3-8 cycloalkenyl, wherein the group is optionally substituted with 1-3 of the same or different halogen, C _1-6 alkoxy, or hydroxy. . In some embodiments, R ³ is a 4-8 membered saturated or partially unsaturated monocyclic heterocycle, wherein the groups are optionally the same or different 1-3 halogen, C _1-6 alkoxy or Optionally substituted with hydroxy). In some embodiments, R ³ is isopropyl where the group is optionally substituted with 1 to 3 halogens, the same or different, C _1-6 alkoxy or hydroxy. In some embodiments, R ³ is tetrahydropyranyl, wherein the group is optionally substituted with 1-3 of the same or different halogen, C _1-6 alkoxy, or hydroxy. In some embodiments, R ³ is dihydropyranyl.

As defined generally above, R ⁴ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens) or (iv) cyano. In some embodiments, R ⁴ is hydrogen. In some embodiments, R ⁴ is halogen. In some embodiments, R ⁴ is C _1-6 alkyl, wherein the groups are optionally substituted with 1 to 3 halogens, which are the same or different. In some embodiments, R ⁴ is cyano.

As defined generally above, R ² and R ⁵ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle. Where the ring may be optionally substituted with 1 to 4 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxy or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). May be)

  In some aspects, the present invention also provides any compound selected from the compounds shown in the Examples disclosed herein, or a pharmaceutically acceptable salt thereof.

4). Pharmaceutical Compositions, Uses, Formulations, and Administration According to another aspect, the invention also provides a compound according to the invention or a pharmaceutically acceptable salt, ester, ester salt thereof; and a pharmaceutically acceptable Provided is a composition comprising a carrier, adjuvant or excipient. In some embodiments, the amount of compound in the composition of the invention is an amount effective to measurablely inhibit PDE1 in a biological sample or patient. In some embodiments, the composition of the invention is formulated for administration to a patient in need of such composition. In some embodiments, the compositions of the invention are formulated for oral administration to a patient in need thereof.

As used herein, the terms “composition” and “pharmaceutical composition” may mean a medicament. Preferred compositions or pharmaceutical compositions include a medicament containing a compound of formula I or Ia.
As used herein, the term “patient” means an animal, preferably a mammal, most preferably a human.

  The term “pharmaceutically acceptable carrier, adjuvant or excipient” refers to a non-toxic carrier, adjuvant or excipient that does not destroy the pharmacological activity of the compound used in formulating the composition. Pharmaceutically acceptable carriers, adjuvants or excipients that can be used in the compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, human serum albumin. Serum proteins such as phosphate, buffer substances such as phosphate, glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acids, water, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride Salts, electrolytes such as zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based materials, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyesters Glycol, and wool fat.

  “Pharmaceutically acceptable derivatives” are any that can provide, directly or indirectly, a compound of the present invention or an inhibitory active metabolite or residue thereof upon administration to a recipient. Non-toxic salts, esters, ester salts or other derivatives of the compounds according to the invention.

  As used herein, the term “inhibitorally active metabolite or residue” means a metabolite or residue of a compound of the invention that can be a PDE1 inhibitor.

  The compositions of the invention can be administered orally, parenterally, by spray inhalation, topically, rectally, nasally, buccally, vaginally, or by implantable container. May be. As used herein, the term “parenteral” refers to subcutaneous, intraperitoneal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection. Or include infusion techniques. Preferably, the composition is administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. The suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Examples of acceptable excipients and solvents that can be used in the present invention include water, Ringer's solution, and physiological saline. In addition, sterile fixed oils are usually used as the solvent or suspending medium in the present invention.

  For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are pharmaceutically acceptable natural oils such as olive oil or castor oil and are therefore useful in injectable formulations, especially in their polyoxyethylated form. These oil solutions or suspensions are also similar to those commonly used in formulating pharmaceutically acceptable dosage forms such as long chain alcohol diluents or dispersants such as carboxymethylcellulose, or emulsions and suspensions. A dispersant may be included. Other commonly used surfactants such as Tween, Span, and other emulsifiers or bioavailability enhancers commonly used in the manufacture of pharmaceutically acceptable solids, liquids or other dosage forms are also formulated. May be used for these purposes.

  The pharmaceutical composition of the present invention may be orally administered in any orally acceptable dosage form such as, but not limited to, capsules, tablets, aqueous suspensions or liquids. In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricants such as magnesium stearate are also commonly added. Diluents useful for oral administration by capsule include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is mixed with emulsifying and suspending agents. If desired, certain sweetening, flavoring, or coloring agents may also be added to the composition.

  Alternatively, the pharmaceutical composition of the present invention may be administered in the form of a suppository for rectal administration. The composition can be prepared by mixing the active ingredient with a suitable non-irritating additive that is solid at room temperature but liquid at the rectal temperature and therefore dissolves in the rectum to release the active ingredient. Such additives include cocoa butter, beeswax and polyethylene glycols.

  The pharmaceutical compositions of the present invention may also be administered topically, especially when the target of treatment includes areas or organs that are easily accessible by topical application, such as in the case of diseases of the eye, skin or lower gastrointestinal tract. . Suitable topical formulations are easily manufactured for each of these areas or organs.

  Topical application for the lower gastrointestinal tract can be accomplished with a rectal suppository (as described above) or with a suitable enema formulation. Topically transdermal patches may also be used for the application.

  For topical application, the pharmaceutical compositions may also be formulated in a suitable ointment with the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds according to the invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated in a suitable lotion or cream in which the active ingredient is suspended or dissolved in one or more pharmaceutically acceptable carriers. Such suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

  For ophthalmic applications, the pharmaceutical composition is preferably as an isotonic pH, as a finely divided suspension in isotonic pH-adjusted sterile saline, with or without a preservative such as benzalkonium chloride. It may be formulated as a solution in controlled sterile saline. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated in an ointment such as petrolatum.

  The pharmaceutical compositions of the invention can also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the field of pharmaceutical formulation and, as a solution in saline, benzyl alcohol or other suitable preservative, absorption enhancer to enhance bioavailability, fluorocarbon And / or other conventional solubilizers or dispersants may be used.

  Most preferably, the pharmaceutical composition of the present invention is formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutical composition of the invention is administered without food. In other embodiments, the pharmaceutical composition of the invention is administered with food.

  The amount of a compound of the present invention that can be combined with a carrier material to produce a composition in a single dosage form will vary depending upon various factors such as the host being treated and the particular mode of administration. Preferably, the composition may be formulated such that a dose of 0.01-100 mg / kg body weight / day can be administered to a patient receiving the composition.

  The specific dose and treatment regimen for any particular patient will include the activity of the specific compound used, the patient's age, weight, general health, sex, diet, administration time, excretion rate, drug combination, and It should be understood that it depends on various factors such as the judgment of the treating physician and the severity of the particular disease being treated. The amount of the compound according to the invention in the composition also depends on which compound is contained in the composition.

Uses of Compounds and Pharmaceutical Compositions Phosphodiesterases (PDEs) are enzymes that catalyze the hydrolysis of cyclic phosphate bonds of cyclic guanosine monophosphate (cGMP) and / or cyclic adenosine monophosphate (cAMP). Lugnier, C., Pharmacology & Therapeutics (2006), 109, 366. The PDE superfamily can be classified into 11 families (PDE1-11) based on its sequence, regulatory and substrate specificity. Each family can contain multiple subtypes, each of which is a product of a separate gene. In particular, the PDE1 family consisting of PDE1A, PDE1B and PDE1C is a so-called dual substrate enzyme that hydrolyzes both cGMP and cAMP and is regulated by Ca ²⁺ and calmodulin. PDE1A is expressed at low concentrations in the striatum and peripheral vasculature throughout the brain, particularly the hippocampus and cerebellum. On the other hand, PDE1B is mainly expressed in the striatum and cerebellum, and is often found in a region having a high dopaminergic tone and a region expressing dopamine D1 receptor. PDE1C is mainly expressed in the heart, olfactory epithelium and striatum. In view of these expression patterns, compounds that are selective for PDE1B over PDE1A and / or PDE1C may have less cardiovascular effects.

  Depending on the expression pattern of the PDE1 family, inhibition of PDE1 may be useful in the treatment of disorders involving learning and memory by enhancing neuroplasticity. Increased intracellular cAMP and cGMP concentrations caused by PDE1 inhibition cause a cascade reaction that ultimately leads to phosphorylation and activation of transcription factors, cAMP response element binding protein (CREB) and serum response factor (SRF) . Josselyn, SA, Nguyen, PV, Current Drug Targets-CNS & Neurological Disorders (2005) 4, 481. Plasticity-related mediating processes important to neuroplasticity such as dendritic spine reconstruction by activation of CREB and SRF Gene expression can result. Therefore, PDE1 inhibitors may be useful for the treatment of cognitive symptoms of disorders such as Alzheimer's disease, Parkinson's disease, stroke, schizophrenia, Down's syndrome, fetal alcohol syndrome.

  Due to its position in the striatum and its role in the regulation level of second messengers such as cyclic nucleotides, PDE1 is also a regulator of locomotor activity. Reed, TMJ, et al., Journal of Neuroscience (2002) 22, 5189). Due to the ability to increase the concentration of cyclic nucleotides in the striatum, PDE1 inhibitors inhibit the degradation of D1 agonists by inhibiting the degradation of cAMP and cGMP. It is expected to enhance the effect. This enhancement of dopamine signaling may be useful in the treatment of diseases such as, but not limited to, cognitive impairment such as Parkinson's disease, depression, and cognitive impairment associated with schizophrenia.

  The activity of the compounds utilized in the present invention as inhibitors of PDE1 or as therapeutic agents for neurological or psychiatric disorders may be assessed in vitro or in vivo. In vivo evaluation of the effectiveness of the compounds according to the invention may be carried out using animal models of neurological or psychiatric disorders, such as rodent models or primate models. Cell-based assays may be performed, for example, using cell lines isolated from tissues that express PDE1 or cell lines that recombinantly express PDE1. Further, for example, biochemical or mechanism-based assay for measuring cAMP or cGMP concentration, Northern blot, RT-PCR and the like may be performed. In vitro assays include assays that measure cell morphology, protein expression, cytotoxicity, enzyme inhibitory activity, and / or functional results associated with the treatment of cells with the compounds of the present invention. An alternative in vitro assay quantifies the ability of an inhibitor to bind to a protein or nucleic acid molecule in a cell. Inhibitor binding may be measured by labeling the inhibitor with a radioisotope prior to binding, isolating the inhibitor / target molecule complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by conducting a competition experiment in which a new inhibitor is incubated with pure protein or nucleic acid bound to a known radioligand. Detailed conditions for assaying the compounds used in the present invention as PDE1 inhibitors are shown in the examples below. The above assay is exemplary and is not intended to limit the scope of the invention. One skilled in the art can appreciate that conventional assays can be modified to develop equivalent assays that achieve the same results.

  As used herein, the terms “treatment”, “treat” and “treating” reverse and alleviate a disease or disorder described herein or one or more symptoms thereof. And delaying onset or inhibiting progression. In some embodiments, treatment may be performed after one or more symptoms have developed. In other embodiments, treatment may be performed when there are no symptoms. For example, treatment may be given to individuals susceptible to illness prior to the onset of symptoms (eg, in light of medical history and / or genetic or other susceptibility factors). Treatment may also continue after symptoms have resolved, eg to prevent or delay recurrence.

  In some embodiments, the compounds and compositions according to the methods of the invention may be administered at any dosage and route effective to treat or reduce the severity of a disease associated with PDE1.

  In some embodiments, the compounds and compositions according to the methods of the invention may be administered at any dosage and route of administration effective to treat or reduce the severity of a neurological or psychiatric disorder.

  In some embodiments, the neurological or psychiatric disorder is schizophrenia (including delusional, disorganized, strained or undifferentiated), schizophrenia-like disorder, schizophrenic emotional disorder, paranoid disorder, short term Psychiatric disorders, shared psychotic disorders, systemic conditions and substance-induced or drug-induced (such as phencyclidine, ketamine and other dissociative anesthetics, amphetamine and other psychostimulants, and cocaine) Psychiatric due to psychosis “Schizophrenia-spectrum” disorders or schizophrenia, such as disorders, psychotic disorders, psychosis associated with affective disorders, short-term reactive psychosis, schizophrenic psychosis, schizophrenic or schizophrenic personality disorder Schizophrenia, such as psychiatric disorders such as major depression, manic depression (bipolar disorder), Alzheimer's disease and post-traumatic stress syndrome Or cognitive disorders such as dementia (Alzheimer's disease, ischemia, multiple infarct dementia, trauma, vascular problems or stroke, HIV disease, Parkinson's disease, Huntington's disease, Down syndrome, or Pick disease, Creutzfeldt-Jakob disease, perinatal hypoxia, associated with other systemic conditions or substance abuse); delirium, amnesia or age-related cognitive decline; acute stress disorder, agoraphobia, generalized anxiety disorder, Anxiety disorders such as obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobia, substance-induced anxiety disorder and anxiety caused by general medical condition; Disability and addiction (substance-induced delirium, persistent dementia, persistent amnestic disorder, psychotic disorder, anxiety disorder, etc.); alcohol, amphetamine, cannabis, coca Tolerance, dependence, or withdrawal of substances such as vitamins, hallucinogens, inhalants, nicotine, opioids, phencyclidine, analgesics, hypnotics or anxiolytics; obesity, bulimia nervosa and obsessive compulsive eating disorders; bipolar Disorders, mood disorders such as depressive disorders; unipolar depression, depression such as seasonal and postpartum depression, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PDD), mood disorders due to systemic pathology, and Substance-induced mood disorders; pervasive developmental disorders such as learning disorders, autistic disorders, attention disorders such as attention deficit hyperactivity disorder (ADHD) and behavioral disorders; autism, depression, benign amnesia, childhood learning disorders and Disorders such as closed head trauma; ataxia and ataxia syndrome (Parkinson's disease, drug-induced Parkinson's disease, Parkinson's disease after encephalitis, progressive supranuclear paralysis, multiple system atrophy, cortical basal ganglia degeneration Disease, -Kinson's disease-including ALS dementia syndrome and basal ganglia calcification), pharmacotherapy-induced Parkinson's disease (neuroblocker-induced Parkinson's disease, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic) Drug-induced acute restlessness, neuroleptic-induced delayed dyskinesia and drug treatment-induced postural tremor), Gilles de la Tourette syndrome, epilepsy, muscle spasms and tremors Dyskinesia {drugs such as L-DOPA-induced dyskinesia tremor (stationary tremor, postural tremor, intention tremor, etc.), atypia (Sydenham anastasia, Huntington's disease, benign Hereditary antonia, neurospinous erythrocytosis, symptomatic anastasis, drug-induced anastasis and unilateral balism), myoclonus (systemic myoclonus and localized) Systemic dystonia such as myoclonus, tics (including simple tics, complex tics and symptomatic tics) and dystonia (spontaneous dystonia, drug-induced dystonia, symptomatic dystonia and paroxysmal dystonia and blepharospasm, stomatognathic dystonia , Convulsive dysphonia, spastic torticollis, axial dystonia, localized dystonia such as dystonia dystonia and hemiplegic dystonia)}; urinary incontinence; eye damage, eye retinopathy or macular degeneration, tinnitus , Hearing impairment and loss, and nerve damage such as brain edema; vomiting; and sleep disorders such as insomnia and paroxysmal sleep.

  In some embodiments, the neurological or psychiatric disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, depression, cognitive impairment, stroke, schizophrenia, Down's syndrome, and fetal alcohol syndrome. In some embodiments, the neurological or psychiatric disorder is Alzheimer's disease. In some embodiments, the neurological or psychiatric disorder is Parkinson's disease. In some embodiments, the neurological or psychiatric disorder is depression. In some embodiments, the neurological or psychiatric disorder is a cognitive disorder. In some embodiments, the neurological or psychiatric disorder is stroke. In some embodiments, the neurological or psychiatric disorder is schizophrenia, including positive, negative and cognitive symptoms. In some embodiments, the neurological or psychiatric disorder is Down's syndrome. In some embodiments, the neurological or psychiatric disorder is fetal alcohol syndrome.

  In some embodiments, the neurological or psychiatric disorder is cognitive impairment (eg, Diagnostic and Statistical Manual of Mental Disorders, 5th Ed., American Psychiatric Publishing (2013) (“DSM-5”)). Deficits in the domain, including complexity attention, executive function, learning and memory, language, perceptual movement and social cognition). In some embodiments, the neurological or psychiatric disorder is associated with a defect in dopamine signaling. In some embodiments, the neurological or psychiatric disorder is associated with basal ganglia dysfunction. In some embodiments, the neurological or psychiatric disorder is associated with unregulated locomotor activity.

  In some embodiments, the neurological or psychiatric disorder is associated with a defect in the cyclic nucleotide signaling molecule. In some embodiments, the neurological or psychiatric disorder is associated with a deficiency in cAMP and / or cGMP. In some embodiments, the neurological or psychiatric disorder is associated with low activity of cAMP response element binding protein (CREB), serum response factor (SRF), or both.

  In some embodiments, the compounds and compositions according to the methods of the invention may be administered at any dosage and route effective to treat or reduce the severity of cardiovascular or cardiovascular disorders. In some embodiments, the cardiovascular or cardiovascular disorder is selected from the group consisting of cerebrovascular disorder, stroke, congestive heart disease, hypertension, pulmonary hypertension and sexual dysfunction.

  In some embodiments, the compounds and compositions according to the methods of the invention may be administered at any dosage and route effective to treat or reduce the severity of respiratory and inflammatory diseases. . In some embodiments, the respiratory and inflammatory diseases are selected from the group consisting of asthma, chronic obstructive pulmonary disease, allergic rhinitis, and autoimmune and inflammatory diseases.

  In some embodiments, the invention provides a method of treating a neurological or psychiatric disorder as described herein, comprising administering a compound of the invention together with one or more agents to a patient in need thereof. I will provide a. Such suitable agents that may be used in combination with the compounds of the present invention include antiparkinsonian, anti-Alzheimer's, antidepressant, antipsychotic, anti-ischemic, CNS inhibitor, anticholinergic Agonists and nootropics are included.

  Such suitable anti-Parkinson drugs include, but are not limited to, dopamine replacement therapy (eg, COMT inhibitors such as L-DOPA, carbidopa, entacapone), dopamine agonists (eg, D1 agonist, D2 agonist, mixed D1 / D2 agonists; bromocriptine, pergolide, cabergoline, ropinirole, pramipexole, or apomorphine), histamine H2 antagonists, and monoamine oxidase inhibitors such as selegiline and tranylcypromine in combination with domperidone.

  In some embodiments, the compounds of the invention comprise levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), biperiden (as appropriate as its hydrochloride or lactate) and trihe hydrochloride. Anticholinergics such as xylphenidyl (benzhexyl), COMT inhibitors such as entacapone, MAO A / B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists, NMDA receptor antagonists, serotonin It may also be used in combination with receptor antagonists and dopamine receptor agonists such as arentemol, bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and pramipexole. Dopamine receptor agonists may be combined in their pharmaceutically acceptable salt forms: for example, arentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, noxagolide hydrochloride and pergolide mesylate Will be recognized. Lisuride and pramipexole are commonly used in non-salt form.

  Such suitable anti-Alzheimer's agents include, but are not limited to, beta secretase inhibitors, gamma secretase inhibitors, HMG-CoA reductase inhibitors, NSAIDs such as ibuprofen, vitamin E, and anti-amyloid antibodies. It is done. In some embodiments, the anti-Alzheimer's disease drug is memantine.

Such suitable antidepressants and anxiolytics include, but are not limited to, norepinephrine reuptake inhibitors (including tertiary amine tricyclic and secondary tricyclic), selective serotonin reuptake Inhibitor (SSRI), monoamine oxidase inhibitor (MAOI), reversible inhibitor of monoamine oxidase (RIMA), serotonin and noradrenaline reuptake inhibitor (SNRI), corticotropin releasing factor (CRF) antagonist, α-adrenergic receptor Body antagonists, neurokinin-1 receptor antagonists, atypical antidepressants, benzodiazepines, 5-HT _1A agonists or antagonists, especially 5-HT _1A partial agonists, and corticotropin releasing factor (CRF) antagonists .

  In particular, suitable antidepressants and anxiolytics include, but are not limited to, amitripitiline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protriptyline; fluoxetine, fluvoxamine, paroxetine and sertraline; Isocarboxazide, phenelzine, tranylcypromine and selegiline; moclobemide; venlafaxine; duloxetine; aprepitant; bupropion, lithium, nefazodone, trazodone and viloxazine; Prazepam; buspirone, flesinoxane, gepirone and ipsapirone And pharmaceutically acceptable salts thereof.

  The exact amount required of the compound or composition of the invention will vary between subjects depending on the species, age and general condition of the subject, the severity of the infection, the particular drug used, the mode of administration and the like. The compounds according to the invention are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. As used herein, the term “unit dosage form” refers to a physically discrete unit of drug appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dosage for a particular patient or organism is the disorder being treated and the severity of the disorder; the activity of the specific compound used; the specific composition used; the age, weight, overall Health status, gender and diet; time of administration, route of administration and excretion rate of the specific compound used; duration of treatment; drugs used in combination or simultaneously with the specific compound used and well known in the medical field It depends on various factors such as other factors. As used herein, the term “patient” means an animal, preferably a mammal, most preferably a human.

  The pharmaceutical composition of the present invention can be administered orally, rectally, parenterally, intracapsularly, intravaginally, intraperitoneally, topically (powder, ointment) depending on the severity of the infection being treated. Or can be administered to humans and other animals in the cheek, as an oral or nasal spray. In some embodiments, the compound of the present invention is administered at least about once per day to about 0.01 mg / kg to about 50 mg / kg, preferably about 1 mg / kg of subject body weight per day to achieve the desired therapeutic effect. It may be administered orally or parenterally at a dose level of kg to about 25 mg / kg.

  Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, liquid dosage forms include, for example, water or other solvents, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, Fields such as oils (especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil), solubilizers and emulsifiers such as glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid esters, and mixtures thereof It may contain an inert diluent usually used in the above. In addition to inert diluents, oral compositions can also include wetting agents, emulsifying and suspending agents, sweetening, flavoring and flavoring agents.

  Injectable preparations, for example, sterile injectable aqueous or oleaginous suspension preparations may be formulated according to the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Examples of acceptable excipients and solvents that can be used in the present invention include water, Ringer's solution (USP), and physiological saline. In addition, sterile fixed oils are usually employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparations for injection.

  Injectable formulations are made sterile by, for example, filtration through a bacteria-retaining filter, or by incorporating a sterilant in the form of a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium before use. can do.

  In order to sustain the effect of the compounds according to the invention, it is often desirable to delay the absorption of the compound from subcutaneous or intramuscular injection. This may be achieved by using a liquid suspension of poorly water soluble crystalline or amorphous material. And the absorption rate of the compound depends on its dissolution rate, and the dissolution rate can depend on the crystal size and crystal form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be adjusted. Examples of other biodegradable polymers include poly (orthoesters) and polyanhydrides. Injectable depot preparations are also made by entrapping the compound in liposomes or microemulsions that are compatible with biological tissues.

  The composition for rectal or vaginal administration is preferably cocoa butter, polyethylene glycol or a suppository wax which is solid at room temperature but is liquid at body temperature and therefore dissolves in the rectum or vaginal cavity to release the active compound. A suppository which can be prepared by mixing a suitable nonirritating additive with a compound of the invention.

  Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound comprises at least one inert pharmaceutically acceptable additive or carrier such as sodium citrate or dicalcium phosphate, and / or a) starch, lactose, sucrose Fillers or fillers such as glucose, mannitol and silicic acid, b) binders such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose and acacia gum, c) humectants such as glycerol, d) agar, Calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates and disintegrants such as sodium carbonate, e) dissolution retardants such as paraffin, f) absorption enhancers such as quaternary ammonium compounds, g) eg cetyl Alcohol and glycero monostearate H) a wetting agent such as h), an absorbent such as kaolin and bentonite viscosity, and i) a lubricant such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. . In the case of capsules, tablets and pills, the dosage forms may also contain buffering agents.

  Similar types of solid compositions may also be used as fillers in soft and hard gelatin capsules using additives such as lactose or lactose and high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. These may contain opacifiers as appropriate, and may be compositions in which the active ingredient is released only at a specific site in the intestinal tract or preferentially at this site, with appropriate delay. Examples of embedding compositions that can be used herein include polymeric substances and waxes.

  The active compound can also be in microencapsulated form with one or more additives as described above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be manufactured with coatings and shells such as enteric coatings, controlled release coatings and other coatings well known in the pharmaceutical formulating art. it can. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also contain, as usual, further substances besides inert diluents, for example tableting lubricants such as magnesium stearate and microcrystalline cellulose and other tableting aids. In the case of capsules, tablets and pills, the dosage forms may also contain buffering agents. These may contain opacifiers as appropriate, and may be compositions in which the active ingredient is released only at a specific site in the intestinal tract or preferentially at this site, with appropriate delay.

  Examples of the dosage form for topical or transdermal administration of the compound according to the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulations such as ear drops and eye drops are also included within the scope of the present invention. Furthermore, the present invention encompasses the use of transdermal patches and has the additional advantage of controlling the delivery of the compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the fluidity of the compound across the skin. The flow rate can be controlled by presenting a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

One aspect of the invention provides a method of inhibiting PDE1 in a biological sample comprising the step of contacting the biological sample with a compound of the invention or a composition comprising the compound. In some embodiments, PDE1 is PDE1A. In some embodiments, PDE1 is PDE1B. In some embodiments, PDE1 is PDE1C. Another aspect of the invention provides a method of selectively inhibiting PDE1B over PDE1A and / or PDE1C. Yet another aspect of the invention provides a method of inhibiting PDE1B selectively with respect to PDE1A. Yet another aspect of the invention provides a method of selectively inhibiting PDE1B relative to PDE1C. Yet another aspect of the invention provides a method of inhibiting PDE1B selectively over PDE1A and PDE1C. In some embodiments, the selectivity for PDE1B over PDE1A and / or PDE1C is 5 times or less. In some embodiments, the selectivity for PDE1B over PDE1A and / or PDE1C is 10 times or less. In some embodiments, the selectivity for PDE1B over PDE1A and / or PDE1C is 20 times or less. In some embodiments, the selectivity for PDE1B over PDE1C is 50 times or less. In some embodiments, the selectivity for PDE1B over PDE1C is 100 times or less. In some embodiments, the selectivity for PDE1B over PDE1C is 200 times or less. Selectivity for another for one PDE1 isoform refers to the inverse ratio of IC ₅₀ values for each isoform determined using the HTRF PDE1 inhibition assay or SPA assay described in the Examples. For example, the selectivity of the compounds of the invention for PDE1B over PDE1C is determined by using the HTRF PDE1 inhibition assay or SPA assay, where the IC ₅₀ (PDE1C) / IC ₅₀ (PDE1B) ratio (where IC ₅₀ (PDE1C) is described). Is the IC ₅₀ value of the compound for PDE1C, and IC ₅₀ (PDE1B) is the IC ₅₀ value of the compound for PDE1B determined using the described HTRF PDE1 inhibition assay or SPA assay). .

  Yet another aspect of the invention provides a method of modulating cyclic nucleotide concentration in a biological sample comprising contacting the biological sample with a compound of the invention or a composition comprising the compound.

  The term “biological sample” as used herein includes, but is not limited to, a cell culture or extract thereof; a biopsy material obtained from a mammal or extract thereof; and blood, saliva, urine, feces, semen , Tears or other body fluids or extracts thereof.

  Inhibition of enzymes in biological samples is useful for a variety of purposes known to those of skill in the art. Examples of such purposes include, but are not limited to, biological assays, gene expression studies, and biological target identification.

Another aspect of the present invention relates to a method for inhibiting PDE1 in a patient, characterized in that the compound according to the present invention or a composition comprising said compound is administered to the patient. In some embodiments, PDE1 is PDE1B. Yet another aspect of the present invention provides a method of selectively inhibiting a patient's PDE1B relative to PDE1A and / or PDE1C. Yet another aspect of the invention provides a method of inhibiting a patient's PDE1B selectively with respect to PDE1A. Yet another aspect of the invention provides a method of inhibiting a patient's PDE1B selectively against PDE1C. Yet another aspect of the present invention provides a method of selectively inhibiting a patient's PDE1B relative to PDE1A and PDE1C. In some embodiments, the selectivity for PDE1B over PDE1A and / or PDE1C is 5 times or less. In some embodiments, the selectivity for PDE1B over PDE1A and / or PDE1C is 10 times or less. In some embodiments, the selectivity for PDE1B over PDE1A and / or PDE1C is 20 times or less. In some embodiments, the selectivity for PDE1B over PDE1C is 50 times or less. In some embodiments, the selectivity for PDE1B over PDE1C is 100 times or less. In some embodiments, the selectivity for PDE1B over PDE1C is 200 times or less. Selectivity for another for one PDE1 isoform refers to the inverse ratio of IC ₅₀ values for each isoform determined using the HTRF PDE1 inhibition assay or SPA assay described in the Examples. For example, the selectivity of the compounds of the invention for PDE1B over PDE1C is determined by using the HTRF PDE1 inhibition assay or SPA assay, where the IC ₅₀ (PDE1C) / IC ₅₀ (PDE1B) ratio (where IC ₅₀ (PDE1C) is described). Is the IC ₅₀ value of the compound for PDE1C, and IC ₅₀ (PDE1B) is the IC ₅₀ value of the compound for PDE1B determined using the described HTRF PDE1 inhibition assay or SPA assay). .

  Depending on the particular condition or disease to be treated, additional therapeutic agents may be administered in combination with the compounds and compositions of the invention, which are usually administered to treat the condition or disease. As used herein, additional therapeutic agents normally administered to treat a particular disease or condition are known in the art as “appropriate for the disease or condition being treated”.

  In some embodiments, a combination of two or more therapeutic agents may be administered with a compound of the present invention. In some embodiments, a combination of three or more therapeutic agents may be administered with a compound of the present invention.

  Other examples of agents that may be combined with the inhibitors of the present invention include, but are not limited to, vitamins and nutritional supplements, antiemetics (eg, 5-HT3 receptor antagonists, dopamine antagonists, NK1 receptor antagonists). Multiple sclerosis such as drugs, histamine receptor antagonists, cannabinoids, benzodiazepines or anticholinergics), beta interferons (eg Avonex® and Rebif®), Copaxone® and mitoxantrone (MS) therapeutic agents; asthma therapeutic agents such as albuterol and Singulair®; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine and sulfasalazine; cyclosporine, tacrolimus, rapamycin, mycophenolic acid Mofetil, interferon, corticosteroid, cyclo Immunomodulators and immunosuppressants such as sufamide, azathioprine and azasulfasalazine; acetylcholinesterase inhibitors, MAO inhibitors, interferons, antispasmodics, ion channel blockers, riluzole, beta blockers and other therapeutic agents for ACE, ACE inhibitors , Diuretics, nitrates, calcium channel blockers, and neurotrophic factors such as statins, fibrates, cholesterol absorption inhibitors, bile acid adsorbents, and niacin; corticosteroids, cholestyramine, interferons, and antiviral agents Hepatic disease treatment agents; corticosteroids, anti-leukemic agents, and blood disorder treatment agents such as growth factors; immunodeficiency treatment agents such as gamma globulin; and biguanides (metformin, phenformin, buformin), thiazolidinedio (Rosiglitazone, pioglitazone, troglitazone), sulfonylureas (tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glyburide, glimepiride, gliclazide), meglitinides (rapaglinide, nateglinide), alpha-glucosidase inhibitors (miglitol, Acarbose), incretin mimetics (exenatide, liraglutide, taspoglutide), gastric inhibitory peptide analogues, DPP-4 inhibitors (virdagliptin, sitagliptin, saxagliptin, linagliptin, alogliptin), amylin analogues (pramlintide) and insulin and insulin analogues And antidiabetic drugs.

  In some embodiments, the compounds of the invention or pharmaceutical compositions comprising the compounds may be administered in combination with antisense agents, monoclonal or polyclonal antibodies, or siRNA therapeutics.

  These additional agents may be administered as part of a multiple dosage regime, separate from the composition comprising a compound according to the present invention. Alternatively, these agents may be part of a single dosage form mixed with a compound of the invention in a single composition. When administered as part of a multiple dosing schedule, the two active agents may be administered simultaneously, sequentially or at regular intervals, usually within 5 hours.

  As used herein, the terms “combination”, “in combination” and related terms refer to administering therapeutic agents simultaneously or sequentially according to the present invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of formula I, an additional therapeutic agent and a pharmaceutically acceptable carrier, adjuvant or excipient.

  The amount of the compound of the invention and the additional therapeutic agent (in the composition comprising the additional therapeutic agent) that may be combined with the carrier material to produce a single dosage form, together with the host to be treated and the particular administration You may change according to a form. Preferably, the compositions of the invention should be formulated so that a dose of 0.01-100 mg / kg body weight / day of the compound of the invention can be administered.

  In these compositions comprising an additional therapeutic agent, the additional therapeutic agent and the compound of the invention may act synergistically. Thus, the amount of additional therapeutic agent in such compositions will be less than that required for monotherapy using only that therapeutic agent. In such compositions, the additional therapeutic agent can be administered at a dose of 0.01-100 μg / kg body weight / day.

  The amount of additional therapeutic agent present in the composition of the present invention may be below the amount normally administered in a composition having that therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the composition of the present invention may range from about 50% to 100% of the amount normally present in a composition comprising that therapeutic agent as the only active agent.

  Another aspect of the present invention provides a medicament comprising at least one compound of formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

  Yet another aspect of the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment of a neurological or psychiatric disorder.

  Yet another aspect of the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment of circulatory or cardiovascular disorders.

  Yet another aspect of the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment of respiratory and inflammatory diseases.

で示される化合物又はその製薬学的に許容される塩を有効成分とする医薬
［式中、
Ｒ^１は
（ｉ）水素、
（ｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
（ｃ）ヒドロキシル、
（ｄ）フェノキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）アミノ（ここに、該基は適宜、同一又は異なる１〜２のＣ_１−６アルキル、Ｃ_３−８シクロアルキル又はフェニル（ここに、フェニルは適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、Ｃ_１−６アルコキシ又はトリフルオロメチルで置換されていてもよい）で置換されていてもよい））、及び
（ｉｉｉ）Ｃ_３−１０シクロアルキル；フェニル；５〜６員単環性ヘテロアリール；４〜８員飽和又は部分的に不飽和の単環性ヘテロ環；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和の単環性ヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）；及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
ＸはＯ又はＳであり；
Ｗは共有結合、−Ｃ≡Ｃ−、−ＣＨ＝ＣＨ−、−Ｏ−又は−Ｎ（Ｒ^５）−であり；
Ｒ^５は水素又はＣ_１−６アルキルであり；
Ｒ^２は
（ｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
（ｃ）ヒドロキシル、
（ｄ）フェノキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）アミノ（ここに、該基は適宜、同一又は異なる１〜２のＣ_１−６アルキル、Ｃ_３−８シクロアルキル又はフェニル（ここに、フェニルは適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、Ｃ_１−６アルコキシ又はトリフルオロメチルで置換されていてもよい）で置換されていてもよい））、及び
（ｉｉ）Ｃ_３−１０シクロアルキル；フェニル；５〜６員ヘテロアリール；４〜８員飽和又は部分的に不飽和のヘテロ環；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和のヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
あるいは、Ｒ^２及びＲ^５は、それらが結合している窒素原子と一緒になって、４〜８員飽和又は部分的に不飽和の単環性ヘテロ環を形成してもよく；ここに、該環は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ、ヒドロキシ又はアミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｅ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｆ）５〜６員単環性ヘテロアリールオキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）Ｃ_１−６アルキルカルボニル（ここに、アルキルは適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はアミノ（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
Ｒ^３は
（ｉ）水素、
（ｉｉ）ハロゲン、
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）ヒドロキシ、及び
（ｄ）オキソ）、又は
（ｉｖ）Ｃ_３−８シクロアルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）オキソ）、
（ｖ）Ｃ_２−６アルケニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲンで置換されていてもよい）、
（ｖｉ）Ｃ_３−８シクロアルケニル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）オキソ）、及び
（ｖｉｉ）４〜８員飽和又は部分的に不飽和の単環性ヘテロ環（ここに、該基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、
（ｄ）ヒドロキシ、及び
（ｅ）シアノ）
から選択され；
Ｒ^４は
（ｉ）水素、
（ｉｉ）ハロゲン、
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）、又は
（ｉｖ）シアノ
から選択され；
但し、Ｒ^１が水素である場合、Ｗは−Ｏ−又は−Ｎ（Ｒ^５）−であり、Ｒ^４は水素である］。
項２．式ＩにおけるＲ^１が
（ｉ）水素、
（ｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、及び
（ｃ）ヒドロキシル）、及び
（ｉｉｉ）Ｃ_３−１０シクロアルキル；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和の単環性ヘテロ環−Ｃ_１−４アルキル
から選択され；
ここに、上記（ｉｉｉ）における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
項１記載の医薬。
項３．式ＩにおけるＲ^１が
（ｉ）水素、
（ｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、及び
（ｃ）ヒドロキシル）、
（ｉｉｉ）Ｃ_３−８シクロアルキル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｉｖ）Ｃ_３−８シクロアルキル−Ｃ_１−４アルキル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）
から選択され；
Ｗが−Ｏ−又は−Ｎ（Ｒ^５）−であり；
Ｒ^５が水素又はＣ_１−６アルキルであり；
Ｒ^２がＣ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；４〜８員飽和又は部分的に不飽和の単環性ヘテロ環−Ｃ_１−４アルキル；Ｃ_３−１０シクロアルキル；又は４〜８員飽和又は部分的に不飽和の単環性ヘテロ環であり；
ここに、Ｒ^２における各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）；
あるいは、Ｒ^２及びＲ^５が、それらが結合している窒素原子と一緒になって、４〜８員飽和又は部分的に不飽和の単環性ヘテロ環を形成してもよく；ここに、該環は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ、ヒドロキシル又はアミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｅ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｆ）５〜６員単環性ヘテロアリールオキシ（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
（ｇ）Ｃ_１−６アルキルカルボニル（ここに、アルキルは適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はアミノ（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）で置換されていてもよい）、及び
（ｈ）アミノカルボニル（ここに、アミノは適宜、同一又は異なる１〜２のＣ_１−６アルキルで置換されていてもよい）、
項１又は２記載の医薬。
項４．式ＩにおけるＲ^１がＣ_１−６アルキルであり（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はＣ_１−６アルコキシで置換されていてもよい）；及び
Ｒ^２がＣ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；又はＣ_３−１０シクロアルキルであり；
ここに、Ｒ^２における各基が適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、
（ｄ）シアノ、
（ｅ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｆ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
項１〜３のいずれか記載の医薬。
項５．式ＩにおけるＲ^２がＣ_３−８シクロアルキル−Ｃ_１−４アルキル又はＣ_３−８シクロアルキルであり；
ここに、各基が適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、
項４記載の医薬。
項６．式ＩにおけるＲ^１がＣ_３−１０シクロアルキル；Ｃ_３−１０シクロアルキル−Ｃ_１−４アルキル；フェニル−Ｃ_１−４アルキル；５又は６員単環性ヘテロアリール−Ｃ_１−４アルキル；又は４〜８員飽和又は部分的に不飽和の単環性ヘテロ環−Ｃ_１−４アルキルであり；
ここに、各基が適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）ヒドロキシ、
（ｅ）シアノ、
（ｆ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｇ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）；
Ｗが−Ｏ−又は−Ｎ（Ｒ^５）−であり；
Ｒ^５が水素又はＣ_１−６アルキルであり；
Ｒ^２がＣ_１−６アルキルであり（ここに、該基は適宜、以下から選択される、同一又は異なる１〜３の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、及び
（ｃ）ヒドロキシ）；
あるいは、Ｒ^２及びＲ^５が、それらが結合している窒素原子と一緒になって、４〜８員飽和又は部分的に不飽和の単環性ヘテロ環を形成してもよく；ここに、該環が適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、
（ｄ）フェニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｅ）５〜６員単環性ヘテロアリール（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、シアノ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）、
項１記載の医薬。
項７．式ＩにおけるＲ^１がＣ_３−８シクロアルキル−Ｃ_１−４アルキル；又はフェニル−Ｃ_１−４アルキルであり；
ここに、各基が適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、Ｃ_１−６アルコキシ又はヒドロキシで置換されていてもよい）、及び
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はヒドロキシで置換されていてもよい）、
項６記載の医薬。
項８．式ＩにおけるＸがＯである、項１〜７のいずれか記載の医薬。
項９．式ＩにおけるＷが−Ｏ−である、項１〜８のいずれか記載の医薬。
項１０．式ＩにおけるＲ^３が
（ｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、
（ｉｉ）Ｃ_３−８シクロアルキル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｉｉｉ）４〜８員飽和又は部分的に不飽和の単環性ヘテロ環（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、ヒドロキシ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）
から選択される、項１〜９のいずれか記載の医薬。
項１１．式ＩにおけるＲ^３がＣ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、テトラヒドロピラニル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、又はジヒドロピラニルである、項１０記載の医薬。
項１２．式ＩにおけるＲ^４が
（ｉ）水素、
（ｉｉ）ハロゲン、又は
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）
から選択される、項１〜１１のいずれか記載の医薬。
項１３．式ＩにおけるＲ^４が水素である、項１〜１２のいずれか記載の医薬。
項１４．式ＩにおけるＲ^１がＣ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はＣ_１−６アルコキシで置換されていてもよい）であり；
Ｒ^２がＣ_３−８シクロアルキル−Ｃ_１−４アルキル又はＣ_３−８シクロアルキルであり；ここに、各基が適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）；
ＸがＯであり；
Ｗが−Ｏ−である、
項１〜５のいずれか記載の医薬。
項１５．式Ｉａ：

［式中、
Ｒ^１はＣ_１−６アルキルであり（ここに、該基は適宜、同一又は異なる１〜３のハロゲン又はＣ_１−６アルコキシで置換されていてもよい）；
Ｒ^２はＣ_３−８シクロアルキル−Ｃ_１−４アルキル又はＣ_３−８シクロアルキルであり；ここに、各基は適宜、以下から選択される、同一又は異なる１〜４の基で置換されていてもよい：
（ａ）ハロゲン、
（ｂ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｃ）Ｃ_１−６アルコキシ（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）；
Ｒ^３は
（ｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲン、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、
（ｉｉ）Ｃ_３−８シクロアルキル（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、Ｃ_１−６アルキル、ヒドロキシ又はＣ_１−６アルコキシで置換されていてもよい）、及び
（ｉｉｉ）４〜８員飽和又は部分的に不飽和の単環性ヘテロ環（ここに、該基は適宜、同一又は異なる１〜４のハロゲン、ヒドロキシ、Ｃ_１−６アルキル又はＣ_１−６アルコキシで置換されていてもよい）から選択され；
Ｒ^４は
（ｉ）水素、
（ｉｉ）ハロゲン、又は
（ｉｉｉ）Ｃ_１−６アルキル（ここに、該基は適宜、同一又は異なる１〜３のハロゲンで置換されていてもよい）から選択される］
で示される化合物又はその製薬学的に許容される塩を有効成分とする、項１記載の医薬。
項１６．式ＩにおけるＲ^３がテトラヒドロピラニル（ここに、該基は適宜、ヒドロキシで置換されていてもよい）又はジヒドロピラニルであり；Ｒ^４が水素である、項１〜１５のいずれか記載の医薬。
項１７．式Ｉの化合物が以下からなる群：
2-[(4,4-ジフルオロシクロヘキシル)メトキシ]-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例1）；
3-(4-クロロベンジル)-2-メトキシ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例109）；
3-[(4,4-ジフルオロシクロヘキシル)メチル]-2-メトキシ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例115）；
5-クロロ-2-[(4,4-ジフルオロシクロヘキシル)メトキシ]-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例119）；
2-{[(5-クロロピリジン-2-イル)メチル]アミノ}-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例149）；
3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)-2-{[trans-4-(トリフルオロメチル)シクロヘキシル]メトキシ}-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例245）；
2-[(trans-4-エトキシシクロヘキシル)メトキシ]-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例246）；
3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)-2-{[cis-4-(トリフルオロメチル)シクロヘキシル]メトキシ}-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例248）；
2-(シクロヘキシルオキシ)-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例255）；
2-{[trans-4-(エトキシメチル)シクロヘキシル]オキシ}-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)-イミダゾ-[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例256）；
2-{[trans-4-(エトキシメチル)シクロヘキシル]メトキシ}-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例288）；
3-(¹³C,²H₃)メチル-7-(テトラヒドロ-2H-ピラン-4-イル)-2-{[trans-4-(トリフルオロメチル)シクロヘキシル]-メトキシ}イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例294）；
2-[(4,4-ジフルオロシクロヘキシル)オキシ]-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例304）；
3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)-2-{[trans-4-(トリフルオロメチル)シクロヘキシル]オキシ}-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例305）；
3-エチル-2-{[trans-4-(メトキシメチル)シクロヘキシル]オキシ}-7-(テトラヒドロ-2H-ピラン-4-イル)-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例317）；
7-(4-ヒドロキシテトラヒドロ-2H-ピラン-4-イル)-3-メチル-2-{[trans-4-(トリフルオロメチル)シクロヘキシル]-メトキシ}イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例326）；及び
7-(3,6-ジヒドロ-2H-ピラン-4-イル)-3-メチル-2-{[trans-4-(トリフルオロメチル)シクロヘキシル]メトキシ}-イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（実施例328）
から選択される、項１記載の医薬。
項１８．項１〜１７のいずれか記載の式Ｉ又はＩａの化合物及び製薬学的に許容される担体、アジュバント又は賦形剤を含む組成物。
項１９．ＰＤＥ１を阻害するための項１〜１７のいずれか記載の医薬。
項２０．神経障害又は精神障害を治療するための項１〜１７又は１９のいずれか記載の医薬。
項２１．神経障害又は精神障害がアルツハイマー病、パーキンソン病、うつ、認知障害、脳卒中、統合失調症、ダウン症候群又は胎児性アルコール症候群である、項２０記載の医薬。
項２２．神経障害又は精神障害がＤＳＭ−５で定義される１つ以上の認知領域における欠損を伴う、項２０記載の医薬。
項２３．神経障害又は精神障害を治療するための医薬の製造における項１又は１５に記載の式Ｉ又はＩａの化合物の使用。 The present invention also includes the following specific embodiments:
Item 1. Formula I:

Or a pharmaceutically acceptable salt thereof as an active ingredient [wherein
R ¹ is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (iii) C _3-10 cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl; 4-8 membered saturated or partially unsaturated monocyclic heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6 membered monocyclic heteroaryl-C _1-4 Al Le; or 4-8 membered saturated or partially selected from monocyclic heterocycle -C _1-4 alkyl unsaturated;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
X is O or S;
W is a covalent bond, —C≡C—, —CH═CH—, —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is (i) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (ii) C _3-10 cycloalkyl; phenyl; 5-6 membered heteroaryl; 4-8 Membered saturated or partially unsaturated heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered heteroaryl-C _1-4 alkyl; or 4-8 Tiredness Or partially selected from heterocyclic -C _1-4 alkyl unsaturated;
Here, each group in the above (ii) may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ), And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxy or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). May be);
R ³ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) hydroxy, and (d) oxo), or (iv) C _3-8 cycloalkyl, wherein the group is optionally substituted with the same or different 1-4 groups selected from: Also good:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo),
(V) C _2-6 alkenyl (wherein the group may be optionally substituted with the same or different 1 to 4 halogens),
(Vi) C _3-8 cycloalkenyl (wherein the group is optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo), and (vii) a 4-8 membered saturated or partially unsaturated monocyclic heterocycle, wherein the groups are suitably selected from: Optionally substituted with 1 to 4 different groups:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) cyano)
Selected from;
R ⁴ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens), or (iv) selected from cyano;
However, when R ¹ is hydrogen, W is —O— or —N (R ⁵ ) —, and R ⁴ is hydrogen].
Item 2. R ¹ in formula I is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens or hydroxy), and (c) hydroxyl), and (iii) C _{3- 10} cycloalkyl; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; or 4-8 membered saturated or partially Selected from unsaturated monocyclic heterocycles -C _1-4 alkyl;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (g) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
Item 1. The medicine according to Item 1.
Item 3. R ¹ in formula I is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens or hydroxy), and (c) hydroxyl),
(Iii) C _3-8 cycloalkyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (iv) ) C _3-8 cycloalkyl-C _1-4 alkyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, C _1-6 alkyl or C _1-6 alkoxy)
Selected from;
W is —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; 4-8 membered saturated or partially unsatisfied A saturated monocyclic heterocycle-C _1-4 alkyl; C _3-10 cycloalkyl; or a 4-8 membered saturated or partially unsaturated monocyclic heterocycle;
Here, each group in R ² may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ), And (h) aminocarbonyl (wherein the amino may be substituted with the same or different 1-2 C _1-6 alkyl);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxyl or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). You may)
Item 3. A medicine according to Item 1 or 2.
Item 4. R ¹ in Formula I is C _1-6 alkyl (wherein the groups may be optionally substituted with the same or different 1-3 halogens or C _1-6 alkoxy); and R ² is C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; or C _3-10 cycloalkyl;
Here, each group in R ² may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(D) cyano,
(E) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (f) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
Item 4. The pharmaceutical according to any one of Items 1 to 3.
Item 5. R ² in formula I is C _3-8 cycloalkyl-C _1-4 alkyl or C _3-8 cycloalkyl;
Here, each group may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups may optionally be substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), and (c) C _1-6 Alkoxy (wherein the radicals may be optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
Item 6. The medicine according to Item 4.
Item 6. R ¹ in formula I is C _3-10 cycloalkyl; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; Or 4-8 membered saturated or partially unsaturated monocyclic heterocycle-C _1-4 alkyl;
Here, each group may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (g) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy);
W is —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens or hydroxy), and (c) hydroxy);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with 1-4 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (e) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
Item 1. The medicine according to Item 1.
Item 7. R ¹ in formula I is C _3-8 cycloalkyl-C _1-4 alkyl; or phenyl-C _1-4 alkyl;
Here, each group may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy), and (c) C _1-6 Alkoxy (wherein the radicals may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
Item 6. The medicine according to Item 6.
Item 8. Item 8. The medicament according to any one of Items 1 to 7, wherein X in Formula I is O.
Item 9. Item 9. The medicament according to any one of Items 1 to 8, wherein W in Formula I is —O—.
Item 10. R ³ in Formula I is (i) C _1-6 alkyl (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(Ii) C _3-8 cycloalkyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl, hydroxy or C _1-6 alkoxy), and (Iii) 4-8 membered saturated or partially unsaturated monocyclic heterocycle (wherein the groups are optionally the same or different 1-4 halogen, hydroxy, C _1-6 alkyl or C _1-6 May be substituted with alkoxy)
Item 10. The pharmaceutical according to any one of Items 1 to 9, which is selected from:
Item 11. R ³ in formula I is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), tetrahydropyranyl (here And the group may be optionally substituted with the same or different 1-4 halogen, hydroxy or C _1-6 alkoxy), or dihydropyranyl.
Item 12. R ⁴ in formula I is (i) hydrogen,
(Ii) halogen, or (iii) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
Item 12. The pharmaceutical according to any one of Items 1 to 11, selected from:
Item 13. Item 13. The medicament according to any one of Items 1 to 12, wherein R ⁴ in Formula I is hydrogen.
Item 14. R ¹ in Formula I is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens or C _1-6 alkoxy);
R ² is C _3-8 cycloalkyl-C _1-4 alkyl or C _3-8 cycloalkyl; wherein each group is optionally substituted with the same or different 1-4 groups selected from: May be:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups may optionally be substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), and (c) C _1-6 Alkoxy (wherein the radicals are optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy);
X is O;
W is -O-
Item 6. The medicine according to any one of Items 1 to 5.
Item 15. Formula Ia:

[Where:
R ¹ is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens or C _1-6 alkoxy);
R ² is C _3-8 cycloalkyl-C _1-4 alkyl or C _3-8 cycloalkyl; wherein each group is optionally substituted with the same or different 1-4 groups selected from: May be:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups may optionally be substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), and (c) C _1-6 Alkoxy (wherein the radicals are optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy);
R ³ is (i) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(Ii) C _3-8 cycloalkyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl, hydroxy or C _1-6 alkoxy), and (Iii) 4-8 membered saturated or partially unsaturated monocyclic heterocycle (wherein the groups are optionally the same or different 1-4 halogen, hydroxy, C _1-6 alkyl or C _1-6 Optionally substituted with alkoxy);
R ⁴ is (i) hydrogen,
Selected from (ii) halogen, or (iii) C _1-6 alkyl, wherein the groups may be optionally substituted with 1 to 3 different halogens]
Item 2. The medicine according to Item 1, comprising a compound represented by the above or a pharmaceutically acceptable salt thereof as an active ingredient.
Item 16. Item 16. The term according to any one of Items 1 to 15, wherein R ³ in Formula I is tetrahydropyranyl (wherein the group may be optionally substituted with hydroxy) or dihydropyranyl; and R ⁴ is hydrogen. Medicine.
Item 17. The group of compounds of formula I consisting of:
2-[(4,4-Difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On (Example 1);
3- (4-Chlorobenzyl) -2-methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one ( Example 109);
3-[(4,4-Difluorocyclohexyl) methyl] -2-methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On (Example 115);
5-Chloro-2-[(4,4-difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one (Example 119);
2-{[(5-chloropyridin-2-yl) methyl] amino} -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) -On (Example 149);
3-Methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] methoxy} -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one (Example 245);
2-[(trans-4-ethoxycyclohexyl) methoxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On (Example 246);
3-Methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[cis-4- (trifluoromethyl) cyclohexyl] methoxy} -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one (Example 248);
2- (Cyclohexyloxy) -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (Examples) 255);
2-{[trans-4- (Ethoxymethyl) cyclohexyl] oxy} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) -imidazo- [5,1-f] [1,2,4 ] Triazine-4 (3H) -one (Example 256);
2-{[trans-4- (Ethoxymethyl) cyclohexyl] methoxy} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) -imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one (Example 288);
3- ( ¹³ C, ² H ₃ ) methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1- f] [1,2,4] triazin-4 (3H) -one (Example 294);
2-[(4,4-Difluorocyclohexyl) oxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On (Example 304);
3-Methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] oxy} -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one (Example 305);
3-ethyl-2-{[trans-4- (methoxymethyl) cyclohexyl] oxy} -7- (tetrahydro-2H-pyran-4-yl) -imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one (Example 317);
7- (4-Hydroxytetrahydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1-f] [1, 2,4] triazin-4 (3H) -one (Example 326); and
7- (3,6-Dihydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] methoxy} -imidazo [5,1-f] [1 , 2,4] Triazine-4 (3H) -one (Example 328)
Item 2. The medicine according to Item 1, selected from
Item 18. Item 18. A composition comprising a compound of Formula I or Ia according to any one of Items 1 to 17 and a pharmaceutically acceptable carrier, adjuvant or excipient.
Item 19. Item 18. The medicine according to any one of Items 1 to 17 for inhibiting PDE1.
Item 20. Item 20. The medicine according to any one of Items 1 to 17 or 19, for treating a neurological disorder or a mental disorder.
Item 21. Item 21. The medicine according to Item 20, wherein the neurological disorder or psychiatric disorder is Alzheimer's disease, Parkinson's disease, depression, cognitive impairment, stroke, schizophrenia, Down's syndrome or fetal alcohol syndrome.
Item 22. Item 21. The medicament according to Item 20, wherein the neurological disorder or psychiatric disorder is accompanied by a defect in one or more cognitive regions as defined by DSM-5.
Item 23. Item 16. Use of a compound of formula I or Ia according to item 1 or 15 in the manufacture of a medicament for treating a neurological or psychiatric disorder.

General Production Method The compounds according to the present invention may be produced, for example, according to the methods described in the following production methods 1 to 9. These methods may be modified as appropriate in view of ordinary general knowledge in the field of organic synthesis. Each compound used as a starting material may be used in the form of a salt thereof as necessary.

  If any functional group other than the reactive site changes under the described reaction conditions or is not preferred for the performance of the described method, the group may be protected as appropriate without the use of a protecting group, and then a series of Deprotection after completion of the reaction may provide the desired compound in subsequent steps. Examples of such protecting groups include conventional protecting groups described in literature such as TW Greene and PGM Wuts “Protective Groups in Organic Synthesis” 3rd edition, John Wiley and Sons, Inc., New York (1999). . Such protecting groups are conventionally used in the field of organic synthetic chemistry such as the method described in TW Greene and PGM Wuts “Protective Groups in Organic Synthesis” 3rd edition, John Wiley and Sons, Inc., New York (1999). The introduction and deprotection may be carried out according to the method of

Examples of bases herein include organic bases such as diisopropylethylamine, triethylamine, pyridine, lithium diisopropylamide, n-butyllithium, hexamethyldisilazane lithium, hexamethyldisilazane sodium, and hexamethyldisilazane potassium; hydrogen Sodium hydride, potassium hydride, potassium fluoride, cesium fluoride, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, sodium bicarbonate, potassium bicarbonate, phosphoric acid Inorganic bases such as potassium, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate; and sodium methoxide, sodium tert-butoxide, and potassium Metal alkoxides such as tert- butoxide and the like.
Examples of inert solvents herein include halogenated hydrocarbons such as chloroform and dichloromethane; aromatic hydrocarbons such as benzene and toluene; alcohol solvents such as methanol, ethanol, 2-propanol, and n-butanol; diethyl Ether solvents such as ether, tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane; aprotic such as acetonitrile, acetone, methyl ethyl ketone, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidinone, and dimethylsulfoxide A polar solvent; a basic solvent such as pyridine; water; and a mixed solvent thereof.
Examples of transition metals in this specification include tris (dibenzylideneacetone) dipalladium (0), tetrakis (triphenylphosphine) palladium (0), bis (tri-tert-butylphosphine) palladium (0), palladium chloride (II), palladium (II) acetate, bis (acetonitrile) palladium chloride (II), bis (triphenylphosphine) palladium chloride (II), dichlorobis (tri-O-tolylphosphine) palladium (II), and [1, 1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II). One of the transition metals may be used alone or in combination with a copper catalyst such as copper (I) iodide.
Examples of ligands herein include triphenylphosphine, tri-O-tolylphosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 1,1′-bis (diphenylphosphino) ferrocene, 2,2-bis. (Diphenylphosphino) -1,1′-binaphthyl, 2-dicyclohexylphosphino-2 ′, 6′-dimethoxybiphenyl, 2-dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl, and 2- And dicyclohexylphosphino-2 ′, 6′-diisopropoxybiphenyl.
Examples of the halogenating agent in the present specification include phosphorus oxychloride, phosphorus oxybromide, oxalyl chloride, N-chlorosuccinimide, and N-bromosuccinimide.
Examples of the sulfonylating agent in the present specification include p-toluenesulfonyl chloride and methylsulfonyl chloride.

式中、Ｒ^１、Ｒ^２、Ｒ^３、Ｒ^４、及びＲ^５は本明細書に定義されるとおりであり、ＬＧはヨウ素原子、臭素原子、塩素原子、及び置換スルホニルオキシ基（例えばメタンスルホニルオキシ基、ｐ−トルエンスルホニルオキシ基）などの脱離基を示す。 Manufacturing method 1
Among the compounds of formula (1), the compounds of formulas (1-5) and (1-6) may be produced, for example, by the following method.

Wherein R ¹ , R ² , R ³ , R ⁴ , and R ⁵ are as defined herein, LG is an iodine atom, a bromine atom, a chlorine atom, and a substituted sulfonyloxy group (eg, methanesulfonyl) And a leaving group such as an oxy group or a p-toluenesulfonyloxy group.

Step 1-1: Production of Compound (1-5) Compound (1-5) is produced by substitution reaction of compound (1-2) with compound (A) in the presence of a base in a suitable inert solvent. May be. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

  Compound (1-5) may also be produced by Mitsunobu reaction between compound (1-2) and alcohol (B) in a suitable inert solvent. The reaction may proceed specifically in the presence of a Mitsunobu reagent such as a combination of triphenylphosphine and diethyl azodicarboxylate, a combination of triphenylphosphine and diisopropyl azodicarboxylate, or a cyanomethylenephosphorane reagent. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 1-2: Production of Compound (1-5) Compound (1-5) can also be produced by substitution reaction of compound (1-3) with alcohol (C) in the presence of a base in an appropriate inert solvent. May be. You may perform reaction in presence of an additive suitably. The reaction temperature is generally in the range of about -20 ° C to about 100 ° C. The reaction time varies depending on the reaction temperature, the base used in this step, the starting material, the solvent, and the like, and is generally in the range of 10 minutes to 96 hours. Additives used in this step include crown ethers such as 12-crown-4, 15-crown-5, and 18-crown-6; and salts such as sodium iodide and potassium iodide.

Step 1-3: Production of Compound (1-6) Compound (1-6) is prepared by subjecting compound (1-4) to substitution reaction with compound (A) or alcohol (B) under the same reaction conditions as in Step 1-1. ) And Mitsunobu reaction.

Step 1-4: Production of Compound (1-6) Compound (1-6) may also be produced by substitution reaction of compound (1-3) with amine (D) in a suitable inert solvent. . The reaction may proceed appropriately in the presence of a base, an additive and the like. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours. Examples of additives used in this step include sodium iodide and potassium iodide.

  Compound (1-6) may also be produced by a coupling reaction between compound (1-3) and amine (D) in the presence of a transition metal catalyst and a base in a suitable inert solvent. The reaction may proceed appropriately in the presence of a ligand. The reaction temperature is generally in the range of about -20 ° C to about 200 ° C. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 1-5: Production of Compound (1-2) Compound (1-2) is produced by a substitution reaction of compound (1-1) with alcohol (C) under the same reaction conditions as in Step 1-2. Also good.

Step 1-6: Production of Compound (1-4) Compound (1-4) is produced by substitution reaction of compound (1-1) with amine (D) under the same reaction conditions as in step 1-4. Also good.

Step 1-7: Production of Compound (1-3) Compound (1-3) is prepared by subjecting compound (1-1) to substitution reaction with compound (A) or alcohol (B) under the same reaction conditions as in Step 1-1. ) And Mitsunobu reaction.

式中、Ｒ^１、Ｒ^２、Ｒ^３、Ｒ^４、及びＬＧは本明細書に定義されるとおりであり、Ｚはボロン酸基（−Ｂ（ＯＨ）_２）、ボロン酸エステル基（例えばボロン酸ピナコールエステル）、有機ボリル基（例えば−Ｂ（Ｅｔ）_３）、有機スズ基（例えば−Ｓｎ（ｎ−Ｂｕ）_３）、ハロゲン化亜鉛（例えばＺｎＣｌ、ＺｎＢｒ）、ハロゲン化マグネシウム（例えばＭｇＣｌ、ＭｇＢｒ）を指す。 Manufacturing method 2
Among the compounds of formula (1), the compounds of formulas (2-1) and (2-2) may be produced, for example, by the following method.

Wherein R ¹ , R ² , R ³ , R ⁴ , and LG are as defined herein, Z is a boronic acid group (—B (OH) ₂ ), a boronic ester group (eg, boron Acid pinacol ester), organoboryl group (eg -B (Et) ₃ ), organotin group (eg -Sn (n-Bu) ₃ ), zinc halide (eg ZnCl, ZnBr), magnesium halide (eg MgCl, MgBr).

Step 2-1: Production of Compound (2-1) Compound (2-1) is a coupling of compound (1-3) and compound (E) in the presence of a transition metal catalyst in a suitable inert solvent. You may manufacture by reaction. The reaction may proceed appropriately in the presence of a ligand, base and the like. The reaction temperature is generally in the range of about -20 ° C to about 200 ° C. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 2-2: Production of Compound (2-2) Compound (2-2) is a coupling of compound (1-3) and compound (F) in the presence of a transition metal catalyst in a suitable inert solvent. You may manufacture by reaction. The reaction may proceed appropriately in the presence of a ligand, base and the like. The reaction temperature is generally in the range of about -20 ° C to about 200 ° C. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

式中、Ｒ^１、Ｒ^２、Ｒ^３、Ｒ^４、ＬＧ、及びＺは本明細書に定義されるとおりである。
化合物（３−１）は、工程２−１と同様の反応条件下、化合物（１−３）と化合物（Ｇ）とのカップリング反応により製造してもよい。 Manufacturing method 3
Among the compounds of formula (1), the compound of formula (3-1) may be produced, for example, by the following method.

Wherein R ¹ , R ² , R ³ , R ⁴ , LG, and Z are as defined herein.
Compound (3-1) may be produced by a coupling reaction between compound (1-3) and compound (G) under the same reaction conditions as in Step 2-1.

式中、Ｒ^１、Ｒ^２、Ｒ^３、及びＲ^４は本明細書に定義されるとおりである。
化合物（１−５）は、工程１−１と同様の反応条件下、化合物（４−１）のアルコール（Ｃ）との光延反応により製造してもよい。 Manufacturing method 4
Among the compounds of formula (1), the compound of formula (1-5) may be produced, for example, by the following method.

Wherein R ¹ , R ² , R ³ , and R ⁴ are as defined herein.
Compound (1-5) may be produced by Mitsunobu reaction of compound (4-1) with alcohol (C) under the same reaction conditions as in Step 1-1.

式中、Ｒ^１、Ｒ^２、Ｒ^３、Ｒ^４、及びＲ^５は本明細書に定義されるとおりであり、ＬＧはヨウ素原子、臭素原子、塩素原子、及び置換スルホニルオキシ基（例えばメタンスルホニル基、ｐ−トルエンスルホニル基）などの脱離基を示す。 Manufacturing method 5
Among the compounds of formula (1), the compounds of formulas (5-2) and (5-3) may be produced, for example, by the following method.

Wherein R ¹ , R ² , R ³ , R ⁴ , and R ⁵ are as defined herein, LG is an iodine atom, a bromine atom, a chlorine atom, and a substituted sulfonyloxy group (eg, methanesulfonyl) Group, p-toluenesulfonyl group) and the like.

Step 5-1: Preparation of Compound (5-2) Compound (5-2) is prepared by substituting compound (5-1) with alcohol (C) under the same reaction conditions as in Step 1-2. Also good.

Step 5-2: Production of Compound (5-3) Compound (5-3) is produced by substitution reaction of compound (5-1) with amine (D) under the same reaction conditions as in Step 1-4. Also good.

式中、Ｒ^３、Ｒ^４、及びＬＧは本明細書に定義されるとおりであり、Ｑ^１はＣ_１−６アルキルを示し、Ａｒは適宜置換されていてもよいフェニルを示す。 Manufacturing method 6
The compound of formula (1-1) may be produced, for example, by the following method.

In the formula, R ³ , R ⁴ , and LG are as defined in this specification, Q ¹ represents C _1-6 alkyl, and Ar represents optionally substituted phenyl.

Step 6-1: Production of Compound (1-1) Compound (1-1) may be produced by reacting compound (6-5) with a base in a suitable inert solvent. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 6-2: Production of Compound (6-5) Compound (6-5) may be produced by reacting compound (6-4) with a halogenating agent or a sulfonylating agent. The reaction may proceed appropriately in the presence of a base, an inert solvent or the like. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 6-3: Production of Compound (6-4) Compound (6-4) may be produced by reacting compound (6-3) in the presence of a base in a suitable inert solvent. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 6-4: Production of Compound (6-3) Compound (6-3) may be produced by reacting compound (6-2) with isocyanate (H) in a suitable inert solvent. The reaction may proceed appropriately in the presence of a base. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 6-5: Production of Compound (6-2) Compound (6-2) may be produced by reacting compound (6-1) with an aminating agent in a suitable inert solvent. The reaction may proceed appropriately in the presence of a base. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours. Examples of the aminating agent used in this step include 2-[(aminooxy) sulfonyl] -1,3,5-trimethylbenzene and O- (diphenylphosphoryl) -hydroxylamine.

式中、Ｒ^１、Ｒ^３、Ｒ^４、ＬＧ及びＱ^１は本明細書に定義されるとおりである。 Manufacturing method 7
The compounds of formulas (1-3), (4-1) and (5-1) may be produced, for example, by the following method.

In which R ¹ , R ³ , R ⁴ , LG and Q ¹ are as defined herein.

Step 7-1: Production of Compound (1-3) Compound (1-3) is produced by halogenating or sulfonylating compound (4-1) under the same reaction conditions as in Step 6-2. Also good.

Step 7-2: Production of Compound (4-1) Compound (4-1) may be produced by reacting compound (7-2) with a carbonylating agent in a suitable inert solvent. The reaction may proceed appropriately in the presence of a base. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours. Examples of the carbonylating agent used in this step include carbonyldiimidazole, triphosgene, and di (N-succinimidyl) carbonate.

Step 7-3: Production of Compound (5-1) Compound (5-1) may be produced by reacting compound (7-2) with compound (I). The reaction may proceed appropriately in the presence of a base and an inert solvent. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 7-4: Production of Compound (7-2) Compound (7-2) is prepared by reacting compound (7-1) with amine (J) in the presence of a condensing agent and an appropriate base in an inert solvent. The amine (J) may be reacted with an acid halide or acid anhydride derived from the compound (7-1) in the presence of a base in an inert solvent. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

  Examples of the condensing agent used in this step include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide (WSC), benzotriazol-1-yl- Tris (dimethylamino) phosphonium hexafluorophosphate (BOP), diphenylphosphonyl diamide (DPPA), N, N-carbonyldiimidazole (CDI), and O- (7-aza-benzotriazol-1-yl)- N, N, N ′, N′-tetramethyluronium hexafluorophosphate (HATU) may be mentioned. The reaction is optionally further such as N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), and 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOOBt). It may proceed with the additive.

Step 7-5: Production of Compound (7-2) Compound (7-2) may also be produced by reacting compound (6-2) with amine (J) in a suitable inert solvent. . The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 7-6: Production of Compound (7-1) Compound (7-1) may be produced by hydrolyzing compound (6-2) under the same reaction conditions as in Step 6-1.

式中、Ｒ^１、Ｒ^２、Ｒ^４、及びＷは本明細書に定義されるとおりであり、Ｑ^２及びＱ^３は独立して水素原子又は適宜置換されていてもよいＣ_１−６アルキルを示すか、或いはＱ^２及びＱ^３はそれらが結合する炭素原子と一緒になって適宜置換されていてもよい飽和炭素環、不飽和炭素環、飽和ヘテロ環又は不飽和ヘテロ環を形成してもよい。 Manufacturing method 8
Among the compounds of formula (1), the compounds of formulas (8-2) and (8-3) may be prepared, for example, by the following method.

Wherein R ¹ , R ² , R ⁴ , and W are as defined herein, and Q ² and Q ³ are independently a hydrogen atom or an optionally substituted C _1-6 alkyl. Or Q ² and Q ³ together with the carbon atom to which they are attached form a saturated carbocyclic, unsaturated carbocyclic, saturated heterocyclic or unsaturated heterocyclic ring that may be optionally substituted. Also good.

Step 8-1: Production of Compound (8-3) Compound (8-3) is obtained by reacting compound (8-2) with a halogenating agent or sulfonylating agent in the presence of a base in an appropriate inert solvent. You may manufacture by. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

Step 8-2: Production of Compound (8-2) Compound (8-2) is produced by reacting compound (8-1) with compound (K) in the presence of a base in a suitable inert solvent. May be. The reaction temperature is generally in the range of about −100 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

式中、Ｒ^１、Ｒ^２、Ｒ^４、及びＷは本明細書に定義されるとおりであり、Ａはハロゲン原子を示し、Ｑ^４及びＱ^５は独立して水素原子又は適宜置換されていてもよいＣ_１−６アルキルを示すか、或いはＱ^４及びＱ^５はそれらが結合する窒素原子と一緒になって適宜置換されていてもよい飽和ヘテロ環又は部分的に不飽和のヘテロ環を形成してもよい。 Manufacturing method 9
Among the compounds of formula (1), the compounds of formulas (9-1) and (9-2) may be produced, for example, by the following method.

Wherein R ¹ , R ² , R ⁴ , and W are as defined herein, A represents a halogen atom, and Q ⁴ and Q ⁵ are independently hydrogen atoms or optionally substituted. ^May represent C _1-6 alkyl, or Q ⁴ and Q ⁵ together with the nitrogen atom to which they are attached form a saturated or partially unsaturated heterocycle that may be optionally substituted May be.

Step 9-1: Production of Compound (9-2) Compound (9-2) is a reaction for substitution or coupling of compound (6-2) with amine (L) under the same reaction conditions as in Step 1-4. You may manufacture by doing.

Step 9-2: Production of Compound (9-1) Compound (9-1) may be produced by reacting compound (8-1) with a halogenating agent in a suitable inert solvent. The reaction may proceed in the presence of a base. The reaction temperature is generally in the range of about −20 ° C. to the boiling point of the solvent used in this step. The reaction time varies depending on conditions such as reaction temperature, base used in this step, starting materials, and solvent, and is generally in the range of 10 minutes to 48 hours.

  Each intermediate and desired compound in each production method is isolated according to conventional purification methods used in the field of synthetic organic chemistry such as neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and various chromatography. And may be purified. Each intermediate may be used in the next step without purification.

  The optically active compounds in the present invention may be prepared by starting from a suitable optically active material or intermediate or by optical resolution of the final racemic product. Optical resolution includes physical separation methods using optically active columns and chemical separation methods such as fractional crystallization. The diastereomers of the compounds of the invention may be prepared, for example, by fractional crystallization.

  A pharmaceutically acceptable salt of the compound of formula (1) is obtained by mixing the compound of formula (1) with a pharmaceutically acceptable acid in a solvent such as water, methanol, ethanol, and acetone. It may be manufactured.

  As described in the following examples, the compounds are prepared according to the following procedures in some exemplary embodiments. Although the synthesis of some compounds of the present invention is shown as a general method, the following methods and other methods known to those skilled in the art include all compounds described herein as well as subclasses and species of each compound. It will be appreciated that it can be applied.

  In the following examples, all temperatures are given in degrees Celsius, and all parts and percentages are by weight unless otherwise specified. Reagents were purchased from suppliers such as Sigma-Aldrich Chemical Company and used without further purification unless otherwise specified. Reagents were prepared according to the following standard literature known to those skilled in the art. The solvent was purchased from Aldrich in a Sure / Seal bottle and used as it was. All solvents that required purification or drying were processed using standard methods known to those skilled in the art unless otherwise specified.

The reactions shown below were generally performed at room temperature unless otherwise specified. A rubber septum was attached to the reaction flask to introduce the substrate and reagents through a syringe. Analytical thin layer chromatography (TLC) was performed using a glass-backed silica gel pre-coated plate (Merck Art 5719) and eluted with an appropriate solvent ratio (v / v). The reaction was assayed by TLC or LCMS and completed as judged by consumption of starting material. Appropriate TLC plate visualization was performed with UV light (254 wavelengths) or with a suitable TLC visualization solvent such as heat activated basic KMnO ₄ aqueous solution. Flash column chromatography (eg Still et al., J. Org. Chem., 43: 2923 (1978)) was performed using silica gel 60 (Merck Art 9385) or various MPLC systems. Reactions under microwave irradiation conditions were carried out in the Biotaj microwave equipment initiator.

The compound structure in the following examples was confirmed by one or more of the following methods: proton magnetic resonance spectroscopy, mass spectrometry, and melting point. Proton magnetic resonance spectroscopy ( ¹ H NMR) spectra were measured by operating a JEOL or Bruker NMR spectrometer at 300 or 400 MHz magnetic field strength. Chemical shifts are reported as delta (δ) values obtained in parts per million (ppm) relative to internal standards such as tetramethylsilane (TMS). Alternatively, ¹ H NMR spectra referenced signals from residual protons in the following heavy solvents: CDCl ₃ = 7.25 ppm; DMSO-d ₆ = 2.49 ppm; C ₆ D ₆ = 7.16 ppm; CD ₃ OD = 3.30 ppm . Peak multiplicity is shown as follows: s, singlet; d, doublet; dd, doublet doublet; t, triplet; dt, doublet triplet; q, quadruplet; Sext, hexat; sept, heptad; br, broad; and m, multiple. The coupling constant is obtained in hertz (Hz). Mass spectral (MS) data was obtained using Agilent Technologies 1200 Series / Agilent Technologies 6110 Quadrupole LC / MS, Waters ACQUITY UPLC or Shimadzu LCMS-2020. Chiral compounds were separated by the following method using Waters supercritical fluid system (SFC).

Method A:
Column: AD-H (4.6 x 250 mm, 5μm)
Cosolvent: MeOH (0.5% DEA)
Column temperature: 40 ° C
CO ₂ flow rate: 2.55 mL / min Cosolvent flow rate: 0.45 mL / min

Method B:
Column: OZ-H (4.6 x 250 mm, 5μm)
Cosolvent: MeOH (0.1% DEA)
Column temperature: 40 ° C
CO ₂ flow rate: 1.95 mL / min Cosolvent flow rate: 1.05 mL / min

  Here, unless otherwise specified, “Me” means methyl, “Et” means ethyl, “Pr” means propyl, “Bu” means butyl, “Ms” means mesyl. “Ac” means acetyl, “BINAP” means 2,2-bis (diphenylphosphino) -1,1′-binaphthyl, “Boc” means tert-butoxycarbonyl, “CDI” means carbonyldiimidazole, “DCM” means dichloromethane, “DEAD” means diethyl azodicarboxylate, “DIAD” means diisopropyl azodicarboxylate, “DIEA” means Diisopropylethylamine means “DME” means dimethoxyethane, “DMF” means dimethylformamide, “DMSO” means dimethyl sulfoxide, “dppf” means 1,1′-bis (diphenylphosphino ) Means ferrocene, `` EtOAc '' means ethyl acetate, `` EtOH '' means ethanol, `` HATU '' means O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium Means hexafluorophosphate, “IPA” means isopropanol, “KHMDS” means potassium bis (trimethylsilyl) amide, “LDA” means lithium diisopropylamide, “LiHMDS” means lithium bis ( `` MeCN '' means acetonitrile, `` MeOH '' means methanol, `` NBS '' means N-bromosuccinimide, `` NCS '' means N-chlorosuccinimide, "NIS" means N-iodosuccinimide, "NMP" means N-methylpyrrolidone, "PE" means petroleum ether, "RT" or "rt" means room temperature, "Ruphos" means 2-dicyclohexylphosphino-2 ', 6'-diisopropoxy-1,1'-biphenyl means `` TEA' 'means triethylamine, `` TFA' 'means trifluoroacetic acid, `` THF' 'means tetrahydrofuran, `` X -phos "means (2 ', 4', 6'-triisopropylbiphenyl-2-yl) phosphine," h "or" hr "means hours," min "means minutes, "cat." means catalyst and "aq" means aqueous.

2,4-ジクロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン（1.2 g）のテトラヒドロフラン（20 mL）溶液に2N KOH（20 mL）を加えた。混合物を50℃にて2時間撹拌した後、1N HClで中和した。混合物をろ過し、表題化合物（0.78 g, 収率70%）を得た。
LC-MS (m/z) = 255 [M + H]⁺. ¹H-NMR (400 MHz, DMSO-d₆): δ1.79-1.88 (m, 4H), 3.34-3.38 (m, 1H), 3.46-3.53 (m, 2H), 3.91-3.95 (m, 2H), 7.76 (s, 1H), 13.01 (br, 1H). Reference Example 1: 2-Chloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

To a solution of 2,4-dichloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine (1.2 g) in tetrahydrofuran (20 mL) was added 2N KOH ( 20 mL) was added. The mixture was stirred at 50 ° C. for 2 hours and then neutralized with 1N HCl. The mixture was filtered to obtain the title compound (0.78 g, yield 70%).
LC-MS (m / z) = 255 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.79-1.88 (m, 4H), 3.34-3.38 (m, 1H) , 3.46-3.53 (m, 2H), 3.91-3.95 (m, 2H), 7.76 (s, 1H), 13.01 (br, 1H).

2- (Tetrahydro-2H-pyran-4-yl) -5- (trifluoromethyl) -1H-imidazole:
A mixture of sodium acetate trihydrate (27.2 g, 200 mmol) and 3,3-dibromo-1,1,1-trifluoropropan-2-one (26.98 g, 100 mmol) in water (75 ml) Heated under reflux for 1 hour. The mixture was then cooled to room temperature and slowly added to a solution of tetrahydro-2H-pyran-4-carbaldehyde (90 mmol, 10.27 g) and concentrated ammonium hydroxide solution (50 mL) in MeOH (150 mL). After the mixture was stirred at room temperature for 18 hours, the solvent was distilled off under reduced pressure. The aqueous residue was extracted with EtOAc (150 mL x 3) and the collected organic solution was dried over magnesium sulfate and concentrated in vacuo to give an oil. The oil was then triturated in water containing a small amount of MeOH to give the title compound as a crystalline solid (19.8 g, 90% yield). LC-MS (m / z) = 221 [M + H] ⁺ .

Methyl 2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate:
To a solution of 2- (tetrahydro-2H-pyran-4-yl) -5- (trifluoromethyl) -1H-imidazole (85 mmol) in MeOH (200 mL) was added NaOH solution (2.7 M, 50 mL) and the mixture Was stirred at 95 ° C. overnight. Concentrated HCl (25 mL) was then added. The mixture was stirred at that temperature for 4 hours. EtOAc (250 mL) was added to the reaction vessel and the resulting biphasic mixture was transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with EtOAc (150 mL x 3). The collected organics were dried over anhydrous Na ₂ SO ₄ , filtered and concentrated under reduced pressure to give the title compound as a solid (16.5 g, 80% yield).
LC-MS (m / z) = 210 [M + H] ⁺

Methyl 1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate:
To a solution of methyl 2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate (70 g, 0.34 mol) in DCM (250 mL) was added 2-[(aminooxy) sulfonyl] -1, 3,5-Trimethylbenzene (110 g, 0.51 mol) and K ₂ CO ₃ (94 g, 0.64 mol) were added. The reaction mixture was cooled to 0 ° C. and stirred at that temperature for 15 hours. Water (50 mL) was added to the reaction vessel and the resulting biphasic mixture was transferred to a separatory funnel. The layers were separated. The collected organics were dried over anhydrous Na ₂ SO ₄ , filtered and concentrated under reduced pressure. The obtained solid was purified by flash column chromatography to obtain the title compound as a white solid (25 g, yield 35%). LC-MS (m / z) = 225 [M + H] ⁺

Methyl 1-[(benzoylcarbamoyl) amino] -2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate:
Methyl 1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate (5 g, 22.2 mmol) in THF (75 mL) in benzoyl isocyanate (3.59 g, 24.42 mmol) ) Was added. The reaction mixture was heated to reflux and stirred at that temperature for 12 hours. The collected organic matter was concentrated under reduced pressure to obtain the title compound (5 g, yield 80%).
LC-MS (m / z) = 373 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.67-1.88 (m, 4H), 3.04-3.12 (m, 1H) , 3.40-3.46 (m, 2H), 3.71 (s, 3H), 3.89-3.94 (m, 2H), 7.56-7.60 (m, 2H), 7.67-7.71 (m, 2H), 8.06-8.08 (m, 2H), 11.19 (s, 1H), 11.34 (s, 1H).

7- (Tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dionemethyl 1-[( benzoylcarbamoyl ) amino] To a solution of -2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate (5 g, 13.43 mmol) in methanol (45 mL) was added potassium carbonate (2.23 g, 16.11 mmol). . The collected organic matter was concentrated under reduced pressure. Water (20 mL) was added to the reaction. The mixture was neutralized with 1N HCl, filtered and washed with MeOH to give the title compound (1.8 g, 56% yield).
LC-MS (m / z) = 237 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.75-1.85 (m, 4H), 3.32-3.35 (m, 1H) , 3.38-3.49 (m, 2H), 3.92-3.95 (m, 2H), 7.50 (br, 1H), 7.74 (s, 1H), 11.15 (s, 1H).

2,4-Dichloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine:
7- (Tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione (1.8 g) phosphoryl trichloride (20 mL) and N, N-diisopropylethylamine (1.48 g) was stirred at 120 ° C. for 3 hours. When the pH was adjusted to 7-8, a white precipitate formed. After filtration, the title compound was collected as a yellow solid (1.2 g, 60% yield).
LC-MS (m / z) = 273 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.24-1.31 (m, 2H), 1.82-1.87 (m, 2H) , 3.40-3.54 (m, 1H), 3.47-3.54 (m, 2H), 3.92-3.96 (m, 2H), 7.88 (s, 1H).

The compounds of Reference Examples 2 to 4 were synthesized in the same manner as Reference Example 1.

2-クロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（10.0 g, 39.3 mmol）及び炭酸セシウム（20.8 g, 63.8 mmol）をDMF（50 mL）に溶解し、60℃まで加熱した。ヨウ化エチル（5.3 mL, 51.5 mmol）を滴下し、60℃で２時間撹拌した。反応混合物を濾紙でろ過し、ろ過ケーキをクロロホルムで洗浄し、濃縮した。水、飽和NH₄Cl水溶液及びEtOAcを加え、有機層を分離した。水層をEtOAc（200 mL x 5）及びクロロホルム（150 mL x 2）で抽出した。有機層を集め、硫酸ナトリウムで乾燥し、溶媒を留去した。樹脂をイソプロピルエーテルで洗浄し、表題化合物（9.45 g, 収率85%）を黄色固体として得た。
¹H-NMR (400 MHz, CDCl₃): δ1.36 (t, J = 7.1 Hz, 3H), 1.88-1.93 (m, 2H), 2.03-2.13 (m, 2H), 3.41 (tt, J = 11.7, 3.9 Hz, 1H), 3.59 (td, J = 11.7, 2.2 Hz, 2H), 4.09 (dq, J = 11.7, 2.2 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 7.83 (s, 1H). Reference Example 5: 2-Chloro-3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

2-Chloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (10.0 g, 39.3 mmol) and cesium carbonate (20.8 g, 63.8 mmol) was dissolved in DMF (50 mL) and heated to 60 ° C. Ethyl iodide (5.3 mL, 51.5 mmol) was added dropwise, and the mixture was stirred at 60 ° C. for 2 hours. The reaction mixture was filtered through filter paper, and the filter cake was washed with chloroform and concentrated. Water, saturated aqueous NH ₄ Cl and EtOAc were added and the organic layer was separated. The aqueous layer was extracted with EtOAc (200 mL x 5) and chloroform (150 mL x 2). The organic layer was collected and dried over sodium sulfate, and the solvent was distilled off. The resin was washed with isopropyl ether to give the title compound (9.45 g, yield 85%) as a yellow solid.
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.36 (t, J = 7.1 Hz, 3H), 1.88-1.93 (m, 2H), 2.03-2.13 (m, 2H), 3.41 (tt, J = 11.7, 3.9 Hz, 1H), 3.59 (td, J = 11.7, 2.2 Hz, 2H), 4.09 (dq, J = 11.7, 2.2 Hz, 2H), 4.23 (q, J = 7.2 Hz, 2H), 7.83 ( s, 1H).

2-クロロ-7-(1-メトキシエチル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（533 mg, 2.38 mmol）の無水THF（30 mL）溶液を1M LiHMDS（3.5 ml, 3.53 mmol）に0℃で窒素雰囲気下加えた。MeI（1.0 g, 7.14 mmol）を0℃で１０分間、溶液の上方に加えた。反応物を50℃に２時間加熱した。反応物を室温まで冷却した後、飽和NH₄Cl（100 mL）を加えて反応を停止させた。粗生成物を水からEtOAc（30 mL x 4）により抽出した後、シリカゲルカラムで精製し、表題化合物（280 mg, 収率50%）を得た。
LC-MS (m/z) = 243 [M + H]⁺. ¹H-NMR (400 MHz, DMSO-d₆): δ1.66 (d, J = 6.4 Hz, 3H), 3.34 (s, 3H), 3.65 (s, 3H), 4.94 (q, J = 5.0 Hz, 1H), 7.91 (s, 1H). Reference Example 6: 2-Chloro-7- (1-methoxyethyl) -3-methylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

2-Chloro-7- (1-methoxyethyl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (533 mg, 2.38 mmol) in anhydrous THF (30 mL) Was added to 1M LiHMDS (3.5 ml, 3.53 mmol) at 0 ° C. under a nitrogen atmosphere. MeI (1.0 g, 7.14 mmol) was added above the solution at 0 ° C. for 10 minutes. The reaction was heated to 50 ° C. for 2 hours. The reaction was cooled to room temperature and then quenched with saturated NH ₄ Cl (100 mL). The crude product was extracted from water with EtOAc (30 mL × 4) and then purified on a silica gel column to give the title compound (280 mg, yield 50%).
LC-MS (m / z) = 243 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.66 (d, J = 6.4 Hz, 3H), 3.34 (s, 3H ), 3.65 (s, 3H), 4.94 (q, J = 5.0 Hz, 1H), 7.91 (s, 1H).

2-クロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（1.02 g, 4 mmol）、トリフェニルホスフィン（1.36 g, 5.2 mmol）及び4,4-ジフルオロシクロヘキシルメタノール（783 mg, 5.2 mmol）のDCM（10 mL）中の混合物にDEAD（1.05 g, 5.2 mmol）を室温で加えた。１時間撹拌した後、混合物を減圧濃縮し、シリカゲルカラムクロマトグラフィー（ヘキサン/EtOAc）で精製し、表題化合物（671 mg, 収率43%）を得た。
LC-MS (m/z) = 387 [M + H]⁺. Reference Example 7: 2-chloro-3-[(4,4-difluorocyclohexyl) methyl] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one:

2-Chloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (1.02 g, 4 mmol), triphenyl To a mixture of phosphine (1.36 g, 5.2 mmol) and 4,4-difluorocyclohexylmethanol (783 mg, 5.2 mmol) in DCM (10 mL) was added DEAD (1.05 g, 5.2 mmol) at room temperature. After stirring for 1 hour, the mixture was concentrated under reduced pressure and purified by silica gel column chromatography (hexane / EtOAc) to obtain the title compound (671 mg, yield 43%).
LC-MS (m / z) = 387 [M + H] ⁺ .

The compounds of Reference Examples 8 to 20 were synthesized in the same manner as Reference Example 5, 6 or 7.

3-シクロプロピル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-2,4(1H,3H)-ジオン（200 mg, 0.724 mmol）の三塩化ホスホリル（0.8 mL）及びDIEA（0.16 mL, 0.941 mmol）溶液を100℃で２２時間撹拌した。完了後、反応混合物を氷水に注いだ。NaOH水溶液で中和した後、水層をEtOAcで抽出した。集めた有機層をNa₂SO₄で乾燥し、減圧濃縮した。得られた化合物をさらなる精製をせずに次の反応に用いた（157 mg, 収率74%）。
LC-MS (m/z) = 295 [M + H]⁺. Reference Example 21: 2-Chloro-3-cyclopropyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

3-Cyclopropyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione (200 mg, 0.724 mmol) in phosphoryl trichloride (0.8 mL) and DIEA (0.16 mL, 0.941 mmol) were stirred at 100 ° C. for 22 hours. After completion, the reaction mixture was poured into ice water. After neutralization with aqueous NaOH solution, the aqueous layer was extracted with EtOAc. The collected organic layer was dried over Na ₂ SO ₄ and concentrated under reduced pressure. The obtained compound was used in the next reaction without further purification (157 mg, yield 74%).
LC-MS (m / z) = 295 [M + H] ⁺ .

1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylic acid:
Of methyl 1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate (1 g, 4.44 mmol) and lithium hydroxide monohydrate (279 mg, 6.66 mmol) A solution of THF (5 mL) and H ₂ O (1.5 mL) was stirred at room temperature for 1 hour. After completion, an aqueous HCl solution was added to adjust the pH to 6-7 at 0 ° C. and a white precipitate formed. After filtration, the title compound was collected as a white solid (540 mg, 57% yield). LC-MS (m / z) = 212 [M + H] ⁺ .

1-amino-N-cyclopropyl-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxamide:
1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylic acid (422 mg, 2.0 mmol), cyclopropylamine (0.21 mL, 3.0 mmol) and DIEA (1.6 mL, To a mixture of 9.0 mmol) DCM (6 mL) was added HATU (1.14 g, 3.0 mmol) at room temperature. After stirring for 1 hour, the mixture was purified by silica gel column chromatography (chloroform / MeOH) to obtain the title compound (382 mg, yield 76%). LC-MS (m / z) = 251 [M + H] ⁺ .

3-Cyclopropyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione:
1-amino-N-cyclopropyl-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxamide (310 mg, 1.24 mmol) and CDI (302 mg, 1.86 mmol) MeCN (6 mL) The solution was stirred at 70 ° C. for 2 h. The mixture was diluted with EtOAc at 0 ° C., and the obtained precipitate was filtered to give the title compound (197 mg, yield 57%). LC-MS (m / z) = 277 [M + H] ⁺ .

MeOH（41 ml, 1.02 mmol）のTHF（4 mL）中の混合物にNaH（103 mg, 2.36 mmol）を室温で加え、混合物を10分間撹拌した。次いで、2-クロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（200 mg, 0.787 mmol）を混合物に加え、60℃で終夜撹拌した。Na₂SO₄ 10H₂Oで反応を停止させ、ろ過し、減圧濃縮した。得られた化合物をさらなる精製をせずに次の反応に用いた。LC-MS (m/z) = 251 [M + H]⁺. Reference Example 22: 2-methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

To a mixture of MeOH (41 ml, 1.02 mmol) in THF (4 mL) was added NaH (103 mg, 2.36 mmol) at room temperature and the mixture was stirred for 10 minutes. Then 2-chloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (200 mg, 0.787 mmol) Added to the mixture and stirred at 60 ° C. overnight. The reaction was quenched with Na ₂ SO ₄ 10H ₂ O, filtered and concentrated under reduced pressure. The obtained compound was used in the next reaction without further purification. LC-MS (m / z) = 251 [M + H] ⁺ .

2-クロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（1.0 g, 3.93 mmol）及びピロリジン（2.0 mL）の溶液を100℃で窒素雰囲気下6時間加熱した。完了後、反応混合物を飽和塩化アンモニウム水溶液で希釈し、クロロホルムで抽出した。集めた有機抽出物を硫酸ナトリウムで乾燥し、ろ過し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（クロロホルム／MeOH）で精製し、表題化合物（1.13 g, 収率99%）を白色固体として得た。
LC-MS (m/z) = 290 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.93-1.96 (m, 2H), 2.05-2.16 (m, 6H), 3.33-3.40 (m, 1H), 3.51-3.62 (m, 6H), 4.07-4.11 (m, 2H), 7.75 (s, 1H), 9.10 (br s, 1H). Reference Example 23: 2- (Pyrrolidin-1-yl) -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

2-Chloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (1.0 g, 3.93 mmol) and pyrrolidine ( 2.0 mL) was heated at 100 ° C. under a nitrogen atmosphere for 6 hours. After completion, the reaction mixture was diluted with saturated aqueous ammonium chloride and extracted with chloroform. The collected organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform / MeOH) to give the title compound (1.13 g, yield 99%) as a white solid.
LC-MS (m / z) = 290 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.93-1.96 (m, 2H), 2.05-2.16 (m, 6H), 3.33 -3.40 (m, 1H), 3.51-3.62 (m, 6H), 4.07-4.11 (m, 2H), 7.75 (s, 1H), 9.10 (br s, 1H).

1-アミノ-2-シクロペンチル-N-メチル-1H-イミダゾール-5-カルボキサミド（1.70 g, 8.2 mmol）の2-クロロアセチルクロリド（3 mL）溶液を窒素下、80℃で3時間撹拌した。室温まで冷却した後、NaHCO₃水溶液（10 mL）で反応を停止させ、DCM（10 ml×3）で抽出した。集めた有機層を乾燥し、減圧濃縮した。残渣をシリカゲルクロマトグラフィー（5% MeOH／DCMで溶出）で精製し、表題化合物（1.3 g, 収率59%）を茶色油状物として得た。
¹H-NMR (400 MHz, CD₃OD): δ1.75-1.94 (m, 6H), 2.10-2.18 (m, 2H), 3.64-3.70 (m, 4H), 4.77 (s, 2H), 7.74 (s, 1H). Reference Example 24: 2- (Chloromethyl) -7-cyclopentyl-3-methylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

A solution of 1-amino-2-cyclopentyl-N-methyl-1H-imidazole-5-carboxamide (1.70 g, 8.2 mmol) in 2-chloroacetyl chloride (3 mL) was stirred at 80 ° C. for 3 hours under nitrogen. After cooling to room temperature, the reaction was quenched with aqueous NaHCO ₃ (10 mL) and extracted with DCM (10 ml × 3). The collected organic layer was dried and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with 5% MeOH / DCM) to give the title compound (1.3 g, 59% yield) as a brown oil.
¹ H-NMR (400 MHz, CD ₃ OD): δ1.75-1.94 (m, 6H), 2.10-2.18 (m, 2H), 3.64-3.70 (m, 4H), 4.77 (s, 2H), 7.74 (s, 1H).

2-Cyclopentyl-5- (trifluoromethyl) -1H-imidazole:
A mixture of 3,3-dibromo-1,1,1-trifluoropropan-2-one (8.1 g, 30 mmol) and sodium acetate (8.1 g, 60 mmol) in water (54 mL) was heated to 30 After refluxing for minutes, the mixture was cooled to room temperature. Cyclopentanecarbaldehyde (2.65 g, 27 mmol) and ammonium hydroxide (33 mL) in methanol (135 mL) were added. The mixture was stirred at room temperature overnight. After completion, methanol was distilled off and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The collected organic layer was dried and concentrated. The crude product (5.5 g) was used in the next step without further purification.
LC-MS (m / z) = 205 [M + H] ⁺ .

2-Cyclopentyl-1H-imidazole-5-carboxylic acid:
A mixture of 2-cyclopentyl-5- (trifluoromethyl) -1H-imidazole (5.5 g, 27 mmol) and sodium hydroxide (3 g, 73 mmol) in water / methanol (40 mL / 60 mL) at room temperature. Stir overnight. After completion, the methanol was distilled off and the pH of the aqueous solution was adjusted to pH = 2 with 1N hydrochloric acid. The solvent was distilled off under reduced pressure, the residue was dissolved in ethanol (15 mL), filtered, and the filtrate was concentrated. The crude product (4.5 g) was used in the next step without further purification.

Methyl 2-cyclopentyl-1H-imidazole-5-carboxylate:
Hydrogen chloride gas was bubbled into a solution of 2-cyclopentyl-1H-imidazole-5-carboxylic acid (4.5 g) in methanol (50 mL) with stirring for 2 hours, and then the mixture was heated and refluxed overnight. After completion, the mixture was washed with sodium bicarbonate solution (30 mL x 3), dried and concentrated. The crude product was purified on silica gel (eluted with petroleum ether: ethyl acetate = 50: 1 to petroleum ether: ethyl acetate = 10: 1) to give the title compound (3 g, yield 62%) as a white solid. LC-MS (m / z) = 195 [M + H] ⁺ .

Methyl 1-amino-2-cyclopentyl-1H-imidazole-5-carboxylate:
To a mixture of methyl 2-cyclopentyl-1H-imidazole-5-carboxylate (3.10 g, 16.0 mmol) in anhydrous DMF (30 mL) was added LiHMDS (1N in THF, 21 mL, 21 mmol) at −10 ° C. . After stirring for 10 minutes, O- (diphenylphosphoryl) -hydroxylamine (4.5 g, 19 mmol) was added at 0 ° C. and an additional 20 ml of anhydrous DMF was added. The reaction was warmed to room temperature and stirred for 16 hours. After completion, the reaction was quenched with water (100 mL) and extracted with ethyl acetate (100 mL × 3). The collected organic layer was dried and concentrated to give a crude product. Purification by silica gel chromatography (eluting with 2% MeOH / DCM) gave the title compound (2.30 g, 71% yield) as a yellow oil. LC-MS (m / z) = 210 [M + H] ⁺ .

1-amino-2-cyclopentyl-N-methyl-1H-imidazole-5-carboxamide:
A 20 mL CH ₃ NH ₂ / EtOH solution of methyl 1-amino-2-cyclopentyl-1H-imidazole-5-carboxylate (2.30 g, 11.0 mmol) in a sealed tube was stirred at 80 ° C. for 16 hours. After cooling to room temperature, most of the solvent was distilled off under reduced pressure to obtain a crude product, which was used in the next step without further purification.

表題化合物を参考例24と同様に合成した。
¹H NMR (400 MHz, CDCl₃): δ1.39 (d, J = 6.8 Hz, 6H), 3.50 (sept, J = 6.8 Hz, 1H), 3.62 (s, 3H), 4.56 (s, 2H), 7.81 (s, 1H). Reference Example 25: 2- (Chloromethyl) -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

The title compound was synthesized as in Reference Example 24.
¹ H NMR (400 MHz, CDCl ₃ ): δ1.39 (d, J = 6.8 Hz, 6H), 3.50 (sept, J = 6.8 Hz, 1H), 3.62 (s, 3H), 4.56 (s, 2H) , 7.81 (s, 1H).

3-(5-メチルピリジン-2-イル)プロパ-2-イン-1-オールのMeOH（7.0 mL）溶液にPd(OH)₂/C（500 mg）を加えた。混合物を4時間、室温でH₂雰囲気下撹拌した。完了後、反応混合物をセライトフィルターでろ過し、ろ液を濃縮して乾燥した。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（183 mg, ２工程で収率42%）を無色油状物として得た。
LC-MS (m/z) = 152 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.85-1.91 (m, 2H), 2.21 (s, 3H), 2.80-2.87 (m, 2H), 3.58-3.63 (m, 2H), 6.99-7.01 (m, 1H), 7.33-7.36 (m, 1H), 8.22 (s, 1H). Reference Example 26: 3- (5-methylpyridin-2-yl) propan-1-ol

Pd (OH) ₂ / C (500 mg) was added to a solution of 3- (5-methylpyridin-2-yl) prop-2-yn-1-ol in MeOH (7.0 mL). The mixture was stirred for 4 hours at room temperature under H ₂ atmosphere. After completion, the reaction mixture was filtered through a celite filter and the filtrate was concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (183 mg, yield 42% over 2 steps) as a colorless oil.
LC-MS (m / z) = 152 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.85-1.91 (m, 2H), 2.21 (s, 3H), 2.80-2.87 (m, 2H), 3.58-3.63 (m, 2H), 6.99-7.01 (m, 1H), 7.33-7.36 (m, 1H), 8.22 (s, 1H).

3- (5-Methylpyridin-2-yl) prop-2-yn-1-ol:
To a solution of 2-bromo-5-methylpyridine (500 mg, 2.91 mmol) and prop-2-yn-1-ol (223 μl, 3.78 mmol) in DMF (0.3 mL) and TEA (1.62 ml) was added Pd (PPh ₃ ) ₄ (336 mg, 0.029 mmol) and CuI (111 mg, 0.582 mmol) were added. The mixture was heated at 70 ° C. under a nitrogen atmosphere overnight. After completion, the reaction mixture was cooled and separated with ethyl acetate and saturated brine. The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was used in the next step without further purification.

表題化合物を参考例27と同様に合成した。
¹H-NMR (300 MHz, CDCl₃): δ1.86-1.95 (m, 2H), 2.87 (t, J = 7.0 Hz, 2H), 3.62 (t, J = 6.2 Hz, 2H), 7.10-7.14 (m, 1H), 7.24-7.31 (m, 1H), 8.28-8.29 (m, 1H). Reference Example 27: 3- (5-fluoropyridin-2-yl) propan-1-ol

The title compound was synthesized as in Reference Example 27.
¹ H-NMR (300 MHz, CDCl ₃ ): δ1.86-1.95 (m, 2H), 2.87 (t, J = 7.0 Hz, 2H), 3.62 (t, J = 6.2 Hz, 2H), 7.10-7.14 (m, 1H), 7.24-7.31 (m, 1H), 8.28-8.29 (m, 1H).

tert-ブチル (3S)-3-[(5-フルオロピリジン-2-イル)オキシ]ピロリジン-1-カルボキシレートをMeOH（3.0 mL）に溶解した後、4N-HCl/AcOEt（6.0 mL）を0℃で加えた。反応混合物を室温で1時間撹拌し、濃縮して所望の生成物を無色固体（560 mg, 収率89%）として得た。
¹H-NMR (300 MHz, CD₃OD): δ2.23-2.35 (m, 2H), 3.44 (t, J = 7.7 Hz, 2H), 3.52 (brs, 2H), 5.57-5.62 (m, 1H), 6.81-6.92 (m, 1H), 7.51-7.61 (m, 1H), 8.01 (dd, J = 6.5, 3.0 Hz, 1H). Reference Example 28: 5-Fluoro-2-[(3S) -pyrrolidin-3-yloxy] pyridine

After dissolving tert-butyl (3S) -3-[(5-fluoropyridin-2-yl) oxy] pyrrolidine-1-carboxylate in MeOH (3.0 mL), 4N-HCl / AcOEt (6.0 mL) was added to 0 Added at ° C. The reaction mixture was stirred at room temperature for 1 hour and concentrated to give the desired product as a colorless solid (560 mg, 89% yield).
¹ H-NMR (300 MHz, CD ₃ OD): δ2.23-2.35 (m, 2H), 3.44 (t, J = 7.7 Hz, 2H), 3.52 (brs, 2H), 5.57-5.62 (m, 1H ), 6.81-6.92 (m, 1H), 7.51-7.61 (m, 1H), 8.01 (dd, J = 6.5, 3.0 Hz, 1H).

tert-butyl (3S) -3-[(5-fluoropyridin-2-yl) oxy] pyrrolidine-1-carboxylate:
tert-Butyl (3S) -3-hydroxypyrrolidine-1-carboxylate (500 mg, 2.67 mmol) and 2,5-difluoropyridine (360 μL, 4.00 mmol) were dissolved in DMF (3.0 mL). After adding NaH (160 mg, 4.00 mmol, 60% in paraffin), the reaction mixture was stirred at 50 ° C. for 23 h. The mixture was cooled to room temperature and quenched with H ₂ O. The aqueous layer was extracted with toluene. The collected organic layers were dried over MgSO ₄ , concentrated and purified by silica gel column chromatography (hexane / EtOAc) to give the desired product as a colorless oil (695 mg, 92% yield).
¹ H-NMR (300 MHz, CDCl ₃ ): δ1.46 (s, 9H), 2.14 (s, 2H), 3.41-3.69 (m, 4H), 5.46 (s, 1H), 6.69 (dd, J = 9.0, 3.3 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.96 (s, 1H).

表題化合物を参考例29と同様に合成した。
¹H-NMR (300 MHz, CD₃OD): δ2.23-2.35 (m, 2H), 3.44 (t, J = 7.7 Hz, 2H), 3.52 (brs, 2H), 5.57-5.62 (m, 1H), 6.81-6.92 (m, 1H), 7.51-7.61 (m, 1H), 8.01 (dd, J = 6.5, 3.0 Hz, 1H). Reference Example 29: 5-Fluoro-2-[(3R) -pyrrolidin-3-yloxy] pyridine

The title compound was synthesized as in Reference Example 29.
¹ H-NMR (300 MHz, CD ₃ OD): δ2.23-2.35 (m, 2H), 3.44 (t, J = 7.7 Hz, 2H), 3.52 (brs, 2H), 5.57-5.62 (m, 1H ), 6.81-6.92 (m, 1H), 7.51-7.61 (m, 1H), 8.01 (dd, J = 6.5, 3.0 Hz, 1H).

3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-2,4(1H,3H)-ジオン（2.68 g, 10.73 mmol）、三塩化ホスホリル（10 mL, 107 mmol）及びDIEA（2.81 mL, 16.09 mmol）の混合物を100℃で15時間撹拌した。完了後、反応混合物を氷水に注いだ。NaOH水溶液で中和した後、得られた沈殿物をろ過し、粗生成物（2.56 g）を得た。粗生成物をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（2.17 g, 8.08 mmol, 収率75%）を得た。
LC-MS (m/z) = 270 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.86-1.95 (m, 2H), 2.01-2.14 (m, 2H), 3.36-3.47 (m, 1H), 3.55-3.66 (m, 5H), 4.05-4.13 (m, 2H), 7.84 (s, 1H). Reference Example 30: 2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

3-Methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione (2.68 g, 10.73 mmol ), Phosphoryl trichloride (10 mL, 107 mmol) and DIEA (2.81 mL, 16.09 mmol) were stirred at 100 ° C. for 15 hours. After completion, the reaction mixture was poured into ice water. After neutralization with NaOH aqueous solution, the resulting precipitate was filtered to obtain a crude product (2.56 g). The crude product was purified by silica gel column chromatography (hexane / EtOAc) to obtain the title compound (2.17 g, 8.08 mmol, yield 75%).
LC-MS (m / z) = 270 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.86-1.95 (m, 2H), 2.01-2.14 (m, 2H), 3.36 -3.47 (m, 1H), 3.55-3.66 (m, 5H), 4.05-4.13 (m, 2H), 7.84 (s, 1H).

1-amino-N-methyl-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxamide:
Mixture of methyl 1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate (10 g, 44.4 mmol) and 40% methylamine in MeOH (115 mL, 444 mmol) Was stirred at 60 ° C. for 4 hours. After evaporation of the solvent, EtOAc (50 mL) and diisopropyl ether (50 mL) were added to the residue. The resulting suspension was stirred at 0 ° C. for 1 hour. The title compound was collected by filtration (9.3 g, 41.5 mmol, 93% yield). LC-MS (m / z) = 225 [M + H] ⁺ .

3-Methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione:
MeCN (50 mL) of 1-amino-N-methyl-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxamide (5 g, 22.3 mmol) and CDI (5.42 g, 33.4 mmol) ) The solution was stirred at 60 ° C. for 3 hours. After completion, the suspension was stirred at 0 ° C. for 30 minutes. The precipitate was filtered to obtain a crude product containing imidazole (6.95 g). 2-Propanol (70 mL) was added to the crude product and the resulting suspension was stirred at 90 ° C. for 2.5 hours. After the suspension was cooled to 0 ° C., the title compound was collected by filtration (5.11 g, 20.42 mmol, 91% yield).
LC-MS (m / z) = 251 [M + H] ⁺ .

表題化合物を参考例24と同様に合成した。
¹H-NMR (400 MHz, CDCl₃): δ1.39 (t, J = 7.1 Hz, 3H), 1.87-1.97 (m, 2H), 2.04-2.17 (m, 2H), 3.38-3.49 (m, 1H), 3.55-3.65 (m, 2H), 4.06-4.14 (m, 2H), 4.18 (q, J = 7.1 Hz, 2H), 4.53 (s, 2H), 7.83 (s, 1H). Reference Example 31: 2- (chloromethyl) -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H)- on

The title compound was synthesized as in Reference Example 24.
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.39 (t, J = 7.1 Hz, 3H), 1.87-1.97 (m, 2H), 2.04-2.17 (m, 2H), 3.38-3.49 (m, 1H), 3.55-3.65 (m, 2H), 4.06-4.14 (m, 2H), 4.18 (q, J = 7.1 Hz, 2H), 4.53 (s, 2H), 7.83 (s, 1H).

The compounds of Reference Examples 32-33 were synthesized in the same manner as Reference Example 30.

The compounds of Reference Examples 34 to 37 were synthesized in the same manner as Reference Example 5, 6 or 7.

3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-2,4(1H,3H)-ジオン（17.56 g, 66.4 mmol）、三塩化ホスホリル（61.9 mL, 664 mmol）及びDIEA（17.41 mL, 100 mmol）の混合物を100℃で17時間撹拌した。撹拌後、反応混合物を氷水（300 mL）に注いだ。混合物を8M KOH水溶液で中和した後、得られた沈殿物をろ過し、表題化合物（15.23 g, 53.9 mmol, 収率81%）を得た。
¹H-NMR (400 MHz, CDCl₃): δ1.36 (t, J = 7.1 Hz, 3H), 1.86-1.95 (m, 2H), 2.02-2.15 (m, 2H), 3.36-3.46 (m, 1H), 3.60 (td, J = 11.6, 1.8 Hz, 2H), 4.05-4.13 (m, 2H), 4.23 (q, J = 7.1 Hz, 2H), 7.83 (s, 1H). Reference Example 38: 2-chloro-3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

3-Ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione (17.56 g, 66.4 mmol ), Phosphoryl trichloride (61.9 mL, 664 mmol) and DIEA (17.41 mL, 100 mmol) were stirred at 100 ° C. for 17 hours. After stirring, the reaction mixture was poured into ice water (300 mL). The mixture was neutralized with 8M aqueous KOH solution, and the resulting precipitate was filtered to give the title compound (15.23 g, 53.9 mmol, 81% yield).
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.36 (t, J = 7.1 Hz, 3H), 1.86-1.95 (m, 2H), 2.02-2.15 (m, 2H), 3.36-3.46 (m, 1H), 3.60 (td, J = 11.6, 1.8 Hz, 2H), 4.05-4.13 (m, 2H), 4.23 (q, J = 7.1 Hz, 2H), 7.83 (s, 1H).

1-amino-N-ethyl-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxamide:
A mixture of methyl 1-amino-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxylate (10 g, 44.4 mmol) and 70% ethylamine solution (28.6 mL, 444 mmol) was added to 60 Stir at ° C. After stirring for 15 hours, 70% ethylamine solution (28.6 mL, 444 mmol) was added to the reaction mixture. The mixture was stirred at the same temperature for 9 hours. The solvent was distilled off with a rotary evaporator to obtain a white solid. The crude solid was dissolved in CHCl ₃ (200 mL) to give a white suspension. After filtration, the solvent was distilled off with a rotary evaporator to obtain the title compound (9.3 g, 39.0 mmol, 88% yield) as a white solid.
LC-MS (m / z) = 239 [M + H] ⁺ .

3-Ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-2,4 (1H, 3H) -dione:
1-Amino-N-ethyl-2- (tetrahydro-2H-pyran-4-yl) -1H-imidazole-5-carboxamide (22.7 g, 95 mmol) and CDI (22.4 g, 138 mmol) MeCN (230 mL ) The solution was stirred at 60 ° C. for 5.5 hours. After stirring, the resulting suspension was stirred at 0 ° C. for 1 hour. The resulting precipitate was filtered to obtain a crude product (26.5 g) containing imidazole. 2-Propanol (210 mL) was added to the crude product and the resulting suspension was stirred at 90 ° C. for 5 hours. After the suspension was cooled to 0 ° C., the crude product (18 g) was collected through a filter. In order to remove the remaining imidazole, purification with 2-propanol was repeated once more to obtain the title compound (17.56 g, 66.4 mmol, 69% yield).
LC-MS (m / z) = 265 [M + H] ⁺

trans-1,4-シクロヘキサンジメタノール（20 g, 139 mmol）、8M KOH溶液（29.5 ml, 236 mmol）及びDMSO（120 ml）の混合物にヨードエタン（13.31 ml, 166 mmol）を室温にて加えた。混合物を2.5時間撹拌した。水を混合物に加えた後、混合物をHCl水溶液で中和し、EtOAcで抽出した。得られた有機層の溶媒を留去し、Na₂SO₄で乾燥した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、[trans-4-(エトキシメチル)シクロヘキシル]メタノール（10.5 g, 61 mmol, 44%）を得た。
¹H-NMR (400 MHz, CDCl₃): δ0.89-1.03 (m, 4H), 1.19 (t, J = 7.0 Hz, 3H), 1.28-1.32 (m, 1H), 1.39-1.59 (m, 2H), 1.76-1.91 (m, 4H), 3.23 (d, J = 6.3 Hz, 2H), 3.41-3.50 (m, 4H). Reference Example 39: [trans-4- (Ethoxymethyl) cyclohexyl] methanol

To a mixture of trans-1,4-cyclohexanedimethanol (20 g, 139 mmol), 8M KOH solution (29.5 ml, 236 mmol) and DMSO (120 ml) was added iodoethane (13.31 ml, 166 mmol) at room temperature. . The mixture was stirred for 2.5 hours. After water was added to the mixture, the mixture was neutralized with aqueous HCl and extracted with EtOAc. The solvent of the obtained organic layer was distilled off and dried over Na ₂ SO ₄ . The residue was purified by silica gel column chromatography (hexane / EtOAc) to obtain [trans-4- (ethoxymethyl) cyclohexyl] methanol (10.5 g, 61 mmol, 44%).
¹ H-NMR (400 MHz, CDCl ₃ ): δ0.89-1.03 (m, 4H), 1.19 (t, J = 7.0 Hz, 3H), 1.28-1.32 (m, 1H), 1.39-1.59 (m, 2H), 1.76-1.91 (m, 4H), 3.23 (d, J = 6.3 Hz, 2H), 3.41-3.50 (m, 4H).

水素化ナトリウム（55%油中懸濁液, 5.8 mg, 0.133 mmol）のTHF（1.0 mL）中の懸濁液に、(4,4-ジフルオロシクロヘキシル)メタノール（15.3 mg, 0.102 mmol）を滴加した。反応混合物を0℃で30分間撹拌した。混合物に2-クロロ-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（29 mg, 0.102 mmol）を加えた後、混合物を室温で3.5時間撹拌した。完了後、反応混合物をH₂O及び飽和NaCl水溶液で希釈した。水層をEtOAcで抽出し、集めた有機層を減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（24 mg, 収率60%）を白色固体として得た。
LC-MS (m/z) = 397 [M + H]^{+ 1}H-NMR (400 MHz, CDCl₃): δ1.27 (t, J = 7.1 Hz, 3H), 1.47-1.57 (m, 2H), 1.71-1.98 (m, 7H), 2.05-2.23 (m, 4H), 3.34 (tt, J = 11.6, 4.0 Hz, 1H), 3.58 (td, J = 11.6, 2.0 Hz, 2H), 4.01-4.12 (m, 4H), 4.25 (d, J = 6.0 Hz, 2H), 7.77 (s, 1H). Example 1: 2-[(4,4-Difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

To a suspension of sodium hydride (55% suspension in oil, 5.8 mg, 0.133 mmol) in THF (1.0 mL), (4,4-difluorocyclohexyl) methanol (15.3 mg, 0.102 mmol) was added dropwise. did. The reaction mixture was stirred at 0 ° C. for 30 minutes. To the mixture was added 2-chloro-3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (29 mg, 0.102 mmol) was added and the mixture was stirred at room temperature for 3.5 hours. After completion, the reaction mixture was diluted with H ₂ O and saturated aqueous NaCl. The aqueous layer was extracted with EtOAc, and the collected organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give the title compound (24 mg, yield 60%) as a white solid.
LC-MS (m / z) = 397 [M + H] ^{+ 1} H-NMR (400 MHz, CDCl ₃ ): δ1.27 (t, J = 7.1 Hz, 3H), 1.47-1.57 (m, 2H) , 1.71-1.98 (m, 7H), 2.05-2.23 (m, 4H), 3.34 (tt, J = 11.6, 4.0 Hz, 1H), 3.58 (td, J = 11.6, 2.0 Hz, 2H), 4.01-4.12 (m, 4H), 4.25 (d, J = 6.0 Hz, 2H), 7.77 (s, 1H).

(5-メチルピリジン-2-イル)メタノール（192 mg, 1.77 mmol）の無水DMF（10 mL）溶液に60% NaH（71 mg, 1.77 mmol）を0℃で0.5時間加えた後、2-クロロ-7-イソプロピル-3-メチルイミダゾ[1,5-f][1,2,4]トリアジン-4(3H)-オン（100 mg, 0.44 mmol）を0℃でさらに0.5時間加えた。混合物を25℃で1時間撹拌した。反応を水で停止させ、EtOAcで抽出し、濃縮した後、フラッシュカラムで精製し、表題化合物（40 mg, 収率33%）を得た。
LC-MS (m/z) = 314.0 [M+H]⁺. ¹H-NMR (400 MHz, CD₃OD): δ1.19-1.21 (m, 6H), 2.28 (s, 3H), 3.31-3.34 (m, 1H), 3.35 (s, 3H), 5.41 (s, 2H), 7.44-7.46 (m, 1H), 7.56 (s, 1H), 7.63-7.65 (m, 1H), 8.32 (s, 1H). Example 2: 3-methyl-2-[(5-methylpyridin-2-yl) methoxy] -7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine- 4 (3H) -ON

To a solution of (5-methylpyridin-2-yl) methanol (192 mg, 1.77 mmol) in anhydrous DMF (10 mL) was added 60% NaH (71 mg, 1.77 mmol) at 0 ° C. for 0.5 hour, and then 2-chloro -7-Isopropyl-3-methylimidazo [1,5-f] [1,2,4] triazin-4 (3H) -one (100 mg, 0.44 mmol) was added at 0 ° C. for a further 0.5 hour. The mixture was stirred at 25 ° C. for 1 hour. The reaction was quenched with water, extracted with EtOAc, concentrated and purified by flash column to give the title compound (40 mg, 33% yield).
LC-MS (m / z) = 314.0 [M + H] ⁺ . ¹ H-NMR (400 MHz, CD ₃ OD): δ1.19-1.21 (m, 6H), 2.28 (s, 3H), 3.31- 3.34 (m, 1H), 3.35 (s, 3H), 5.41 (s, 2H), 7.44-7.46 (m, 1H), 7.56 (s, 1H), 7.63-7.65 (m, 1H), 8.32 (s, 1H).

2-(ピリジン-4-イル)エタノール（2.46 g, 20 mmol）のTHF（16 mL）中の混合物に-78℃でLiHMDS（22 mL, 22 mmol）を滴加した。混合物を-78℃で20分間撹拌した後、2-クロロ-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（452 mg, 2 mmol）を加えた。混合物を室温に昇温し、終夜撹拌した。混合物を0℃に冷却し、水で反応を停止させ、EtOAcで抽出し、濃縮した後、分取用HPLCで精製し、表題化合物（12 mg, 収率2%）を白色固体として得た。
LC-MS (m/z) = 314 [M+H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.39 (d, J = 7.2 Hz, 6H), 3.16-3.19 (m, 2H), 3.33 (s, 3H), 3.40-3.44 (m, 1H), 4.63 (t, J = 6.8 Hz, 2H), 7.22-7.24 (m, 2H), 7.77 (s, 1H), 8.59-8.60 (m, 2H). Example 3: 3-Methyl-7- (propan-2-yl) -2- [2- (pyridin-4-yl) ethoxy] imidazo [5,1-f] [1,2,4] triazine-4 (3H) -ON

LiHMDS (22 mL, 22 mmol) was added dropwise at −78 ° C. to a mixture of 2- (pyridin-4-yl) ethanol (2.46 g, 20 mmol) in THF (16 mL). The mixture was stirred at −78 ° C. for 20 minutes before 2-chloro-3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) -On (452 mg, 2 mmol) was added. The mixture was warmed to room temperature and stirred overnight. The mixture was cooled to 0 ° C., quenched with water, extracted with EtOAc, concentrated and purified by preparative HPLC to give the title compound (12 mg, 2% yield) as a white solid.
LC-MS (m / z) = 314 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.39 (d, J = 7.2 Hz, 6H), 3.16-3.19 (m, 2H ), 3.33 (s, 3H), 3.40-3.44 (m, 1H), 4.63 (t, J = 6.8 Hz, 2H), 7.22-7.24 (m, 2H), 7.77 (s, 1H), 8.59-8.60 ( m, 2H).

The compounds of Examples 4 to 114 were synthesized in the same manner as in Example 1, 2 or 3.

2-メトキシ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（50.0 mg, 0.2 mmol）及び炭酸カリウム（44 mg, 0.32 mmol）をDMF（50 mL）に溶解した。1,1-ジフルオロ-4-(ヨードメチル)シクロヘキサン（78 mg, 0.3 mmol）を滴加し、室温で終夜撹拌した。完了後、反応混合物を酢酸エチル及び水で分液した。水層をEtOAcで抽出し、集めた有機層を硫酸ナトリウムで乾燥し、濃縮して乾燥させた。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（17.3 mg, 収率23%）を白色固体として得た。
LC-MS (m/z) = 383 [M + H]⁺. ¹H-NMR (300 MHz, CDCl₃): δ1.33-1.46 (m, 2H), 1.59-1.93 (m, 7H), 2.03-2.17 (m, 4H), 3.30-3.40 (m, 1H), 3.56 (td, J = 11.6, 2.0 Hz, 2H), 3.87 (d, J = 7.3 Hz, 2H), 4.04-4.11 (m, 5H), 7.76 (s, 1H). Example 115: 3-[(4,4-difluorocyclohexyl) methyl] -2-methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2-Methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (50.0 mg, 0.2 mmol) and potassium carbonate (44 mg, 0.32 mmol) was dissolved in DMF (50 mL). 1,1-Difluoro-4- (iodomethyl) cyclohexane (78 mg, 0.3 mmol) was added dropwise and stirred overnight at room temperature. After completion, the reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (17.3 mg, yield 23%) as a white solid.
LC-MS (m / z) = 383 [M + H] ⁺ . ¹ H-NMR (300 MHz, CDCl ₃ ): δ1.33-1.46 (m, 2H), 1.59-1.93 (m, 7H), 2.03 -2.17 (m, 4H), 3.30-3.40 (m, 1H), 3.56 (td, J = 11.6, 2.0 Hz, 2H), 3.87 (d, J = 7.3 Hz, 2H), 4.04-4.11 (m, 5H ), 7.76 (s, 1H).

2-[(4-フルオロベンジル)オキシ]-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（0.1 g, 0.28 mmol）のDMF（1.0 mL）溶液にSelectfluor（登録商標）（0.165 g, 0.419 mmol）を加えた。混合物を窒素雰囲気下、70℃で80分間加熱した。完了後、反応混合物を冷却し、酢酸エチル及び飽和食塩水で分液した。水層をEtOAcで抽出し、集めた有機層を硫酸ナトリウムで乾燥し、濃縮して乾燥した。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（28.0 mg, 収率13%）を白色固体として得た。
LC-MS (m/z) = 377 [M + H]⁺. ¹H-NMR (300 MHz, CDCl₃): δ1.79-1.83 (m, 2H), 1.94-2.08 (m, 2H), 3.24-3.39 (m, 4H), 3.54 (td, J = 11.6, 2.0 Hz, 2H), 4.04-4.08 (m, 2H), 5.32 (s, 2H), 7.06-7.11 (m, 2H), 7.39-7.44 (m, 2H). Example 116: 5-Fluoro-2-[(4-fluorobenzyl) oxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2, 4] Triazine-4 (3H) -one

2-[(4-Fluorobenzyl) oxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) -Selectfluor (0.165 g, 0.419 mmol) was added to a solution of -one (0.1 g, 0.28 mmol) in DMF (1.0 mL). The mixture was heated at 70 ° C. for 80 minutes under a nitrogen atmosphere. After completion, the reaction mixture was cooled and partitioned between ethyl acetate and saturated brine. The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (28.0 mg, yield 13%) as a white solid.
LC-MS (m / z) = 377 [M + H] ⁺ . ¹ H-NMR (300 MHz, CDCl ₃ ): δ1.79-1.83 (m, 2H), 1.94-2.08 (m, 2H), 3.24 -3.39 (m, 4H), 3.54 (td, J = 11.6, 2.0 Hz, 2H), 4.04-4.08 (m, 2H), 5.32 (s, 2H), 7.06-7.11 (m, 2H), 7.39-7.44 (m, 2H).

2-[(4-フルオロベンジル)オキシ]-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（0.1 g, 0.28 mmol）のMeCN（1.0 mL）溶液にN-クロロスクシンイミド（55.7 mg, 0.419 mmol）及びTFA（103μl, 1.40 mmol）を加えた。混合物を窒素雰囲気下、80℃で4時間加熱した。完了後、反応混合物を飽和NaHCO₃で反応停止処理した。水層をEtOAcで抽出し、集めた有機層を硫酸ナトリウムで乾燥し、濃縮して乾燥させた。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（28 mg, 収率26%）を白色固体として得た。
LC-MS (m/z) = 393 [M + H]⁺. ¹H-NMR (300 MHz, CDCl₃): δ1.79-1.86 (m, 2H), 1.99-2.13 (m, 2H), 3.25-3.37 (m, 4H), 3.50-3.59 (m, 2H), 4.05-4.09 (m, 2H), 5.33 (s, 2H), 7.06-7.13 (m, 2H), 7.39-7.44 (m, 2H). Example 117: 5-chloro-2-[(4-fluorobenzyl) oxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2, 4] Triazine-4 (3H) -one

2-[(4-Fluorobenzyl) oxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) N-chlorosuccinimide (55.7 mg, 0.419 mmol) and TFA (103 μl, 1.40 mmol) were added to a solution of -one (0.1 g, 0.28 mmol) in MeCN (1.0 mL). The mixture was heated at 80 ° C. for 4 hours under a nitrogen atmosphere. After completion, the reaction mixture was quenched with saturated NaHCO ₃ . The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give the title compound (28 mg, yield 26%) as a white solid.
LC-MS (m / z) = 393 [M + H] ⁺ . ¹ H-NMR (300 MHz, CDCl ₃ ): δ1.79-1.86 (m, 2H), 1.99-2.13 (m, 2H), 3.25 -3.37 (m, 4H), 3.50-3.59 (m, 2H), 4.05-4.09 (m, 2H), 5.33 (s, 2H), 7.06-7.13 (m, 2H), 7.39-7.44 (m, 2H) .

The compounds of Examples 118 and 119 were synthesized in the same manner as Example 117.

2-[(4-フルオロベンジル)オキシ]-5-ヨード-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（30 mg, 0.062 mmol）のTHF（0.5 mL）溶液にPd(PtBu₃)₂（6.3 mg, 0.012 mmol）及びMeZnCl（THF中2M, 0.248 ml, 0.496 mmol）を加えた。混合物を窒素雰囲気下、室温で4時間撹拌した。完了後、反応混合物をH₂Oで反応停止処理した。水層をEtOAcで抽出し、集めた有機層を硫酸ナトリウムで乾燥し、濃縮して乾燥させた。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（20 mg, 収率87%）を白色固体として得た。
LC-MS (m/z) = 373 [M + H]⁺. ¹H-NMR (300 MHz, CDCl₃): δ1.79-1.85 (m, 2H), 2.01-2.16 (m, 2H), 2.56 (s, 3H), 3.23-3.35 (m, 4H), 3.55 (td, J = 11.7, 2.2 Hz, 2H), 4.05-4.11 (m, 2H), 5.32 (s, 2H), 7.05-7.12 (m, 2H), 7.40-7.44 (m, 2H). Example 120: 2-[(4-Fluorobenzyl) oxy] -3,5-dimethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2-[(4-Fluorobenzyl) oxy] -5-iodo-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine- Pd (PtBu ₃ ) ₂ (6.3 mg, 0.012 mmol) and MeZnCl (2M in THF, 0.248 ml, 0.496 mmol) were added to a solution of 4 (3H) -one (30 mg, 0.062 mmol) in THF (0.5 mL). . The mixture was stirred at room temperature for 4 hours under a nitrogen atmosphere. After completion, the reaction mixture was quenched with H ₂ O. The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (20 mg, yield 87%) as a white solid.
LC-MS (m / z) = 373 [M + H] ⁺ . ¹ H-NMR (300 MHz, CDCl ₃ ): δ1.79-1.85 (m, 2H), 2.01-2.16 (m, 2H), 2.56 (s, 3H), 3.23-3.35 (m, 4H), 3.55 (td, J = 11.7, 2.2 Hz, 2H), 4.05-4.11 (m, 2H), 5.32 (s, 2H), 7.05-7.12 (m , 2H), 7.40-7.44 (m, 2H).

2-[(4-Fluorobenzyl) oxy] -5-iodo-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine- 4 (3H) -On:
2-[(4-Fluorobenzyl) oxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) N-iodosuccinimide (126 mg, 0.558 mmol) and TFA (103 μl, 1.40 mmol) were added to a solution of -one (0.1 g, 0.28 mmol) in MeCN (1.0 mL). The mixture was stirred at room temperature for 4 hours under a nitrogen atmosphere. After completion, the reaction was quenched with saturated NaHCO ₃ . The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give the title compound (129 mg, yield 96%) as a white solid.
LC-MS (m / z) = 485 [M + H] ⁺ . ¹ H-NMR (300 MHz, CDCl ₃ ): δ1.78-1.84 (m, 2H), 2.02-2.16 (m, 2H), 3.25 -3.36 (m, 4H), 3.54 (td, J = 11.7, 2.2 Hz, 2H), 4.05-4.11 (m, 2H), 5.33 (s, 2H), 7.06-7.13 (m, 2H), 7.38-7.44 (m, 2H).

The compounds of Examples 121 and 122 were synthesized in the same manner as Example 120.

2-[(4,4-ジフルオロシクロヘキシル)メトキシ]-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（68 mg, 0.18 mmol）のトルエン（4 mL）溶液にローソン試薬（149 mg, 0.37 mmol）を室温で加えた。混合物を窒素雰囲気下、100℃で4時間加熱した。完了後、反応混合物を濃縮した。残渣をシリカゲルカラムクロマトグラフィー（CHCl₃/MeOH）で精製し、表題化合物（60 mg, 収率81%）を薄黄色油状物として得た。
LC-MS (m/z) = 413 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ7.92 (s, 1H), 4.55 (q, J = 7.0 Hz, 2H), 4.26 (d, J = 5.9 Hz, 2H), 4.09-4.06 (m, 2H), 3.58-3.54 (m, 2H), 3.39-3.34 (m, 1H), 2.20-1.68 (m, 10H), 1.57-1.46 (m, 2H), 1.31 (t, J = 7.0 Hz, 3H). Example 123: 2-[(4,4-difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -thione

2-[(4,4-Difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( To a solution of 3H) -one (68 mg, 0.18 mmol) in toluene (4 mL) was added Lawesson's reagent (149 mg, 0.37 mmol) at room temperature. The mixture was heated at 100 ° C. for 4 hours under a nitrogen atmosphere. After completion, the reaction mixture was concentrated. The residue was purified by silica gel column chromatography (CHCl ₃ / MeOH) to give the title compound (60 mg, yield 81%) as a pale yellow oil.
LC-MS (m / z) = 413 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ7.92 (s, 1H), 4.55 (q, J = 7.0 Hz, 2H), 4.26 (d, J = 5.9 Hz, 2H), 4.09-4.06 (m, 2H), 3.58-3.54 (m, 2H), 3.39-3.34 (m, 1H), 2.20-1.68 (m, 10H), 1.57- 1.46 (m, 2H), 1.31 (t, J = 7.0 Hz, 3H).

2-クロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（61 mg, 0.24 mmol）、(2R)-2-フェニルピロリジン（71 mg, 0.48 mmol）及びDIEA（155 mg, 1.2 mmol）の無水ジオキサン（3 mL）溶液を16時間還流した。混合物を濃縮して乾燥した。残渣を分取用HPLC（移動相としてMeCN及び0.1% NH₃.H₂Oを含むH₂O）で精製し、表題化合物（36 mg, 収率41%）を得た。
¹H NMR (400 MHz, CD₃OD): δ1.16-1.27 (m, 1H), 1.40-1.55 (m, 1H), 1.67-1.78 (m, 1H), 1.82-1.98 (m, 2H), 1.98-2.20 (m, 2H), 2.39-2.55 (m, 1H), 3.00-3.15 (m, 1H), 3.26-3.40 (m, 1H), 3.44-3.55 (m, 1H), 3.65-3.72 (m, 1H), 3.72-3.82 (m, 1H), 3.85-3.93 (m, 1H), 3.93-4.03 (m, 1H), 5.00-5.10 (m, 1H), 7.15-7.23 (m, 1H), 7.23-7.35 (m, 4H), 7.53 (s, 1H). Example 124: 2-[(2R) -2-phenylpyrrolidin-1-yl] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine -4 (3H) -ON

2-Chloro-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (61 mg, 0.24 mmol), (2R ) A solution of 2-phenylpyrrolidine (71 mg, 0.48 mmol) and DIEA (155 mg, 1.2 mmol) in anhydrous dioxane (3 mL) was refluxed for 16 hours. The mixture was concentrated to dryness. The residue was purified by preparative HPLC (H ₂ O containing MeCN and 0.1% NH ₃ .H ₂ O as mobile phase) to give the title compound (36 mg, 41% yield).
¹ H NMR (400 MHz, CD ₃ OD): δ1.16-1.27 (m, 1H), 1.40-1.55 (m, 1H), 1.67-1.78 (m, 1H), 1.82-1.98 (m, 2H), 1.98-2.20 (m, 2H), 2.39-2.55 (m, 1H), 3.00-3.15 (m, 1H), 3.26-3.40 (m, 1H), 3.44-3.55 (m, 1H), 3.65-3.72 (m , 1H), 3.72-3.82 (m, 1H), 3.85-3.93 (m, 1H), 3.93-4.03 (m, 1H), 5.00-5.10 (m, 1H), 7.15-7.23 (m, 1H), 7.23 -7.35 (m, 4H), 7.53 (s, 1H).

(2R)-2-(4-クロロフェニル)ピロリジン（55 mg, 0.3 mmol）、2-クロロ-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（64 mg, 0.3 mmol）、NaI（45 mg, 0.3 mmol）及びDIEA（78 mg, 0.6 mmol）のn-BuOH（2 mL）溶液をマイクロ波照射下、12時間160℃で撹拌した。完了後、混合物を水で反応停止処理し、EtOAcで抽出した。集めた有機層を飽和食塩水で洗浄し、Na₂SO₄で乾燥し、減圧濃縮した。残渣を逆相クロマトグラフィー（0.01% NH₃／水及びMeCN）で精製し、白色固体として表題化合物を得た（30 mg, 収率45%）。
¹H NMR (400 MHz, CD₃OD): δ0.99-1.03 (m, 3H), 1.22-1.24 (m, 3H), 1.86-1.93 (m, 1H), 2.00-2.08 (m, 2H), 2.40-2.47 (m, 1H), 3.14-3.23 (m, 1H), 3.67-3.73 (m, 1H), 3.86-3.91 (m, 1H), 4.92-5.11 (m, 1H), 7.25-7.31 (m, 4H), 7.47 (s, 1H). Example 125: 2-[(2R) -2- (4-chlorophenyl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine -4 (3H) -ON

(2R) -2- (4-Chlorophenyl) pyrrolidine (55 mg, 0.3 mmol), 2-chloro-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine- 4 (3H) -one (64 mg, 0.3 mmol), NaI (45 mg, 0.3 mmol) and DIEA (78 mg, 0.6 mmol) in n-BuOH (2 mL) under microwave irradiation for 12 hours at 160 ° C Stir with. After completion, the mixture was quenched with water and extracted with EtOAc. The collected organic layer was washed with saturated brine, dried over Na ₂ SO ₄ and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (0.01% NH ₃ / water and MeCN) to give the title compound as a white solid (30 mg, 45% yield).
¹ H NMR (400 MHz, CD ₃ OD): δ0.99-1.03 (m, 3H), 1.22-1.24 (m, 3H), 1.86-1.93 (m, 1H), 2.00-2.08 (m, 2H), 2.40-2.47 (m, 1H), 3.14-3.23 (m, 1H), 3.67-3.73 (m, 1H), 3.86-3.91 (m, 1H), 4.92-5.11 (m, 1H), 7.25-7.31 (m , 4H), 7.47 (s, 1H).

The compounds of Examples 126 to 134 were synthesized in the same manner as in Example 124 or 125.

1-(5-メトキシピリジン-2-イル)メタンアミン（138 mg, 1 mmol）及び2-クロロ-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（90 mg, 0.4 mmol）のDMF（1.5 mL）溶液にDIEA（104 mg, 0.8 mmol）を加えた。反応混合物を50℃で10時間撹拌し、分取用HPLC（移動相としてMeCN及び0.01% NH₃.H₂Oを含むH₂O）で精製し、表題化合物（40 mg, 収率30 %）を得た。
LC-MS (m/z) = 329 [M + H]⁺. ¹H-NMR (400 MHz, DMSO-d₆): δ1.40 (d, J = 7.2 Hz, 6H), 3.46-3.52 (m, 1H), 3.53 (s, 3H), 3.89 (s, 3H), 4.55 (d, J = 4.0 Hz, 2H), 6.07 (s, 1H), 7.27-7.31 (m, 2H), 7.75 (s, 1H), 8.26 (d, J = 2.4 Hz, 1H). Example 135: 2-{[(5-methoxypyridin-2-yl) methyl] amino} -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one

1- (5-Methoxypyridin-2-yl) methanamine (138 mg, 1 mmol) and 2-chloro-3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2 , 4] Triazin-4 (3H) -one (90 mg, 0.4 mmol) in DMF (1.5 mL) was added DIEA (104 mg, 0.8 mmol). The reaction mixture was stirred at 50 ° C. 10 h, and purified by preparative HPLC (H ₂ O containing MeCN and 0.01% NH ₃ .H ₂ O as mobile phase) to give the title compound (40 mg, 30% yield) Got.
LC-MS (m / z) = 329 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.40 (d, J = 7.2 Hz, 6H), 3.46-3.52 (m , 1H), 3.53 (s, 3H), 3.89 (s, 3H), 4.55 (d, J = 4.0 Hz, 2H), 6.07 (s, 1H), 7.27-7.31 (m, 2H), 7.75 (s, 1H), 8.26 (d, J = 2.4 Hz, 1H).

2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（40 mg, 0.149 mmol）及びTEA（23 mg, 0.224 mmol）のNMP（1 mL）溶液に2-フルオロ-4-メチルベンジルアミン（25 mg, 0.179 mmol）を加えた。混合物を100℃で終夜加熱した。完了後、反応混合物を冷却し、酢酸エチル及び飽和食塩水で分液した。集めた有機抽出物を硫酸ナトリウムで乾燥した後、ろ過した。減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィー（クロロホルム/MeOH）で精製し、表題化合物を薄黄色固体として得た（28 mg, 収率50%）。
LC-MS (m/z) = 372 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.82-1.91 (m, 2H), 2.04-2.18 (m, 2H), 2.35 (s, 3H), 3.35-3.42 (m, 1H), 3.43 (s, 3H), 3.55-3.65 (m, 2H), 4.06-4.15 (m, 2H), 4.54 (d, J = 5.6 Hz, 2H), 4.63-4.75 (m, 1H), 6.89-6.96 (m, 2H), 7.27-7.33 (m, 1H), 7.75 (s, 1H). Example 136: 2-[(2-Fluoro-4-methylbenzyl) amino] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2, 4] Triazine-4 (3H) -one

2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (40 mg, 0.149 mmol ) And TEA (23 mg, 0.224 mmol) in NMP (1 mL) was added 2-fluoro-4-methylbenzylamine (25 mg, 0.179 mmol). The mixture was heated at 100 ° C. overnight. After completion, the reaction mixture was cooled and partitioned between ethyl acetate and saturated brine. The collected organic extract was dried over sodium sulfate and then filtered. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (chloroform / MeOH) to give the title compound as a pale yellow solid (28 mg, yield 50%).
LC-MS (m / z) = 372 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.82-1.91 (m, 2H), 2.04-2.18 (m, 2H), 2.35 (s, 3H), 3.35-3.42 (m, 1H), 3.43 (s, 3H), 3.55-3.65 (m, 2H), 4.06-4.15 (m, 2H), 4.54 (d, J = 5.6 Hz, 2H ), 4.63-4.75 (m, 1H), 6.89-6.96 (m, 2H), 7.27-7.33 (m, 1H), 7.75 (s, 1H).

2-クロロ-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（100 mg, 0.44 mmol）のDMSO（5 mL）溶液に1-(6-メチルピリジン-2-イル)メタンアミン（54 mg, 0.44 mmol）及びK₂CO₃（122 mg, 0.88 mmol）を加えた。混合物を100℃で終夜撹拌し、カラムクロマトグラフィー（EtOAc/石油エーテル）で精製し、表題化合物を白色固体として得た（8 mg, 収率6%）。
LC-MS (m/z) = 313 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.39 (d, J = 6.4 Hz, 6H), 2.58 (s, 3H), 3.44-3.51 (m, 1H), 3.54 (s, 3H), 4.56 (d, J = 4.4 Hz, 2H), 6.33 (s, 1H), 7.10-7.16 (m, 2H), 7.59-7.63 (m, 1H), 7.74 (s, 1H). Example 137: 3-methyl-2-{[(6-methylpyridin-2-yl) methyl] amino} -7- (propan-2-yl) imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one

2-Chloro-3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (100 mg, 0.44 mmol) in DMSO ( 5 mL) solution was added 1- (6-methylpyridin-2-yl) methanamine (54 mg, 0.44 mmol) and K ₂ CO ₃ (122 mg, 0.88 mmol). The mixture was stirred at 100 ° C. overnight and purified by column chromatography (EtOAc / petroleum ether) to give the title compound as a white solid (8 mg, 6% yield).
LC-MS (m / z) = 313 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.39 (d, J = 6.4 Hz, 6H), 2.58 (s, 3H), 3.44-3.51 (m, 1H), 3.54 (s, 3H), 4.56 (d, J = 4.4 Hz, 2H), 6.33 (s, 1H), 7.10-7.16 (m, 2H), 7.59-7.63 (m, 1H), 7.74 (s, 1H).

2-クロロ-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（150 mg, 0.66 mmol）、1,2,3,4-テトラヒドロナフタレン-1-アミン（146 mg, 1.0 mmol）、Cs₂CO₃（324 mg, 1.0 mmol）、Ruphos（10 mg, 0.021 mmol）及びPd(OAc)₂（10 mg, 0.045 mmol）のジオキサン（3 mL）中の混合物を110℃で16時間撹拌した。反応混合物をろ過し、ろ液を分取用HPLC（移動相としてMeCN及び0.05% NH₃.H₂Oを含むH₂O）で精製し、表題化合物（18 mg, 収率8%）を得た。
¹H-NMR (400 MHz, CDCl₃): δ1.35-1.47 (m, 6H), 1.84-1.95 (m, 2H), 2.05-2.20 (m, 2H), 2.75-2.95 (m, 2H), 3.37 (s, 3H), 3.41-3.54 (m, 1H), 4.25-4.40 (m, 1H), 5.10-5.23 (m, 1H), 7.14-7.30 (m, 3H), 7.35-7.43 (m, 1H), 7.77 (s, 1H). Example 138: 3-methyl-7- (propan-2-yl) -2- (1,2,3,4-tetrahydronaphthalen-1-ylamino) imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one

2-chloro-3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (150 mg, 0.66 mmol), 1, 2,3,4-tetrahydronaphthalen-1-amine (146 mg, 1.0 mmol), Cs ₂ CO ₃ (324 mg, 1.0 mmol), Ruphos (10 mg, 0.021 mmol) and Pd (OAc) ₂ (10 mg, 0.045 mmol) in dioxane (3 mL) was stirred at 110 ° C. for 16 h. The reaction mixture was filtered and the resulting filtrate was purified by preparative HPLC (H ₂ O containing MeCN and 0.05% NH ₃ .H ₂ O as mobile phase) to give the title compound (18 mg, 8% yield) It was.
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.35-1.47 (m, 6H), 1.84-1.95 (m, 2H), 2.05-2.20 (m, 2H), 2.75-2.95 (m, 2H), 3.37 (s, 3H), 3.41-3.54 (m, 1H), 4.25-4.40 (m, 1H), 5.10-5.23 (m, 1H), 7.14-7.30 (m, 3H), 7.35-7.43 (m, 1H ), 7.77 (s, 1H).

The compounds of Examples 139 to 205 were synthesized in the same manner as in Examples 135, 136, 137, and 138.

2-(ピロリジン-1-イル)-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（50 mg, 0.173 mmol）、炭酸カリウム（48 mg, 0.346 mmol）及び(ブロモメチル)シクロプロパン（25μL, 0.259 mmol）のDMF（350μL）溶液を室温で14時間撹拌した。得られた混合物をシリカゲルカラムクロマトグラフィー（クロロホルム／MeOH）で精製し、表題化合物（35 mg, 収率59%）を白色固体として得た。
¹H-NMR (400 MHz, CDCl₃): δ0.38-0.42 (m, 2H), 0.62-0.67 (m, 2H), 1.31-1.38 (m, 1H), 1.95-2.18 (m, 8H), 3.39-3.64 (m, 7H), 4.07-4.11 (m, 2H), 4.32 (d, J = 7.6 Hz, 2H), 7.54 (s, 1H). Example 206: 3- (Cyclopropylmethyl) -2- (pyrrolidin-1-yl) -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2- (Pyrrolidin-1-yl) -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (50 mg, 0.173 mmol), potassium carbonate (48 mg, 0.346 mmol) and (bromomethyl) cyclopropane (25 μL, 0.259 mmol) in DMF (350 μL) were stirred at room temperature for 14 hours. The obtained mixture was purified by silica gel column chromatography (chloroform / MeOH) to give the title compound (35 mg, yield 59%) as a white solid.
¹ H-NMR (400 MHz, CDCl ₃ ): δ0.38-0.42 (m, 2H), 0.62-0.67 (m, 2H), 1.31-1.38 (m, 1H), 1.95-2.18 (m, 8H), 3.39-3.64 (m, 7H), 4.07-4.11 (m, 2H), 4.32 (d, J = 7.6 Hz, 2H), 7.54 (s, 1H).

The compounds of Examples 207 to 215 were synthesized in the same manner as Example 206.

Examples 216 and 217

3-methyl-2-[(2R) -2- (6-methylpyridin-3-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f] [1, 2,4] Triazine-4 (3H) -one:
3-Methyl-2- [2- (6-methylpyridin-3-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f] [1,2,4] Chiral separation of triazin-4 (3H) -one (150 mg) gave the title compound. Retention time: 4.03 min./Method A.
LC-MS (m / z) = 353 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.11-1.12 (m, 3H), 1.32-1.34 (m, 3H), 1.93 -2.01 (m, 1H), 2.03-2.19 (m, 1H), 2.18-2.24 (m, 1H), 2.41-2.46 (m, 1H), 2.47 (s, 3H), 3.34-3.41 (m, 1H) , 3.45-3.49 (m, 1H), 3.52 (s, 3H), 3.94-4.01 (m, 1H), 5.06-5.11 (m, 1H), 7.27-7.25 (m, 1H), 7.57 (s, 1H) , 7.83-7.85 (m, 1H), 8.49 (s, 1H).

3-methyl-2-[(2S) -2- (6-methylpyridin-3-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f] [1, 2,4] Triazine-4 (3H) -one:
3-Methyl-2- [2- (6-methylpyridin-3-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f] [1,2,4] Chiral separation of triazin-4 (3H) -one (150 mg) gave the title compound. Retention time: 4.79 min./Method A.
LC-MS (m / z) = 353 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.11-1.12 (m, 3H), 1.32-1.34 (m, 3H), 1.93 -2.01 (m, 1H), 2.03-2.19 (m, 1H), 2.18-2.24 (m, 1H), 2.41-2.46 (m, 1H), 2.47 (s, 3H), 3.34-3.41 (m, 1H) , 3.45-3.49 (m, 1H), 3.52 (s, 3H), 3.94-4.01 (m, 1H), 5.06-5.11 (m, 1H), 7.27-7.25 (m, 1H), 7.57 (s, 1H) , 7.83-7.85 (m, 1H), 8.49 (s, 1H).

3-Methyl-2- [2- (6-methylpyridin-3-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one:
2-Chloro-3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (200 mg, 0.89 mmol), 2- A mixture of methyl-5- (pyrrolidin-2-yl) pyridine (290 mg, 1.73 mmol) and Cs ₂ CO ₃ (582 mg, 1.79 mmol) in anhydrous DMF (20 mL) was heated at 50 ° C. for 1 hour. The reaction was quenched by the addition of 20 mL saturated NH ₄ Cl and 20 mL EtOAc. The product was purified by a silica gel column to obtain the title compound (150 mg, yield 48%).

表題化合物を実施例216及び217と同様に合成した。
保持時間: 3.76 min.／方法Ｂ。
LC-MS (m/z) = 353 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.01-1.03 (m, 3H), 1.27-1.28 (m, 3H), 1.92-1.99 (m, 1H), 2.05-2.11 (m, 1H), 2.17-2.21 (m, 1H), 2.30 (s, 3H), 2.43-2.49 (m, 1H), 3.31-3.35 (m, 1H), 3.49-3.51 (m, 1H), 3.52 (s, 3H), 3.95-4.01 (m, 1H), 5.15-5.19 (m, 1H), 7.44-7.46 (m, 1H), 7.55 (s, 1H), 7.60-7.62 (m, 1H), 8.32 (s, 1H). Example 218: 3-methyl-2-[(2R) -2- (5-methylpyridin-2-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f ] [1,2,4] Triazine-4 (3H) -one

The title compound was synthesized as in Examples 216 and 217.
Retention time: 3.76 min./Method B.
LC-MS (m / z) = 353 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.01-1.03 (m, 3H), 1.27-1.28 (m, 3H), 1.92 -1.99 (m, 1H), 2.05-2.11 (m, 1H), 2.17-2.21 (m, 1H), 2.30 (s, 3H), 2.43-2.49 (m, 1H), 3.31-3.35 (m, 1H) , 3.49-3.51 (m, 1H), 3.52 (s, 3H), 3.95-4.01 (m, 1H), 5.15-5.19 (m, 1H), 7.44-7.46 (m, 1H), 7.55 (s, 1H) , 7.60-7.62 (m, 1H), 8.32 (s, 1H).

表題化合物を実施例216及び217と同様に合成した。
保持時間: 4.51 min.／方法Ｂ。
LC-MS (m/z) = 353 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.01-1.03 (m, 3H), 1.27-1.28 (m, 3H), 1.92-1.99 (m, 1H), 2.05-2.11 (m, 1H), 2.17-2.21 (m, 1H), 2.30 (s, 3H), 2.43-2.49 (m, 1H), 3.31-3.35 (m, 1H), 3.49-3.51 (m, 1H), 3.52 (s, 3H), 3.95-4.01 (m, 1H), 5.15-5.19 (m, 1H), 7.44-7.46 (m, 1H), 7.55 (s, 1H), 7.60-7.62 (m, 1H), 8.32 (s, 1H). Example 219: 3-methyl-2-[(2S) -2- (5-methylpyridin-2-yl) pyrrolidin-1-yl] -7- (propan-2-yl) imidazo [5,1-f ] [1,2,4] Triazine-4 (3H) -one

The title compound was synthesized as in Examples 216 and 217.
Retention time: 4.51 min./Method B.
LC-MS (m / z) = 353 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.01-1.03 (m, 3H), 1.27-1.28 (m, 3H), 1.92 -1.99 (m, 1H), 2.05-2.11 (m, 1H), 2.17-2.21 (m, 1H), 2.30 (s, 3H), 2.43-2.49 (m, 1H), 3.31-3.35 (m, 1H) , 3.49-3.51 (m, 1H), 3.52 (s, 3H), 3.95-4.01 (m, 1H), 5.15-5.19 (m, 1H), 7.44-7.46 (m, 1H), 7.55 (s, 1H) , 7.60-7.62 (m, 1H), 8.32 (s, 1H).

2-(1,4-ジアゼパン-1-イル)-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（40 mg, 0.12 mmol）のTHF（2 mL）溶液に2-クロロエチルメチルエーテル（23 mg, 0.24 mmol）及びCs₂CO₃（117 mg, 0.36 mmol）を加えた。混合物を50℃で終夜撹拌した。生成物を逆相（0.01% NH₃／水及びMeCN）で精製し、表題化合物（8 mg, 収率17%）を得た。
LC-MS (m/z) = 391.2 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.91-2.15 (m, 6H), 2.78 (t, J = 5.2 Hz, 2H), 2.85 (t, J = 5.6 Hz, 2H), 2.90-2.91 (m, 2H), 3.31-3.52 (m, 1H), 3.38 (s, 3H), 3.39-3.42 (m, 2H), 3.45 (s, 5H), 3.52-3.61 (m, 4H), 4.09 (d, J = 11.6 Hz, 2H), 7.75 (s, 1H). Example 220: 2- [4- (2-methoxyethyl) -1,4-diazepan-1-yl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1- f] [1,2,4] triazine-4 (3H) -one

2- (1,4-diazepan-1-yl) -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( To a solution of 3H) -one (40 mg, 0.12 mmol) in THF (2 mL) was added 2-chloroethyl methyl ether (23 mg, 0.24 mmol) and Cs ₂ CO ₃ (117 mg, 0.36 mmol). The mixture was stirred at 50 ° C. overnight. The product was purified by reverse phase (0.01% NH ₃ / water and MeCN) to give the title compound (8 mg, 17% yield).
LC-MS (m / z) = 391.2 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.91-2.15 (m, 6H), 2.78 (t, J = 5.2 Hz, 2H ), 2.85 (t, J = 5.6 Hz, 2H), 2.90-2.91 (m, 2H), 3.31-3.52 (m, 1H), 3.38 (s, 3H), 3.39-3.42 (m, 2H), 3.45 ( s, 5H), 3.52-3.61 (m, 4H), 4.09 (d, J = 11.6 Hz, 2H), 7.75 (s, 1H).

2-(1,4-ジアゼパン-1-イル)-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（20 mg, 0.06 mmol）、メトキシアセチルクロリド（26 mg, 0.24 mmol）及びTEA（0.2 mL）のDCM（1 mL）溶液を室温で2時間撹拌した。次いで、該溶液を水で洗浄し、EtOAcで抽出し、集めた有機層を水及び飽和食塩水で洗浄し、Na₂SO₄で乾燥し、濃縮して残渣を得た後、逆相（0.01% NH₃／水及びMeCN）で精製し、表題化合物を白色固体として得た（15 mg, 収率70%）。
LC-MS (m/z) = 405.2 [M + H]⁺. ¹H-NMR (400 MHz, CD₃OD): δ1.89-2.14 (m, 6H), 3.36 (s, 1H), 3.39-3.42 (m, 4H), 3.48-3.50 (m, 5H), 3.58-3.68 (m, 4H), 3.72-3.77 (m, 2H), 3.83-3.86 (m, 1H), 4.04-4.07 (m, 2H), 4.15 (s, 1H), 4.23 (s, 1H), 7.66-7.67 (m, 1H). Example 221: 2- [4- (methoxyacetyl) -1,4-diazepan-1-yl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2- (1,4-diazepan-1-yl) -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -one (20 mg, 0.06 mmol), methoxyacetyl chloride (26 mg, 0.24 mmol) and a solution of TEA (0.2 mL) in DCM (1 mL) were stirred at room temperature for 2 hours. The solution was then washed with water and extracted with EtOAc, and the collected organic layers were washed with water and brine, dried over Na ₂ SO ₄ and concentrated to give a residue that was then the reverse phase (0.01 % NH ₃ / water and MeCN) to give the title compound as a white solid (15 mg, 70% yield).
LC-MS (m / z) = 405.2 [M + H] ⁺ . ¹ H-NMR (400 MHz, CD ₃ OD): δ1.89-2.14 (m, 6H), 3.36 (s, 1H), 3.39- 3.42 (m, 4H), 3.48-3.50 (m, 5H), 3.58-3.68 (m, 4H), 3.72-3.77 (m, 2H), 3.83-3.86 (m, 1H), 4.04-4.07 (m, 2H ), 4.15 (s, 1H), 4.23 (s, 1H), 7.66-7.67 (m, 1H).

N,N-ジメチルグリシン（10 mg, 0.099 mmol）及び2-(1,4-ジアゼパン-1-イル)-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（22 mg, 0.066 mmol）のDMF（3 mL）溶液にHATU（38 mg, 0.099 mmol）及びDIEA（21 mg, 0.166 mmol）を加えた。反応混合物を室温で終夜撹拌し、分取用HPLC（移動相としてMeCN及び0.01% NH₃.H₂Oを含むH₂O）で精製し、表題化合物を白色固体として得た（10 mg, 収率36%）。
LC-MS (m/z) = 418.2 [M + H]⁺; ¹H-NMR (400 MHz, CDCl₃): δ1.87-1.92 (m, 2H), 2.04-2.12 (m, 4H), 2.29-2.33 (m, 6H), 3.16-3.18 (m, 2H), 3.30-3.41 (m, 4H), 3.46-3.51 (m, 4H), 3.55-3.61 (m, 2H), 3.71-3.78 (m, 2H), 3.82-3.87 (m, 2H), 4.08-4.10 (m, 2H), 7.61-7.77 (s, 1H). Example 222: 2- {4-[(dimethylamino) acetyl] -1,4-diazepan-1-yl} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1 -f] [1,2,4] triazine-4 (3H) -one

N, N-dimethylglycine (10 mg, 0.099 mmol) and 2- (1,4-diazepan-1-yl) -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1 -f] [1,2,4] Triazin-4 (3H) -one (22 mg, 0.066 mmol) in DMF (3 mL) with HATU (38 mg, 0.099 mmol) and DIEA (21 mg, 0.166 mmol) Was added. The reaction mixture was stirred overnight at room temperature, and purified by preparative HPLC (H ₂ O containing MeCN and 0.01% NH ₃ .H ₂ O as mobile phase), the title compound was obtained as a white solid (10 mg, yield Rate 36%).
LC-MS (m / z) = 418.2 [M + H] ⁺ ; ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.87-1.92 (m, 2H), 2.04-2.12 (m, 4H), 2.29 -2.33 (m, 6H), 3.16-3.18 (m, 2H), 3.30-3.41 (m, 4H), 3.46-3.51 (m, 4H), 3.55-3.61 (m, 2H), 3.71-3.78 (m, 2H), 3.82-3.87 (m, 2H), 4.08-4.10 (m, 2H), 7.61-7.77 (s, 1H).

2-(クロロメチル)-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（111 mg, 0.46 mmol）及びK₂CO₃（127 mg, 0.92 mmol）のMeCN（4 mL）中の混合物に4-クロロフェノール（71 mg, 0.55 mmol）を室温で加えた。混合物を25℃で12時間撹拌した。反応混合物をろ過し、分取用HPLC（移動相としてMeCN及び0.05% NH₃.H₂Oを含むH₂O）で精製し、表題化合物を得た（55 mg, 収率37%）。
¹H-NMR (400 MHz, CDCl₃): δ1.42 (d, J = 7.2 Hz, 6H), 3.51-3.54 (m, 1H), 3.62 (s, 3H), 5.07 (s, 2H), 6.99-7.01 (m, 2H), 7.28-7.33 (m, 2H), 7.84 (s, 1H). Example 223: 2-[(4-chlorophenoxy) methyl] -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) -on

2- (Chloromethyl) -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (111 mg, 0.46 mmol) And 4-chlorophenol (71 mg, 0.55 mmol) was added at room temperature to a mixture of K ₂ CO ₃ (127 mg, 0.92 mmol) in MeCN (4 mL). The mixture was stirred at 25 ° C. for 12 hours. The reaction mixture was filtered and purified by preparative HPLC (including MeCN and 0.05% NH ₃ .H ₂ O as the mobile phase H ₂ O), to give the title compound (55 mg, 37% yield).
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.42 (d, J = 7.2 Hz, 6H), 3.51-3.54 (m, 1H), 3.62 (s, 3H), 5.07 (s, 2H), 6.99 -7.01 (m, 2H), 7.28-7.33 (m, 2H), 7.84 (s, 1H).

2-(クロロメチル)-7-シクロペンチル-3-メチルイミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（100 mg, 0.37 mmol）及びK₂CO₃（102 mg, 0.74 mmol）のMeCN（4 mL）中の混合物に4-クロロフェノール（100 mg, 0.44 mmol）を室温で加えた。次いで、混合物を12時間80℃に加熱した。反応混合物をろ過し、分取用HPLC（移動相としてMeCN及び0.05% NH₃.H₂Oを含むH₂O）で精製し、表題化合物を得た（25 mg, 収率19%）。
¹H-NMR (400 MHz, CDCl₃): δ1.72-1.75 (m, 2H), 1.89-1.97 (m, 4H), 2.12-2.19 (m, 2H), 3.55-3.63 (m, 4H), 5.06 (s, 2H), 6.98-7.02 (m, 2H), 7.29-7.32 (m, 2H), 7.83 (s, 1H). Example 224: 2-[(4-chlorophenoxy) methyl] -7-cyclopentyl-3-methylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

2- (Chloromethyl) -7-cyclopentyl-3-methylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (100 mg, 0.37 mmol) and K ₂ CO ₃ ( To a mixture of 102 mg, 0.74 mmol) in MeCN (4 mL) was added 4-chlorophenol (100 mg, 0.44 mmol) at room temperature. The mixture was then heated to 80 ° C. for 12 hours. The reaction mixture was filtered and purified by preparative HPLC (including MeCN and 0.05% NH ₃ .H ₂ O as the mobile phase H ₂ O), to give the title compound (25 mg, 19% yield).
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.72-1.75 (m, 2H), 1.89-1.97 (m, 4H), 2.12-2.19 (m, 2H), 3.55-3.63 (m, 4H), 5.06 (s, 2H), 6.98-7.02 (m, 2H), 7.29-7.32 (m, 2H), 7.83 (s, 1H).

The compounds of Examples 225 to 228 were synthesized in the same manner as in Example 223 or 224.

2-(クロロメチル)-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（96 mg, 0.4 mmol）、Cs₂CO₃（260 mg, 0.8 mmol）及び6-クロロ-1,2,3,4-テトラヒドロキノリン（134 mg, 0.8 mmol）のMeCN（3 mL）中の混合物を80℃で12時間にわたり加熱した。沈殿物をろ過し、ろ液を分取用HPLC（移動相としてMeCN及び0.05% NH₃.H₂Oを含むH₂O）で精製し、表題化合物を得た（40 mg, 収率27%）。
¹H-NMR (400 MHz, CDCl₃): δ1.30 (d, J = 6.8 Hz, 6H), 2.03-2.06 (m, 2H), 2.80-2.84 (m, 2H), 3.37-3.41 (m, 3H), 3.54 (s, 3H), 4.49 (s, 2H), 6.50-6.52 (m, 1H), 6.98-7.03 (m, 2H), 7.85 (s, 1H). Example 229: 2-[(6-chloro-3,4-dihydroquinolin-1 (2H) -yl) methyl] -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2- (Chloromethyl) -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (96 mg, 0.4 mmol) , Cs ₂ CO ₃ (260 mg, 0.8 mmol) and 6-chloro-1,2,3,4-tetrahydroquinoline (134 mg, 0.8 mmol) in MeCN (3 mL) at 80 ° C. for 12 hours. Heated. The precipitate was filtered, the filtrate was purified by preparative HPLC (H ₂ O containing MeCN and 0.05% NH ₃ .H ₂ O as mobile phase) to give the title compound (40 mg, yield 27% ).
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.30 (d, J = 6.8 Hz, 6H), 2.03-2.06 (m, 2H), 2.80-2.84 (m, 2H), 3.37-3.41 (m, 3H), 3.54 (s, 3H), 4.49 (s, 2H), 6.50-6.52 (m, 1H), 6.98-7.03 (m, 2H), 7.85 (s, 1H).

2-(クロロメチル)-3-メチル-7-(プロパン-2-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（100 mg, 0.42 mmol）、N-メチル-4-(トリフルオロメチル)アニリン（88 mg, 0.50 mmol）、K₂CO₃（116 mg, 0.84 mmol）及びKI（14 mg, 0.084 mmol）のMeCN（3 mL）中の混合物を50℃で16時間撹拌した。反応混合物をろ過し、分取用HPLC（移動相としてMeCN及び0.05% NH₃.H₂Oを含むH₂O）で精製し、表題化合物を得た（15 mg, 収率10%）。
¹H-NMR (400 MHz, CD₃CN): δ1.08 (d, J = 7.2 Hz, 6H), 3.11 (sept, J = 7.2 Hz, 1H), 3.18 (s, 3H), 3.44 (s, 3H), 4.73 (s, 2H), 6.93 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.60 (s, 1H). Example 230: 3-methyl-2-({methyl [4- (trifluoromethyl) phenyl] amino} methyl) -7- (propan-2-yl) imidazo [5,1-f] [1,2, 4] Triazine-4 (3H) -one

2- (Chloromethyl) -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (100 mg, 0.42 mmol) , N-methyl-4- (trifluoromethyl) aniline (88 mg, 0.50 mmol), K ₂ CO ₃ (116 mg, 0.84 mmol) and KI (14 mg, 0.084 mmol) in MeCN (3 mL) Was stirred at 50 ° C. for 16 hours. The reaction mixture was filtered and purified by preparative HPLC (including MeCN and 0.05% NH ₃ .H ₂ O as the mobile phase H ₂ O), to give the title compound (15 mg, 10% yield).
¹ H-NMR (400 MHz, CD ₃ CN): δ1.08 (d, J = 7.2 Hz, 6H), 3.11 (sept, J = 7.2 Hz, 1H), 3.18 (s, 3H), 3.44 (s, 3H), 4.73 (s, 2H), 6.93 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.60 (s, 1H).

2,3-ジヒドロ-1H-イソインドール-1-オン（60 mg）の無水NMP（2 mL）溶液にN₂雰囲気下0℃でNaH（鉱油中60%, 30 mg）を加え、混合物を室温で20分間撹拌した。0℃に冷却した後、NMP（1 mL）中の2-(クロロメチル)-7-シクロペンチル-3-メチルイミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（100 mg）を加え、0℃で30分間撹拌した。反応混合物を水（3 mL）で反応停止処理し、EtOAc（5 mL×3）で抽出した。集めた有機層を水（10 mL×2）で洗浄し、濃縮して粗生成物を得、これを分取用HPLC（移動相としてMeCN及び0.05% NH₃.H₂Oを含むH₂O）で精製し、表題化合物を得た（23 mg, 収率17%）。
¹H-NMR (400 MHz, CDCl₃): δ1.58-1.72 (m, 4H), 1.88-1.98 (m, 4H), 3.37 (quint, J = 8.4 Hz, 1H), 3.54 (s, 3H), 4.52 (s, 2H), 4.87 (s, 2H), 7.49-7.54 (m, 2H), 7.60-7.61 (m, 1H), 7.81 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H). Example 231: 7-cyclopentyl-3-methyl-2-[(1-oxo-1,3-dihydro-2H-isoindol-2-yl) methyl] imidazo [5,1-f] [1,2, 4] Triazine-4 (3H) -one

To a solution of 2,3-dihydro-1H-isoindol-1-one (60 mg) in anhydrous NMP (2 mL) was added NaH (60% in mineral oil, 30 mg) at 0 ° C. under N ₂ atmosphere, and the mixture was cooled to room temperature. For 20 minutes. After cooling to 0 ° C, 2- (chloromethyl) -7-cyclopentyl-3-methylimidazo [5,1-f] [1,2,4] triazine-4 (3H)-in NMP (1 mL) On (100 mg) was added, and the mixture was stirred at 0 ° C. for 30 min. The reaction mixture was quenched with water (3 mL) and extracted with EtOAc (5 mL × 3). The combined organic layers were washed with water (10 mL × 2), and concentrated to give the crude product, H ₂ O containing MeCN and 0.05% NH ₃ .H ₂ O as a preparative HPLC (mobile phase To give the title compound (23 mg, 17% yield).
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.58-1.72 (m, 4H), 1.88-1.98 (m, 4H), 3.37 (quint, J = 8.4 Hz, 1H), 3.54 (s, 3H) , 4.52 (s, 2H), 4.87 (s, 2H), 7.49-7.54 (m, 2H), 7.60-7.61 (m, 1H), 7.81 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H ).

The compounds of Examples 232 to 235 were synthesized in the same manner as in Example 229, 230 or 231.

2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（50 mg, 0.186 mmol）、4-メチルフェニルボロン酸（64 mg, 0.372 mmol）及び10% KF水溶液（0.35 mL）のDME（1.0 mL）中の混合物にテトラキス(トリフェニルホスフィン)パラジウム（42 mg, 0.028 mmol）を窒素雰囲気下加えた。混合物をマイクロウェーブ照射下、120℃で1時間加熱した。反応を水で停止し、酢酸エチルで抽出した。集めた有機抽出物を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥し、ろ過した。減圧濃縮した後、残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、粗製固体を得た。固体をiPr₂O/IPAで洗浄し、表題化合物を得た（11 mg, 収率18%）。LC-MS (m/z) = 325 [M + H]+. Example 236: 3-methyl-2- (4-methylphenyl) -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H )-on

2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (50 mg, 0.186 mmol ), 4-methylphenylboronic acid (64 mg, 0.372 mmol) and 10% aqueous KF solution (0.35 mL) in DME (1.0 mL) with tetrakis (triphenylphosphine) palladium (42 mg, 0.028 mmol) in nitrogen Added under atmosphere. The mixture was heated at 120 ° C. for 1 hour under microwave irradiation. The reaction was quenched with water and extracted with ethyl acetate. The collected organic extract was washed with saturated brine, dried over sodium sulfate, and filtered. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (hexane / EtOAc) to give a crude solid. The solid was washed with iPr ₂ O / IPA to give the title compound (11 mg, 18% yield). LC-MS (m / z) = 325 [M + H] +.

2-クロロ-3-[(4,4-ジフルオロシクロヘキシル)メチル]-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（130 mg, 0.34 mmol）、トリメチルボロキシン（105 mg, 0.84 mmol）及びCs₂CO₃（329 mg, 1.01 mmol）のDME（2.0 mL）及びH₂O（0.8 mL）中の混合物に[1,1'-ビス（ジフェニルホスフィノ)フェロセン]塩化パラジウム（ＩＩ）ジクロロメタン付加物（41 mg, 0.051 mmol）を窒素雰囲気下にて加えた。混合物をマイクロウェーブ照射下、120℃で1時間加熱した。反応を水で停止し、酢酸エチルで抽出した。集めた有機抽出物を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥し、ろ過した。減圧濃縮後、残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物を得た（91 mg, 収率73%）。
¹H-NMR (400 MHz, CDCl₃): δ1.37-1.52 (m, 2H), 1.56-1.97 (m, 7H), 2.02-2.20 (m, 4H), 2.48 (s, 3H), 3.37-3.47 (m, 1H), 3.59 (td, J = 11.7, 2.0 Hz, 2H), 3.87 (d, J = 7.3 Hz, 2H), 4.05-4.13 (m, 2H), 7.78 (s, 1H). Example 237: 3-[(4,4-difluorocyclohexyl) methyl] -2-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2-Chloro-3-[(4,4-difluorocyclohexyl) methyl] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -one (130 mg, 0.34 mmol), trimethylboroxine (105 mg, 0.84 mmol) and Cs ₂ CO ₃ (329 mg, 1.01 mmol) in DME (2.0 mL) and H ₂ O (0.8 mL). [1,1′-Bis (diphenylphosphino) ferrocene] palladium (II) chloride adduct (41 mg, 0.051 mmol) was added to the mixture under a nitrogen atmosphere. The mixture was heated at 120 ° C. for 1 hour under microwave irradiation. The reaction was quenched with water and extracted with ethyl acetate. The collected organic extract was washed with saturated brine, dried over sodium sulfate, and filtered. After concentration under reduced pressure, the residue was purified by silica gel column chromatography (hexane / EtOAc) to give the title compound (91 mg, yield 73%).
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.37-1.52 (m, 2H), 1.56-1.97 (m, 7H), 2.02-2.20 (m, 4H), 2.48 (s, 3H), 3.37- 3.47 (m, 1H), 3.59 (td, J = 11.7, 2.0 Hz, 2H), 3.87 (d, J = 7.3 Hz, 2H), 4.05-4.13 (m, 2H), 7.78 (s, 1H).

表題化合物を実施例237と同様に合成した。
¹H-NMR (300 MHz, CDCl₃): δ1.87-1.92 (m, 2H), 2.02-2.16 (m, 2H), 2.37 (s, 3H), 3.36-3.46 (m, 1H), 3.52-3.61 (m, 2H), 4.05-4.10 (m, 2H), 5.22 (s, 2H), 7.18-7.36 (m, 5H), 7.84 (s, 1H). Example 238: 3-Benzyl-2-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

The title compound was synthesized as in Example 237.
¹ H-NMR (300 MHz, CDCl ₃ ): δ1.87-1.92 (m, 2H), 2.02-2.16 (m, 2H), 2.37 (s, 3H), 3.36-3.46 (m, 1H), 3.52- 3.61 (m, 2H), 4.05-4.10 (m, 2H), 5.22 (s, 2H), 7.18-7.36 (m, 5H), 7.84 (s, 1H).

2-クロロ-3-[(4,4-ジフルオロシクロヘキシル)メチル]-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（50 mg, 0.13 mmol）、Cs₂CO₃（127 mg, 0.39 mmol）及び[1,1'-ビス（ジフェニルホスフィノ)フェロセン]塩化パラジウム（ＩＩ）ジクロロメタン付加物（21 mg, 0.026 mmol）のTHF（1 mL）中の混合物にトリエチルボラン（THF中約1 mol/l, 0.26 ml, 0.26 mmol）を加えた。混合物を窒素雰囲気下60℃で終夜加熱した。反応を水で停止し、酢酸エチルで抽出した。集めた有機抽出物を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥し、ろ過した。減圧濃縮した後、残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（23 mg, 収率46%）を白色固体として得た。
LC-MS (m/z) = 381 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.37 (t, J = 7.2 Hz, 3H), 1.41-1.51 (m, 2H), 1.59-1.71 (m, 1H), 1.71-1.81 (m, 3H), 1.81-1.98 (m, 3H), 2.04-2.20 (m, 4H), 2.75 (q, J = 7.3 Hz, 2H), 3.38-3.49 (m, 1H), 3.55-3.65 (m, 2H), 3.84-3.92 (m, 2H), 4.06-4.14 (m, 2H), 7.79 (s, 1H). Example 239: 3-[(4,4-difluorocyclohexyl) methyl] -2-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2-Chloro-3-[(4,4-difluorocyclohexyl) methyl] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -one (50 mg, 0.13 mmol), Cs ₂ CO ₃ (127 mg, 0.39 mmol) and [1,1′-bis (diphenylphosphino) ferrocene] palladium chloride (II) dichloromethane adduct (21 mg, To a mixture of 0.026 mmol) in THF (1 mL) was added triethylborane (about 1 mol / l in THF, 0.26 ml, 0.26 mmol). The mixture was heated at 60 ° C. overnight under a nitrogen atmosphere. The reaction was quenched with water and extracted with ethyl acetate. The collected organic extract was washed with saturated brine, dried over sodium sulfate, and filtered. After concentration under reduced pressure, the residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (23 mg, yield 46%) as a white solid.
LC-MS (m / z) = 381 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.37 (t, J = 7.2 Hz, 3H), 1.41-1.51 (m, 2H ), 1.59-1.71 (m, 1H), 1.71-1.81 (m, 3H), 1.81-1.98 (m, 3H), 2.04-2.20 (m, 4H), 2.75 (q, J = 7.3 Hz, 2H), 3.38-3.49 (m, 1H), 3.55-3.65 (m, 2H), 3.84-3.92 (m, 2H), 4.06-4.14 (m, 2H), 7.79 (s, 1H).

2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（0.1 g, 0.373 mmol）及び[(E)-2-(4-フルオロフェニル)エテニル]ボロン酸（124 mg, 0.746 mmol）のDME（1.5 mL）及び10% KF水溶液（0.5 mL）中の溶液にテトラキス(トリフェニルホスフィン)パラジウム（64.7 mg, 0.056 mmol）を加えた。混合物を窒素雰囲気及びマイクロウェーブ照射下、120℃で1時間加熱した。完了後、反応混合物を冷却し、酢酸エチル及び飽和食塩水で分液した。水層をEtOAcで抽出し、集めた有機層を硫酸ナトリウムで乾燥し、濃縮して乾燥させた。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（53 mg, 収率40%）を白色固体として得た。
LC-MS (m/z) = 355 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.91-1.96 (m, 2H), 2.05-2.15 (m, 2H), 3.45-3.54 (m, 1H), 3.56-3.63 (m, 5H), 4.06-4.10 (m, 2H), 6.78 (d, J = 15.6 Hz, 1H), 7.08-7.13 (m, 2H), 7.54-7.59 (m, 3H), 7.79 (s, 1H). Example 240: 2-[(E) -2- (4-fluorophenyl) ethenyl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1, 2,4] Triazine-4 (3H) -one

2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (0.1 g, 0.373 mmol ) And [(E) -2- (4-fluorophenyl) ethenyl] boronic acid (124 mg, 0.746 mmol) in DME (1.5 mL) and 10% aqueous KF solution (0.5 mL) with tetrakis (triphenylphosphine ) Palladium (64.7 mg, 0.056 mmol) was added. The mixture was heated at 120 ° C. for 1 hour under nitrogen atmosphere and microwave irradiation. After completion, the reaction mixture was cooled and partitioned between ethyl acetate and saturated brine. The aqueous layer was extracted with EtOAc and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (53 mg, yield 40%) as a white solid.
LC-MS (m / z) = 355 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.91-1.96 (m, 2H), 2.05-2.15 (m, 2H), 3.45 -3.54 (m, 1H), 3.56-3.63 (m, 5H), 4.06-4.10 (m, 2H), 6.78 (d, J = 15.6 Hz, 1H), 7.08-7.13 (m, 2H), 7.54-7.59 (m, 3H), 7.79 (s, 1H).

2-[(E)-2-(4-フルオロフェニル)エテニル]-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（32.9 mg, 0.093 mmol）のMeOH（1.0 mL）溶液にPd/フィブロイン（150 mg）を加えた。混合物をH₂雰囲気下、室温で4時間撹拌した。完了後、反応混合物をセライトフィルターでろ過し、ろ液を濃縮乾燥した。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（27 mg, 収率82%）を白色固体として得た。
LC-MS (m/z) = 357 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.82-1.86 (m, 2H), 1.99-2.10 (m, 2H), 2.97-3.01 (m, 2H), 3.07-3.10 (m, 2H), 3.33-3.40 (m, 1H), 3.45 (s, 3H), 3.52-3.59 (m, 2H), 4.04-4.08 (m, 2H), 6.96-7.01 (m, 2H), 7.18-7.21 (m, 2H), 7.76 (s, 1H). Example 241: 2- [2- (4-fluorophenyl) ethyl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2-[(E) -2- (4-Fluorophenyl) ethenyl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Pd / fibroin (150 mg) was added to a solution of triazine-4 (3H) -one (32.9 mg, 0.093 mmol) in MeOH (1.0 mL). The mixture was stirred at room temperature for 4 hours under H ₂ atmosphere. After completion, the reaction mixture was filtered through a celite filter and the filtrate was concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (27 mg, yield 82%) as a white solid.
LC-MS (m / z) = 357 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.82-1.86 (m, 2H), 1.99-2.10 (m, 2H), 2.97 -3.01 (m, 2H), 3.07-3.10 (m, 2H), 3.33-3.40 (m, 1H), 3.45 (s, 3H), 3.52-3.59 (m, 2H), 4.04-4.08 (m, 2H) , 6.96-7.01 (m, 2H), 7.18-7.21 (m, 2H), 7.76 (s, 1H).

2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（50 mg, 0.187 mmol）及び1-エチニル-4-メトキシベンゼン（87.4μL, 0.674 mmol）のMeCN（0.3 mL）及びTEA（0.3 mL）中の溶液にPdCl₂(MeCN)₂（9.7 mg, 0.037 mmol）及びx-phos（35.7 mg, 0.075 mmol）を加えた。混合物を窒素雰囲気下80℃で終夜加熱した。完了後、反応混合物を冷却し、酢酸エチル及び飽和食塩水で分液した。水層をEtOAcで抽出し、集めた有機層を硫酸ナトリウムで乾燥し、濃縮乾燥した。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（26 mg, 収率38%）を白色固体として得た。LC-MS (m/z) = 365 [M + H]⁺. Example 242: 2-[(4-methoxyphenyl) ethynyl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine- 4 (3H) -ON

2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (50 mg, 0.187 mmol ) And 1-ethynyl-4-methoxybenzene (87.4 μL, 0.674 mmol) in MeCN (0.3 mL) and TEA (0.3 mL) were added to PdCl ₂ (MeCN) ₂ (9.7 mg, 0.037 mmol) and x-phos. (35.7 mg, 0.075 mmol) was added. The mixture was heated at 80 ° C. overnight under a nitrogen atmosphere. After completion, the reaction mixture was cooled and partitioned between ethyl acetate and saturated brine. The aqueous layer was extracted with EtOAc, and the collected organic layers were dried over sodium sulfate and concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (26 mg, yield 38%) as a white solid. LC-MS (m / z) = 365 [M + H] ⁺ .

2-[(4-メトキシフェニル)エチニル]-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（25.7 mg）のMeOH（1.0 mL）溶液にPd/フィブロイン（151 mg）を加えた。混合物をH₂雰囲気下、室温で4時間撹拌した。完了後、反応混合物をセライトフィルターでろ過し、ろ液を濃縮乾燥した。残渣をアミノシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（15 mg, 収率58%）を黄色固体として得た。
LC-MS (m/z) = 369 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.84-1.87 (m, 2H), 2.00-2.10 (m, 2H), 2.96-2.99 (m, 2H), 3.03-3.07 (m, 2H), 3.35-3.44 (m, 4H), 3.53-3.60 (m, 2H), 3.77 (s, 3H), 4.05-4.09 (m, 2H), 6.83 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.8 Hz, 2H), 7.76 (s, 1H). Example 243: 2- [2- (4-methoxyphenyl) ethyl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

2-[(4-Methoxyphenyl) ethynyl] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) -Pd / fibroin (151 mg) was added to a solution of -one (25.7 mg) in MeOH (1.0 mL). The mixture was stirred at room temperature for 4 hours under H ₂ atmosphere. After completion, the reaction mixture was filtered through a celite filter and the filtrate was concentrated to dryness. The residue was purified by amino silica gel column chromatography (hexane / EtOAc) to give the title compound (15 mg, yield 58%) as a yellow solid.
LC-MS (m / z) = 369 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.84-1.87 (m, 2H), 2.00-2.10 (m, 2H), 2.96 -2.99 (m, 2H), 3.03-3.07 (m, 2H), 3.35-3.44 (m, 4H), 3.53-3.60 (m, 2H), 3.77 (s, 3H), 4.05-4.09 (m, 2H) , 6.83 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.8 Hz, 2H), 7.76 (s, 1H).

表題化合物を実施例243と同様に合成した。
¹H-NMR (400 MHz, CDCl₃): δ1.74-1.78 (m, 2H), 1.94-2.04 (m, 2H), 3.25-3.33 (m, 5H), 3.49-3.55 (m, 5H), 4.02-4.05 (m, 2H), 7.11-7.14 (m, 1H), 7.24-7.26 (m, 1H), 7.59-7.63 (m, 1H), 7.74 (s, 1H), 8.50-8.51 (m, 1H). Example 244: 3-methyl-2- [2- (pyridin-2-yl) ethyl] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one

The title compound was synthesized as in Example 243.
¹ H-NMR (400 MHz, CDCl ₃ ): δ1.74-1.78 (m, 2H), 1.94-2.04 (m, 2H), 3.25-3.33 (m, 5H), 3.49-3.55 (m, 5H), 4.02-4.05 (m, 2H), 7.11-7.14 (m, 1H), 7.24-7.26 (m, 1H), 7.59-7.63 (m, 1H), 7.74 (s, 1H), 8.50-8.51 (m, 1H ).

[trans-4-(トリフルオロメチル)シクロヘキシル]メタノール（1.017 g, 5.58 mmol）のTHF（10 mL）溶液に、水素化ナトリウム（55%油懸濁液, 292 mg, 6.7 mmol）を0℃で加えた。反応混合物を室温で10分間撹拌した。2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（1 g, 3.72 mmol）を加えた後、混合物を室温で2時間撹拌した。完了後、反応混合物をH₂O（10 mL）及び飽和NaCl水溶液（10 mL）で反応停止処理した。水層をEtOAc（20 mL＋10 mL x 2）で抽出し、集めた有機層を減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、粗生成物（947 mg）を得た。粗製物をIPA/ヘプタン =1/3で再結晶し、表題化合物（839 mg, 2.025 mmol, 54%）を得た。
LC-MS (m/z) = 415 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.12-1.26 (m, 2H), 1.32-1.48 (m, 2H), 1.84-1.95 (m, 3H), 1.97-2.17 (m, 7H), 3.29-3.39 (m, 1H), 3.41 (s, 3H), 3.54-3.63 (m, 2H), 4.05-4.13 (m, 2H), 4.21 (d, J = 6.3 Hz, 2H), 7.78 (s, 1H). Example 245: 3-methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1-f] [1 , 2,4] Triazine-4 (3H) -one

To a solution of [trans-4- (trifluoromethyl) cyclohexyl] methanol (1.017 g, 5.58 mmol) in THF (10 mL) was added sodium hydride (55% oil suspension, 292 mg, 6.7 mmol) at 0 ° C. added. The reaction mixture was stirred at room temperature for 10 minutes. 2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (1 g, 3.72 mmol ) Was added and the mixture was stirred at room temperature for 2 hours. After completion, the reaction mixture was quenched with H ₂ O (10 mL) and saturated aqueous NaCl (10 mL). The aqueous layer was extracted with EtOAc (20 mL + 10 mL × 2), and the collected organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give a crude product (947 mg). The crude product was recrystallized with IPA / heptane = 1/3 to obtain the title compound (839 mg, 2.025 mmol, 54%).
LC-MS (m / z) = 415 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.12-1.26 (m, 2H), 1.32-1.48 (m, 2H), 1.84 -1.95 (m, 3H), 1.97-2.17 (m, 7H), 3.29-3.39 (m, 1H), 3.41 (s, 3H), 3.54-3.63 (m, 2H), 4.05-4.13 (m, 2H) , 4.21 (d, J = 6.3 Hz, 2H), 7.78 (s, 1H).

The compounds of Examples 246 to 253 were synthesized in the same manner as in Example 1, 2, 3 or 245.

trans-4-メチルシクロヘキサノール（76 mg, 0.67 mmol）及び18-クラウン-6（212 mg, 0.804 mmol）のTHF（2.7 mL）溶液にカリウムヘキサメチルジシラジド（160 mg, 0.804 mmol）を0℃で加えた。次いで、2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（90 mg, 0.335 mmol）を加え、混合物を同温で15分間撹拌した。完了後、反応混合物をH₂O及び飽和NaCl水溶液で反応停止処理した。水層をEtOAcで抽出し、集めた有機層を減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（51 mg, 0.147 mmol, 44%）を得た。
LC-MS (m/z) = 347 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ0.96 (d, J = 6.6 Hz, 3H), 1.06-1.19 (m, 2H), 1.41-1.59 (m, 3H), 1.80-1.98 (m, 4H), 2.04-2.16 (m, 2H), 2.19-2.29 (m, 2H), 3.28-3.36 (m, 1H), 3.37 (s, 3H), 3.59 (td, J = 11.6, 2.3 Hz, 2H), 4.07-4.14 (m, 2H), 4.80-4.90 (m, 1H), 7.77 (s, 1H). Example 254: 3-methyl-2-[(trans-4-methylcyclohexyl) oxy] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

Add potassium hexamethyldisilazide (160 mg, 0.804 mmol) to a solution of trans-4-methylcyclohexanol (76 mg, 0.67 mmol) and 18-crown-6 (212 mg, 0.804 mmol) in THF (2.7 mL). Added at ° C. Then 2-chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (90 mg, 0.335 mmol) was added and the mixture was stirred at the same temperature for 15 minutes. After completion, the reaction mixture was quenched with H ₂ O and saturated aqueous NaCl. The aqueous layer was extracted with EtOAc, and the collected organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give the title compound (51 mg, 0.147 mmol, 44%).
LC-MS (m / z) = 347 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ0.96 (d, J = 6.6 Hz, 3H), 1.06-1.19 (m, 2H ), 1.41-1.59 (m, 3H), 1.80-1.98 (m, 4H), 2.04-2.16 (m, 2H), 2.19-2.29 (m, 2H), 3.28-3.36 (m, 1H), 3.37 (s , 3H), 3.59 (td, J = 11.6, 2.3 Hz, 2H), 4.07-4.14 (m, 2H), 4.80-4.90 (m, 1H), 7.77 (s, 1H).

The compounds of Examples 255 to 258 were synthesized in the same manner as in Example 1, 2 or 254.

4-フルオロフェノール（17 mg, 0.152 mmol）のTHF（1.0 mL）溶液に水素化ナトリウム（55%油懸濁液, 6.6 mg, 0.152 mmol）を0℃で加えた。反応混合物を同温で10分間撹拌した。2-(クロロメチル)-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（30 mg, 0.101 mmol）を加えた後、混合物を室温で17時間撹拌した。反応を完了するために、THF（4 mL）、4-フルオロフェノール（17 mg, 0.152 mmol）及び水素化ナトリウム（55%油懸濁液, 7 mg, 0.161 mmol）を加え、混合物を同温で7時間撹拌した。完了後、混合物をH₂O及び飽和NaCl水溶液で反応停止処理した。水層をEtOAcで抽出し、集めた有機層をNa₂SO₄で乾燥し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、表題化合物（23 mg, 収率62%）を白色固体として得た。
LC-MS (m/z) = 373 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.39 (t, J = 7.0 Hz, 3H), 1.85-1.97 (m, 2H), 2.04-2.18 (m, 2H), 3.36-3.50 (m, 1H), 3.53-3.66 (m, 2H), 4.04-4.22 (m, 4H), 5.02 (s, 2H), 6.94-7.09 (m, 4H), 7.83 (s, 1H). Example 259: 3-ethyl-2-[(4-fluorophenoxy) methyl] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine- 4 (3H) -ON

Sodium hydride (55% oil suspension, 6.6 mg, 0.152 mmol) was added to a solution of 4-fluorophenol (17 mg, 0.152 mmol) in THF (1.0 mL) at 0 ° C. The reaction mixture was stirred at the same temperature for 10 minutes. 2- (Chloromethyl) -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (30 mg , 0.101 mmol), and the mixture was stirred at room temperature for 17 hours. To complete the reaction, THF (4 mL), 4-fluorophenol (17 mg, 0.152 mmol) and sodium hydride (55% oil suspension, 7 mg, 0.161 mmol) were added and the mixture was at the same temperature. Stir for 7 hours. After completion, the mixture was quenched with H ₂ O and saturated aqueous NaCl. The aqueous layer was extracted with EtOAc, and the collected organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give the title compound (23 mg, yield 62%) as a white solid.
LC-MS (m / z) = 373 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.39 (t, J = 7.0 Hz, 3H), 1.85-1.97 (m, 2H ), 2.04-2.18 (m, 2H), 3.36-3.50 (m, 1H), 3.53-3.66 (m, 2H), 4.04-4.22 (m, 4H), 5.02 (s, 2H), 6.94-7.09 (m , 4H), 7.83 (s, 1H).

表題化合物を実施例259と同様に合成した。
LC-MS (m/z) = 397 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.36 (t, J = 7.1 Hz, 3H), 1.82-1.98 (m, 8H), 1.99-2.19 (m, 4H), 3.36-3.51 (m, 1H), 3.55-3.67 (m, 2H), 3.69-3.79 (m, 1H), 4.06-4.23 (m, 4H), 4.51 (s, 2H), 7.81 (s, 1H). Example 260: 2-{[(4,4-difluorocyclohexyl) oxy] methyl} -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2 , 4] Triazine-4 (3H) -one

The title compound was synthesized as in Example 259.
LC-MS (m / z) = 397 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.36 (t, J = 7.1 Hz, 3H), 1.82-1.98 (m, 8H ), 1.99-2.19 (m, 4H), 3.36-3.51 (m, 1H), 3.55-3.67 (m, 2H), 3.69-3.79 (m, 1H), 4.06-4.23 (m, 4H), 4.51 (s , 2H), 7.81 (s, 1H).

(4,4-ジフルオロシクロヘキシル)メタノール（347 mg, 2.3 mmol）のTHF（50 mL）溶液にNaH（油中60%, 93 mg, 2.3 mmol）を0℃で加えた後、2-クロロ-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（100 mg, 0.29 mmol）を加えた。混合物を80℃で3日間加熱した。溶媒を減圧留去した。残渣をEtOAc（30 mL）に溶解し、水（30 mL x 3）で洗浄した。有機層を無水Na₂SO₄で乾燥し、減圧留去して粗生成物を得、これをさらに精製せずに用いた（105 mg, 収率98 %）。LC-MS (m/z) = 369 [M + H]⁺ Example 261: 2-[(4,4-difluorocyclohexyl) methoxy] -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -ON

NaH (60% in oil, 93 mg, 2.3 mmol) was added to a solution of (4,4-difluorocyclohexyl) methanol (347 mg, 2.3 mmol) in THF (50 mL) at 0 ° C., and then 2-chloro-7 -(Tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (100 mg, 0.29 mmol) was added. The mixture was heated at 80 ° C. for 3 days. The solvent was removed under reduced pressure. The residue was dissolved in EtOAc (30 mL) and washed with water (30 mL x 3). The organic layer was dried over anhydrous Na ₂ SO ₄ and evaporated under reduced pressure to give the crude product, which was used without further purification (105 mg, 98% yield). LC-MS (m / z) = 369 [M + H] ⁺

The compounds of Examples 262 to 277 were synthesized in the same manner as Example 115 or Reference Example 7.

Examples 278 to 298 were synthesized in the same manner as Example 1, 2, 3 or 245.

実施例288の化合物は、以下の手順に従っても合成した。[trans-4-(エトキシメチル)シクロヘキシル]メタノール（1.14 g, 6.62 mmol）のTHF（10 mL）溶液に水素化ナトリウム（55%油懸濁液, 0.346 g, 7.94 mmol）を0℃で加えた。反応混合物を室温で10分間撹拌した。2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（1.18 g, 4.41 mmol）を混合物に加えた後、混合物を室温で1.5時間撹拌した。撹拌後、反応混合物をH₂Oで反応停止処理した。水層をEtOAcで抽出し、集めた有機層をNa₂SO₄で乾燥し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、粗生成物（1.56 g）を得た。iPr₂O（7 mL）を粗生成物に加えた後、混合物を室温で30分間撹拌し、懸濁物を得た。ヘキサン（7 mL）を懸濁物に加え、混合物を0℃で1時間撹拌した。得られた固体をろ過し、表題化合物（1.16 g, 2.87 mmol, 65%）を得た。
LC-MS (m/z) = 405 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ0.94-1.08 (m, 2H), 1.08-1.23 (m, 5H), 1.53-1.65 (m, 1H), 1.77-1.96 (m, 7H), 2.02-2.15 (m, 2H), 3.25 (d, J = 6.3 Hz, 2H), 3.29-3.42 (m, 4H), 3.47 (q, J = 7.0 Hz, 2H), 3.58 (td, J = 11.6, 2.2 Hz, 2H), 4.03-4.12 (m, 2H), 4.17 (d, J = 6.1 Hz, 2H), 7.76 (s, 1H). Example 288: 2-{[trans-4- (ethoxymethyl) cyclohexyl] methoxy} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2 , 4] Triazine-4 (3H) -one

The compound of Example 288 was also synthesized according to the following procedure. Sodium hydride (55% oil suspension, 0.346 g, 7.94 mmol) was added at 0 ° C to a solution of [trans-4- (ethoxymethyl) cyclohexyl] methanol (1.14 g, 6.62 mmol) in THF (10 mL). . The reaction mixture was stirred at room temperature for 10 minutes. 2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (1.18 g, 4.41 mmol ) Was added to the mixture and the mixture was stirred at room temperature for 1.5 hours. After stirring, the reaction mixture was quenched with H ₂ O. The aqueous layer was extracted with EtOAc, and the collected organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give a crude product (1.56 g). After iPr ₂ O (7 mL) was added to the crude product, the mixture was stirred at room temperature for 30 minutes to give a suspension. Hexane (7 mL) was added to the suspension and the mixture was stirred at 0 ° C. for 1 h. The obtained solid was filtered to obtain the title compound (1.16 g, 2.87 mmol, 65%).
LC-MS (m / z) = 405 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ0.94-1.08 (m, 2H), 1.08-1.23 (m, 5H), 1.53 -1.65 (m, 1H), 1.77-1.96 (m, 7H), 2.02-2.15 (m, 2H), 3.25 (d, J = 6.3 Hz, 2H), 3.29-3.42 (m, 4H), 3.47 (q , J = 7.0 Hz, 2H), 3.58 (td, J = 11.6, 2.2 Hz, 2H), 4.03-4.12 (m, 2H), 4.17 (d, J = 6.1 Hz, 2H), 7.76 (s, 1H) .

実施例288の化合物は、以下の手順に従っても合成した。[trans-4-(エトキシメチル)シクロヘキシル]メタノール（231 mg, 1.34 mmol）のTHF（4 mL）溶液にKHMDS（223 mg, 1.11 mmol）を0℃で加えた。反応混合物を室温で10分間撹拌した。2-クロロ-3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（200 mg, 0.74 mmol）を混合物に加えた後、混合物を0℃で15分間撹拌した。撹拌した後、反応混合物をH₂Oで反応停止処理した。水層をEtOAcで抽出し、集めた有機層をNa₂SO₄で乾燥し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、粗生成物（241 mg）を得た。iPr₂O（1.2 mL）を粗生成物に加えた後、混合物を室温で30分間撹拌し、懸濁物を得た。ヘプタン（1.2 mL）を懸濁物に加え、混合物を0℃で1時間撹拌した。得られた固体をろ過し、表題化合物（166 mg, 0.410 mmol, 55%）を得た。
LC-MS (m/z) = 405 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ0.94-1.08 (m, 2H), 1.08-1.23 (m, 5H), 1.53-1.65 (m, 1H), 1.77-1.96 (m, 7H), 2.02-2.15 (m, 2H), 3.25 (d, J = 6.3 Hz, 2H), 3.29-3.42 (m, 4H), 3.47 (q, J = 7.0 Hz, 2H), 3.58 (td, J = 11.6, 2.2 Hz, 2H), 4.03-4.12 (m, 2H), 4.17 (d, J = 6.1 Hz, 2H), 7.76 (s, 1H). Example 288: 2-{[trans-4- (ethoxymethyl) cyclohexyl] methoxy} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2 , 4] Triazine-4 (3H) -one

The compound of Example 288 was also synthesized according to the following procedure. To a solution of [trans-4- (ethoxymethyl) cyclohexyl] methanol (231 mg, 1.34 mmol) in THF (4 mL) was added KHMDS (223 mg, 1.11 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 10 minutes. 2-Chloro-3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (200 mg, 0.74 mmol ) Was added to the mixture and the mixture was stirred at 0 ° C. for 15 min. After stirring, the reaction mixture was quenched with H ₂ O. The aqueous layer was extracted with EtOAc, and the collected organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give a crude product (241 mg). After iPr ₂ O (1.2 mL) was added to the crude product, the mixture was stirred at room temperature for 30 minutes to give a suspension. Heptane (1.2 mL) was added to the suspension and the mixture was stirred at 0 ° C. for 1 hour. The obtained solid was filtered to obtain the title compound (166 mg, 0.410 mmol, 55%).
LC-MS (m / z) = 405 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ0.94-1.08 (m, 2H), 1.08-1.23 (m, 5H), 1.53 -1.65 (m, 1H), 1.77-1.96 (m, 7H), 2.02-2.15 (m, 2H), 3.25 (d, J = 6.3 Hz, 2H), 3.29-3.42 (m, 4H), 3.47 (q , J = 7.0 Hz, 2H), 3.58 (td, J = 11.6, 2.2 Hz, 2H), 4.03-4.12 (m, 2H), 4.17 (d, J = 6.1 Hz, 2H), 7.76 (s, 1H) .

The compounds of Examples 299 to 323 were synthesized in the same manner as in Example 1, 2 or 254.

実施例317の化合物は、以下の手順に従っても合成した。trans-4-(メトキシメチル)シクロヘキサノールはUS 2009/215624A1に記載の手順に従い合成することができる。trans-4-(メトキシメチル)シクロヘキサノール（3.57 g, 24.76 mmol）のTHF（70 mL）溶液にKHMDS（3.7 g, 18.57 mmol）を0℃で加えた。反応混合物を0℃で10分間撹拌した。2-クロロ-3-エチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（3.5 g, 12.38 mmol）を混合物に加えた後、混合物を0℃で15分間撹拌した。撹拌後、反応混合物をH₂Oで反応停止処理した。水層をEtOAcで抽出し、集めた有機層をNa₂SO₄で乾燥し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（ヘキサン／EtOAc）で精製し、粗生成物（5.13 g）を得た。iPr₂O（15 mL）を粗生成物に加えた後、混合物を室温で30分間撹拌し、懸濁物を得た。ヘキサン（5 mL）を懸濁物に加え、混合物を0℃で30分間撹拌した。得られた固体をろ過し、表題化合物（3.54 g, 9.07 mmol, 73%）を得た。
LC-MS (m/z) = 391 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.14-1.27 (m, 5H), 1.47-1.59 (m, 2H), 1.64-1.72 (m, 1H), 1.87-2.00 (m, 4H), 2.04-2.16 (m, 2H), 2.25-2.34 (m, 2H), 3.25-3.37 (m, 6H), 3.58 (td, J = 11.6, 2.3 Hz, 2H), 4.02 (q, J = 7.1 Hz, 2H), 4.07-4.13 (m, 2H), 4.81-4.93 (m, 1H), 7.76 (s, 1H). Example 317: 3-ethyl-2-{[trans-4- (methoxymethyl) cyclohexyl] oxy} -7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2 , 4] Triazine-4 (3H) -one

The compound of Example 317 was also synthesized according to the following procedure. trans-4- (Methoxymethyl) cyclohexanol can be synthesized according to the procedure described in US 2009 / 215624A1. To a solution of trans-4- (methoxymethyl) cyclohexanol (3.57 g, 24.76 mmol) in THF (70 mL) was added KHMDS (3.7 g, 18.57 mmol) at 0 ° C. The reaction mixture was stirred at 0 ° C. for 10 minutes. 2-Chloro-3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (3.5 g, 12.38 mmol ) Was added to the mixture and the mixture was stirred at 0 ° C. for 15 min. After stirring, the reaction mixture was quenched with H ₂ O. The aqueous layer was extracted with EtOAc, and the collected organic layers were dried over Na ₂ SO ₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / EtOAc) to give a crude product (5.13 g). After iPr ₂ O (15 mL) was added to the crude product, the mixture was stirred at room temperature for 30 minutes to give a suspension. Hexane (5 mL) was added to the suspension and the mixture was stirred at 0 ° C. for 30 minutes. The obtained solid was filtered to obtain the title compound (3.54 g, 9.07 mmol, 73%).
LC-MS (m / z) = 391 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.14-1.27 (m, 5H), 1.47-1.59 (m, 2H), 1.64 -1.72 (m, 1H), 1.87-2.00 (m, 4H), 2.04-2.16 (m, 2H), 2.25-2.34 (m, 2H), 3.25-3.37 (m, 6H), 3.58 (td, J = 11.6, 2.3 Hz, 2H), 4.02 (q, J = 7.1 Hz, 2H), 4.07-4.13 (m, 2H), 4.81-4.93 (m, 1H), 7.76 (s, 1H).

表題化合物を、製造方法4に従うことによっても製造した。[trans-4-(トリフルオロメチル)シクロヘキシル]メタノールはUS2011/53974、WO2014/179564又はWO2014/123882に記載の手順に従い製造することができる。[trans-4-(トリフルオロメチル)シクロヘキシル]メタノール（1.30 g, 7.14 mmol）、3-メチル-7-(テトラヒドロ-2H-ピラン-4-イル)イミダゾ[5,1-f][1,2,4]トリアジン-2,4(1H,3H)-ジオン（1.49 g, 5.95 mmol）及びトリフェニルホスフィン（2.34 g, 8.93 mmol）のTHF（15 ml）中の混合物にジイソプロピルアゾジカルボキシレート（1.76 ml, 8.93 mmol）を滴加し、混合物を室温で2時間撹拌した。完了後、混合物の溶媒を留去した。トルエン（10 mL）を残渣に加えた後、得られた沈殿物をろ過した。MgCl₂（1.7 g, 17.86 g）をろ液に加え、混合物を60℃で3時間撹拌した。ろ過後、飽和食塩水及びEtOAcをろ液に加えた。有機層を抽出し、Na₂SO₄で乾燥した。得られた固体をIPA/ｎ−ヘプタン（1/3）で二度再結晶し、表題化合物（1.67 g, 収率67%）を得た。
LC-MS (m/z) = 415 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.12-1.26 (m, 2H), 1.32-1.48 (m, 2H), 1.84-1.95 (m, 3H), 1.97-2.17 (m, 7H), 3.29-3.39 (m, 1H), 3.41 (s, 3H), 3.54-3.63 (m, 2H), 4.05-4.13 (m, 2H), 4.21 (d, J = 6.3 Hz, 2H), 7.78 (s, 1H). Example 324: 3-methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1-f] [1 , 2,4] Triazine-4 (3H) -one

The title compound was also prepared according to Preparation Method 4. [trans-4- (Trifluoromethyl) cyclohexyl] methanol can be produced according to the procedure described in US2011 / 53974, WO2014 / 179564 or WO2014 / 123882. [trans-4- (trifluoromethyl) cyclohexyl] methanol (1.30 g, 7.14 mmol), 3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2 , 4] triazine-2,4 (1H, 3H) -dione (1.49 g, 5.95 mmol) and triphenylphosphine (2.34 g, 8.93 mmol) in THF (15 ml) in diisopropyl azodicarboxylate (1.76). ml, 8.93 mmol) was added dropwise and the mixture was stirred at room temperature for 2 h. After completion, the solvent of the mixture was distilled off. Toluene (10 mL) was added to the residue, and the resulting precipitate was filtered. MgCl ₂ (1.7 g, 17.86 g) was added to the filtrate and the mixture was stirred at 60 ° C. for 3 hours. After filtration, saturated brine and EtOAc were added to the filtrate. The organic layer was extracted and dried over Na ₂ SO ₄ . The obtained solid was recrystallized twice with IPA / n-heptane (1/3) to obtain the title compound (1.67 g, yield 67%).
LC-MS (m / z) = 415 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.12-1.26 (m, 2H), 1.32-1.48 (m, 2H), 1.84 -1.95 (m, 3H), 1.97-2.17 (m, 7H), 3.29-3.39 (m, 1H), 3.41 (s, 3H), 3.54-3.63 (m, 2H), 4.05-4.13 (m, 2H) , 4.21 (d, J = 6.3 Hz, 2H), 7.78 (s, 1H).

[trans-4-(トリフルオロメチル)シクロヘキシル]メタノール（1.81 g, 9.96 mmol）のTHF（15 mL）中の混合物に水素化ナトリウム（239 mg, 9.96 mmol）を室温で加えた後、混合物を同温で0.5時間撹拌した。2-クロロ-3-メチルイミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（0.92 g, 4.98 mmol）を加えた後、混合物を0.5時間撹拌した。水（1 mL）を混合物に加え、EtOAc（50 mL x 2）で抽出し、集めた有機層を無水Na₂SO₄で乾燥し、濃縮した。粗製の残渣をPE/EtOAc=1/1を溶離液としたシリカゲルカラムクロマトグラフィーで精製し、表題化合物を得た（1.2 g, 収率73%）。
LC-MS (m/z) = 331 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.11-1.20 (m, 2H), 1.36-1.46 (m, 2H), 1.85-1.94 (m, 1H), 1.99-2.08 (m, 5H), 3.43 (s, 3H), 4.21 (d, J = 6.0 Hz, 2H), 7.85 (s, 1H), 7.95 (s, 1H). Example 325: 3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] methoxy} imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

To a mixture of [trans-4- (trifluoromethyl) cyclohexyl] methanol (1.81 g, 9.96 mmol) in THF (15 mL) was added sodium hydride (239 mg, 9.96 mmol) at room temperature, and the mixture was then added. Stir at temperature for 0.5 h. After 2-chloro-3-methylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (0.92 g, 4.98 mmol) was added, the mixture was stirred for 0.5 h. Water (1 mL) was added to the mixture, extracted with EtOAc (50 mL x 2), and the combined organic layers were dried over anhydrous Na ₂ SO ₄ and concentrated. The crude residue was purified by silica gel column chromatography using PE / EtOAc = 1/1 as an eluent to give the title compound (1.2 g, yield 73%).
LC-MS (m / z) = 331 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.11-1.20 (m, 2H), 1.36-1.46 (m, 2H), 1.85 -1.94 (m, 1H), 1.99-2.08 (m, 5H), 3.43 (s, 3H), 4.21 (d, J = 6.0 Hz, 2H), 7.85 (s, 1H), 7.95 (s, 1H).

3-メチル-2-{[trans-4-(トリフルオロメチル)シクロヘキシル]メトキシ}イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（330 mg, 1 mmol）のTHF（4 mL）中の混合物にリチウムジイソプロピルアミド（128 mg, 1.20 mmol）を-78℃で加えた後、-78℃で0.4時間撹拌した。THF（4 mL）中のテトラヒドロ-4H-ピラン-4-オン（150 mg, 1.50 mmol）を加えた後、混合物を-78℃で0.5時間撹拌した。NH₄Cl水溶液（2 mL）を加え、混合物をEtOAc（30 mL x 2）で抽出した。集めた有機層を無水Na₂SO₄で乾燥し、濃縮した後、分取用HPLC（CH₃NH₂:H₂O=30:70）で精製し、表題化合物（0.19 g, 収率44%）を得た。
LC-MS (m/z) = 431 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.15-1.24 (m, 2H), 1.36-1.46 (m, 2H), 1.86-1.94 (m, 3H), 2.00-2.09 (m, 5H), 2.48-2.55 (m, 2H), 3.44 (s, 3H), 3.85-3.90 (m, 2H), 3.96-4.02 (m, 2H), 4.14 (s, 1H), 4.19 (d, J = 6.0 Hz, 2H), 7.78 (s, 1H). Example 326: 7- (4-hydroxytetrahydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) -cyclohexyl] methoxy} imidazo [5,1-f ] [1,2,4] Triazine-4 (3H) -one

3-Methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] methoxy} imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (330 mg, 1 mmol ) In THF (4 mL) was added lithium diisopropylamide (128 mg, 1.20 mmol) at −78 ° C. and then stirred at −78 ° C. for 0.4 hours. After addition of tetrahydro-4H-pyran-4-one (150 mg, 1.50 mmol) in THF (4 mL), the mixture was stirred at −78 ° C. for 0.5 h. NH ₄ Cl aqueous solution (2 mL) was added and the mixture was extracted with EtOAc (30 mL × 2). The collected organic layer was dried over anhydrous Na ₂ SO ₄ , concentrated, and purified by preparative HPLC (CH ₃ NH ₂ : H ₂ O = 30: 70) to give the title compound (0.19 g, yield 44%). )
LC-MS (m / z) = 431 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.15-1.24 (m, 2H), 1.36-1.46 (m, 2H), 1.86 -1.94 (m, 3H), 2.00-2.09 (m, 5H), 2.48-2.55 (m, 2H), 3.44 (s, 3H), 3.85-3.90 (m, 2H), 3.96-4.02 (m, 2H) , 4.14 (s, 1H), 4.19 (d, J = 6.0 Hz, 2H), 7.78 (s, 1H).

表題化合物を実施例326と同様に合成した。
LC-MS (m/z) = 429 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.14-1.23 (m, 2H), 1.33-1.46 (m, 3H), 1.63-1.73 (m, 3H), 1.78-2.22 (m, 12H), 3.43 (s, 3H), 4.03 (s, 1H), 4.19 (d, J = 6.0 Hz, 2H), 7.78 (s, 1H). Example 327: 7- (1-hydroxycyclohexyl) -3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one

The title compound was synthesized as in Example 326.
LC-MS (m / z) = 429 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.14-1.23 (m, 2H), 1.33-1.46 (m, 3H), 1.63 -1.73 (m, 3H), 1.78-2.22 (m, 12H), 3.43 (s, 3H), 4.03 (s, 1H), 4.19 (d, J = 6.0 Hz, 2H), 7.78 (s, 1H).

7-(4-ヒドロキシテトラヒドロ-2H-ピラン-4-イル)-3-メチル-2-{[trans-4-(トリフルオロメチル)-シクロヘキシル]メトキシ}イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（21.5 mg, 0.05 mmol）のDMF（1 mL）中の混合物にメタンスルホニルクロリド（14.3 mg, 0.125 mmol）及びDIEA（14.3 mg, 0.125 mmol）を室温で加えた後、混合物を16時間撹拌した。集めた有機層をろ過し、分取用TLC（PE/EtOAc=3:1）で精製し、表題化合物（4.2 mg, 収率20 %）を白色固体として得た。
LC-MS (m/z) = 413 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.15-1.24 (m, 2H), 1.36-1.46 (m, 2H), 1.99-2.09 (m, 6H), 2.79-2.81 (m, 2H), 3.44 (s, 3H), 3.95-3.97 (m, 2H), 4.20 (d, J = 6.0 Hz, 2H), 4.41-4.43 (m, 2H), 7.12-7.13 (m, 1H),7.86 (s, 1H). Example 328: 7- (3,6-dihydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) -cyclohexyl] methoxy} imidazo [5,1- f] [1,2,4] triazine-4 (3H) -one

7- (4-Hydroxytetrahydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) -cyclohexyl] methoxy} imidazo [5,1-f] [1, 2,4] Triazin-4 (3H) -one (21.5 mg, 0.05 mmol) in DMF (1 mL) with methanesulfonyl chloride (14.3 mg, 0.125 mmol) and DIEA (14.3 mg, 0.125 mmol) at room temperature After adding at rt, the mixture was stirred for 16 hours. The collected organic layer was filtered and purified by preparative TLC (PE / EtOAc = 3: 1) to give the title compound (4.2 mg, yield 20%) as a white solid.
LC-MS (m / z) = 413 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.15-1.24 (m, 2H), 1.36-1.46 (m, 2H), 1.99 -2.09 (m, 6H), 2.79-2.81 (m, 2H), 3.44 (s, 3H), 3.95-3.97 (m, 2H), 4.20 (d, J = 6.0 Hz, 2H), 4.41-4.43 (m , 2H), 7.12-7.13 (m, 1H), 7.86 (s, 1H).

7-(1-ヒドロキシシクロヘキシル)-3-メチル-2-{[trans-4-(トリフルオロメチル)-シクロヘキシル]-メトキシ}イミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（0.15 g, 0.35 mmol）のピリジン（2 mL）中の混合物にホスホリルクロリド（321 mg, 2.10 mmol）を加えた後、混合物を室温で16時間撹拌した。反応を水で停止し、DCMで抽出した。有機層を乾燥し、溶媒を留去して表題化合物（17.2 mg, 収率12 %）を白色固体として得た。
LC-MS (m/z) = 411 [M + H]⁺. ¹H-NMR (400 MHz, CDCl₃): δ1.15-1.24 (m, 2H), 1.36-1.46 (m, 2H), 1.68-1.74 (m, 2H), 1.77-1.83 (m, 2H), 1.88-1.95 (m, 1H), 1.99-2.08 (m, 5H), 2.29-2.33 (m, 2H), 2.64-2.67 (m, 2H), 3.42 (s, 3H), 4.21 (d, J = 6.0 Hz, 2H), 7.10-7.12 (m, 1H), 7.84 (s, 1H). Example 329: 7- (cyclohex-1-en-1-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1-f] [1 , 2,4] Triazine-4 (3H) -one

7- (1-Hydroxycyclohexyl) -3-methyl-2-{[trans-4- (trifluoromethyl) -cyclohexyl] -methoxy} imidazo [5,1-f] [1,2,4] triazine-4 To a mixture of (3H) -one (0.15 g, 0.35 mmol) in pyridine (2 mL) was added phosphoryl chloride (321 mg, 2.10 mmol) and the mixture was stirred at room temperature for 16 hours. The reaction was quenched with water and extracted with DCM. The organic layer was dried and the solvent was distilled off to give the title compound (17.2 mg, 12% yield) as a white solid.
LC-MS (m / z) = 411 [M + H] ⁺ . ¹ H-NMR (400 MHz, CDCl ₃ ): δ1.15-1.24 (m, 2H), 1.36-1.46 (m, 2H), 1.68 -1.74 (m, 2H), 1.77-1.83 (m, 2H), 1.88-1.95 (m, 1H), 1.99-2.08 (m, 5H), 2.29-2.33 (m, 2H), 2.64-2.67 (m, 2H), 3.42 (s, 3H), 4.21 (d, J = 6.0 Hz, 2H), 7.10-7.12 (m, 1H), 7.84 (s, 1H).

(4,4-ジフルオロシクロヘキシル)メタノール（1.65g, 11 mmol）のTHF（25 mL）溶液にNaH（528 mg, 22 mmol）を0℃で加え、同温で0.5時間撹拌した。次いで、2-クロロ-3-エチルイミダゾ[1,5-f][1,2,4]トリアジン-4(3H)-オン（1.45 g,7.5 mmol）を加えた。次いで反応混合物を0℃で1時間撹拌した。完了後、反応を水で停止した後、EtOAc（30 mL x 2）で抽出し、減圧濃縮し、表題化合物を得た（1.5 g, 収率66 %）。
LC-MS (m/z) = 313 [M + H]⁺. ¹H-NMR (400 MHz, DMSO-d₆): δ1.27-1.30 (m, 4H), 1.44-1.54 (m, 2H), 1.71-1.95 (m, 3H), 2.07-2.23 (m, 3H), 4.06 (q, J = 7.2 Hz, 2H), 4.26 (q, J = 6.4 Hz, 2H), 7.83 (s, 1H), 7.94 (s, 1H). Example 330: 2-[(4,4-Difluorocyclohexyl) methoxy] -3-ethylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

To a THF (25 mL) solution of (4,4-difluorocyclohexyl) methanol (1.65 g, 11 mmol) was added NaH (528 mg, 22 mmol) at 0 ° C., and the mixture was stirred at the same temperature for 0.5 hr. Then 2-chloro-3-ethylimidazo [1,5-f] [1,2,4] triazin-4 (3H) -one (1.45 g, 7.5 mmol) was added. The reaction mixture was then stirred at 0 ° C. for 1 hour. After completion, the reaction was quenched with water, extracted with EtOAc (30 mL x 2), and concentrated under reduced pressure to give the title compound (1.5 g, yield 66%).
LC-MS (m / z) = 313 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.27-1.30 (m, 4H), 1.44-1.54 (m, 2H) , 1.71-1.95 (m, 3H), 2.07-2.23 (m, 3H), 4.06 (q, J = 7.2 Hz, 2H), 4.26 (q, J = 6.4 Hz, 2H), 7.83 (s, 1H), 7.94 (s, 1H).

2-[(4,4-ジフルオロシクロヘキシル)メトキシ]-3-エチルイミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（1.4 g, 4.5 mmol）のMeCN（20 mL）溶液にNBS（880 mg, 4.95 mmol）を0℃で加え、同温で1時間撹拌した。完了後、反応物を減圧濃縮し、シリカゲルクロマトグラフィー（PE:EtOAc = 5:1で溶出）で精製し、表題化合物を得た（900 mg, 収率51 %）。
LC-MS (m/z) = 393 [M + H]⁺. ¹H-NMR (400 MHz, DMSO-d₆): δ1.25-1.31 (m, 4H), 1.43-1.52 (m, 2H), 1.74-1.93 (m, 4H), 2.15-2.18 (m, 2H), 4.02 (q, J = 7.2 Hz, 2H), 4.23 (d, J = 6.4 Hz, 2H), 7.80 (s, 1H). Example 331: 7-bromo-2-[(4,4-difluorocyclohexyl) methoxy] -3-ethylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one

2-[(4,4-Difluorocyclohexyl) methoxy] -3-ethylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (1.4 g, 4.5 mmol) MeCN ( 20 mL) NBS (880 mg, 4.95 mmol) was added to the solution at 0 ° C. and stirred at the same temperature for 1 hour. After completion, the reaction was concentrated in vacuo and purified by silica gel chromatography (eluting with PE: EtOAc = 5: 1) to give the title compound (900 mg, 51% yield).
LC-MS (m / z) = 393 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.25-1.31 (m, 4H), 1.43-1.52 (m, 2H) , 1.74-1.93 (m, 4H), 2.15-2.18 (m, 2H), 4.02 (q, J = 7.2 Hz, 2H), 4.23 (d, J = 6.4 Hz, 2H), 7.80 (s, 1H).

7-ブロモ-2-[(4,4-ジフルオロシクロヘキシル)メトキシ]-3-エチルイミダゾ[5,1-f][1,2,4]トリアジン-4(3H)-オン（98 mg, 0.25 mmol）のトルエン（2 mL）溶液にピロリジン（36 mg, 0.5 mmol）、tBuONa（48 mg, 0.5 mmol）、Pd₂(dba)₃（35 mg, 0.038 mmol）及びBINAP（47 mg, 0.075 mmol）を加えた。次いで反応物を100℃で16時間撹拌した。完了後、反応物を減圧濃縮し、シリカゲルクロマトグラフィー（PE:EtOAc = 5:1で溶出）及び分取用HPLC（MeCN/H₂O = 0〜100%）で精製し、表題化合物（55 mg, 収率58 %）を得た。
LC-MS (m/z) = 382 [M + H]⁺. ¹H-NMR (400 MHz, DMSO-d₆): δ1.21-1.26 (m, 4H), 1.43-1.52 (m, 2H), 1.72-1.84 (m, 2H), 1.87-1.97 (m, 6H), 2.15-2.21 (m, 2H), 3.66-3.70 (m, 4H), 3.94 (q, J = 7.2 Hz, 2H), 4.17 (d, J = 6.4 Hz, 2H), 7.53 (s, 1H). Example 332: 2-[(4,4-difluorocyclohexyl) methoxy] -3-ethyl-7- (pyrrolidin-1-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -ON

7-Bromo-2-[(4,4-difluorocyclohexyl) methoxy] -3-ethylimidazo [5,1-f] [1,2,4] triazin-4 (3H) -one (98 mg, 0.25 mmol ) In toluene (2 mL) with pyrrolidine (36 mg, 0.5 mmol), tBuONa (48 mg, 0.5 mmol), Pd ₂ (dba) ₃ (35 mg, 0.038 mmol) and BINAP (47 mg, 0.075 mmol). added. The reaction was then stirred at 100 ° C. for 16 hours. After completion, the reaction was concentrated in vacuo and purified by silica gel chromatography (eluting with PE: EtOAc = 5: 1) and preparative HPLC (MeCN / H ₂ O = 0-100%) to give the title compound (55 mg Yield 58%).
LC-MS (m / z) = 382 [M + H] ⁺ . ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ1.21-1.26 (m, 4H), 1.43-1.52 (m, 2H) , 1.72-1.84 (m, 2H), 1.87-1.97 (m, 6H), 2.15-2.21 (m, 2H), 3.66-3.70 (m, 4H), 3.94 (q, J = 7.2 Hz, 2H), 4.17 (d, J = 6.4 Hz, 2H), 7.53 (s, 1H).

Test Example 1: In Vitro HTRF PDE1 Inhibition Assay A typical procedure for an in vitro homogeneity time-resolved fluorometric assay is as follows, which is used to determine the inhibitory action of a compound of the invention on PDE1 or its isoforms be able to.

  The HTRF PDE1 assay using the HTRF (homogeneous time-resolved fluorescence measurement) method is based on the competition between unlabeled cyclic nucleotides and XL665 labeled cyclic nucleotides for binding to cryptate labeled cyclic nucleotide specific antibodies. Thus, the HTRF signal is inversely proportional to the concentration of cyclic nucleotide measured. Since phosphodiesterase degrades cyclic nucleotides, PDE activity was measured using HTRF signals.

A cis-bio cGMP HTRF assay kit (catalog number: 62GM2PEC) was used. Cyclic GMP was diluted to 200 nM in HTRF assay buffer (1 mM CaCl ₂ , 10 mM MgCl ₂ , 10 mM Tris-HCl, 0.1% BSA, pH 7.4). 10 μl of compound or DMSO was diluted in 200 nM cyclic GMP solution and added to the wells of a 96-well white plate to give 100 nM cyclic GMP at a final concentration of 1% DMSO. PDE (1A3, 1B or 1C) was diluted to a 2-fold working concentration with HTRF assay buffer containing 2 μg / ml calmodulin, and 10 μl was added to initiate the reaction. The plates were then incubated for 45 minutes at 27 ° C. d2-labeled cyclic GMP and anti-cGMP cryptate were diluted with 50 mM phosphate buffer, 0.8 M KF, 1% Triton X100, 0.2% BSA, pH 7.0. After incubation with 10 μl d2-cGMP, 10 μl anti-cGMP cryptate was added to each well and the plate was incubated for 60 minutes at room temperature. The plates were then measured by Perkin Elmer EnVision at two different FRET measurements ex / em 340 nm / 665 nm and 340 nm / 615 nm.

第2表：インビトロPDE1A3 HTRFアッセイ結果

第3表：インビトロPDE1C HTRFアッセイ結果

The HTRF assay data for selected compounds of the present invention is shown in the table below. Compounds with IC ₅₀ values <1 μM are indicated with +++, compounds with IC ₅₀ values of 1-10 μM are indicated with ++, and compounds with IC ₅₀ values of 10-100 μM are indicated with +.
Table 1: In vitro PDE1B HTRF assay results

Table 2: In vitro PDE1A3 HTRF assay results

Table 3: In vitro PDE1C HTRF assay results

Test Example 2: In vitro SPA PDE1 inhibition assay
A commercially available scintillation proximity assay (SPA) system (Perkinelmer) was used for the PDE1 inhibition assay. SPA yttrium silicate beads bind preferentially to acyclic GMP over cyclic GMP (cGMP) in the presence of zinc sulfate, and therefore measure the amount of enzymatic reaction product ([ ³ H] -GMP) by scintillation counting be able to.

For PDE1 inhibition assay, 96-well white microtiter plate containing 10 μl of test compound in 5% dimethyl sulfoxide diluted in SPA assay buffer (1 mM CaCl ₂ , 10 mM MgSO ₄ , 10 mM Tris-HCl, pH 7.4) And 20 μl of [ ³ H] -cGMP solution in SPA assay buffer (100 nM final concentration, Perkinelmer) was added. The assay was started by adding 20 μl of PDE (1A3, 1B or 1C) enzyme solution containing calmodulin (final concentration 1 μg / ml). After 30 minutes incubation at 27 ° C., the reaction was stopped by adding 50 μl of a suspension of 10 mg / ml SPA beads in 18 mM ZnSO ₄ . The microtiter plate was allowed to settle for 60 minutes and then measured with a TopCount NXT scintillation counter (PerkinElmer). IC ₅₀ values were determined from sigmoidal curves by plotting the percentage of PDE activity against the logarithm of compound concentration. IC ₅₀ was defined as the concentration of test compound required to inhibit the cyclic nucleotide hydrolysis activity of the tested PDE by 50%.

第5表：インビトロPDE1A3 SPAアッセイ結果

第6表：インビトロPDE1C SPAアッセイ結果

SPA assay data for selected compounds of the invention is shown in the following table.
Table 4: In vitro PDE1B SPA assay results

Table 5: In vitro PDE1A3 SPA assay results

Table 6: In vitro PDE1C SPA assay results

Test Example 3: Evaluation of bioavailability
Pharmacokinetic study in rats This test can be used to evaluate the pharmacokinetics of the compounds according to the invention. Seven weeks old SD rats were intravenously administered with a solution of each compound according to the present invention in 0.1N HCl = 9: 1 or orally with a 0.5% suspension in methylcellulose, and each blood sample was Collected at appropriate intervals such as:
5, 15 and 30 minutes after intravenous administration and 1, 2, 4, 6 and 24 hours after oral administration 15 and 30 minutes after oral administration and 1, 2, 4, 6 and 24 hours Was measured by LC-MS, and each pharmacokinetic parameter based on the concentration change was calculated.

Test Example 4: Evaluation of drug delivery to the brain
Brain Drug Delivery Test in Rats This test can be used to evaluate the delivery of the compounds of the invention to the brain. Seven-week-old SD rats were orally administered a 0.5% suspension of each compound of the present invention in methylcellulose, and each plasma and brain were collected 1 hour after administration, and each compound concentration in plasma and brain was analyzed by LC-MS Was measured.
Each protein binding rate of plasma and brain compounds was measured by equilibrium dialysis.
The obtained plasma and brain compound concentrations and protein binding rates can be applied to the following equations to calculate Kp, uu, brain (that is, the unbound drug concentration ratio between the brain and plasma).

Kp, uu, brain = [cerebral compound concentration × (100−protein binding rate in brain (%)) / 100] / [plasma compound concentration × (100−protein binding rate in plasma (%)) / 100]

The results of Test Examples 3 and 4 are shown in the following table.

Test Example 5: Evaluation of the effects of compounds on cognitive impairment in rats treated repeatedly with phencyclidine
Because the N-methyl-D-aspartate receptor antagonist phencyclidine (PCP) is known to cause schizophrenia-like symptoms such as cognitive impairment in humans, PCP-treated animals are animal models of schizophrenia As widely used. Improvement of the cognitive impairment by the compounds of the present invention was evaluated in a novel object recognition test using rats that were repeatedly administered PCP as an animal model of schizophrenia. Rats were habituated to the test environment, which is an empty box (50 cm x 50 cm x 35 cm) for 1 hour per day for 3 days. On the test day, the rats were again habituated for 3 minutes in a test box with nothing inside. The rats were then placed in a test box with two identical objects inside and allowed to explore the interior for 3 minutes for a training trial. After 1 minute, the rat is placed in a test box with one of the same objects (ie familiar objects) and another object (ie new objects) used in the training trial for the trial trial. The inside was searched for 3 minutes. Cognitive function was evaluated based on the preference for new objects in trials, using the rat's habit of searching for new objects longer than familiar objects. The discriminant index was calculated from the following equation as an index for the priority trend of new objects.

Discriminant index = (search time for new object−search time for familiar object) / (search time for new object + search time for familiar object)

The discriminant index was significantly reduced when PCP 3 mg / kg was administered intraperitoneally to rats for 10 days twice a day compared to when excipients were administered to rats, which impaired cognitive function Showed that. When the compound of Example 1, 115, 149, 245 or 288 (1 or 3 mg / kg) was orally administered to a rat administered with PCP for 10 days 60 minutes before the start of the new object recognition test, PCP + excipient A significant increase in discriminant index was observed for the administration group (FIGS. 1, 2, 3, 4 or 5).

  Although we have described many aspects of the present invention, the examples described herein may be modified to provide alternative embodiments utilizing the compounds, medicaments and methods of the present invention. Therefore, it will be understood that the scope of this invention is to be defined by the appended claims rather than the specific embodiments shown by way of example.

Claims (22)

Formula I:

Or a pharmaceutically acceptable salt thereof as an active ingredient [wherein
R ¹ is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (iii) C _3-10 cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl; 4-8 membered saturated or partially unsaturated monocyclic heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6 membered monocyclic heteroaryl-C _1-4 Al Le; or 4-8 membered saturated or partially selected from monocyclic heterocycle -C _1-4 alkyl unsaturated;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
X is O or S;
W is a covalent bond, —C≡C—, —CH═CH—, —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is (i) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
(C) hydroxyl,
(D) phenoxy (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (e) amino (wherein The group is optionally the same or different 1-2 C _1-6 alkyl, C _3-8 cycloalkyl or phenyl (wherein phenyl is optionally the same or different 1-4 halogen, C _1-6 alkyl, _Optionally substituted with C _1-6 alkoxy or trifluoromethyl)), and (ii) C _3-10 cycloalkyl; phenyl; 5-6 membered heteroaryl; 4-8 Membered saturated or partially unsaturated heterocycle; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered heteroaryl-C _1-4 alkyl; or 4-8 Tiredness Or partially selected from heterocyclic -C _1-4 alkyl unsaturated;
Here, each group in the above (ii) may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ), And (h) aminocarbonyl (wherein amino is optionally substituted with the same or different 1-2 C _1-6 alkyl);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxy or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). May be);
R ³ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) hydroxy, and (d) oxo), or (iv) C _3-8 cycloalkyl, wherein the group is optionally substituted with the same or different 1-4 groups selected from: Also good:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo),
(V) C _2-6 alkenyl (wherein the group may be optionally substituted with the same or different 1 to 4 halogens),
(Vi) C _3-8 cycloalkenyl (wherein the group is optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) oxo), and (vii) a 4-8 membered saturated or partially unsaturated monocyclic heterocycle, wherein the groups are suitably selected from: Optionally substituted with 1 to 4 different groups:
(A) halogen,
(B) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens),
(D) hydroxy, and (e) cyano)
Selected from;
R ⁴ is (i) hydrogen,
(Ii) halogen,
(Iii) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens), or (iv) selected from cyano;
However, when R ¹ is hydrogen, W is —O— or —N (R ⁵ ) —, and R ⁴ is hydrogen]. R ¹ in formula I is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens or hydroxy), and (c) hydroxyl), and (iii) C _{3- 10} cycloalkyl; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; or 4-8 membered saturated or partially Selected from unsaturated monocyclic heterocycles -C _1-4 alkyl;
Here, each group in the above (iii) may be appropriately substituted with the same or different 1-4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (g) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
The medicament according to claim 1. R ¹ in formula I is (i) hydrogen,
(Ii) C _1-6 alkyl (wherein the group is optionally substituted with 1 to 3 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens or hydroxy), and (c) hydroxyl),
(Iii) C _3-8 cycloalkyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl or C _1-6 alkoxy), and (iv) ) C _3-8 cycloalkyl-C _1-4 alkyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, C _1-6 alkyl or C _1-6 alkoxy)
Selected from;
W is —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; 4-8 membered saturated or partially unsatisfied A saturated monocyclic heterocycle-C _1-4 alkyl; C _3-10 cycloalkyl; or a 4-8 membered saturated or partially unsaturated monocyclic heterocycle;
Here, each group in R ² may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(G) 5- to 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ), And (h) aminocarbonyl (wherein the amino may be substituted with the same or different 1-2 C _1-6 alkyl);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with the same or different 1 to 4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally the same or different 1 to 3 halogens, C _1-6 alkoxy, hydroxyl or aminocarbonyl (where amino is the same or different 1 to 2) Which may be substituted with C _1-6 alkyl of
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
(E) 5- to 6-membered monocyclic heteroaryl (wherein the groups are optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) ),
(F) a 5- to 6-membered monocyclic heteroaryloxy (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy) Good),
(G) C _1-6 alkylcarbonyl (wherein alkyl is optionally the same or different 1-3 halogen, C _1-6 alkoxy or amino (where amino is optionally the same or different 1-2 C _{1 And} (h) aminocarbonyl (wherein the amino is optionally substituted with the same or different 1-2 C _1-6 alkyl). You may)
The medicine according to claim 1 or 2. R ¹ in Formula I is C _1-6 alkyl (wherein the groups may be optionally substituted with the same or different 1-3 halogens or C _1-6 alkoxy); and R ² is C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; or C _3-10 cycloalkyl;
Here, each group in R ² may be appropriately substituted with the same or different 1 to 4 groups selected from the following:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(D) cyano,
(E) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (f) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
The medicine according to any one of claims 1 to 3. R ² in formula I is C _3-8 cycloalkyl-C _1-4 alkyl or C _3-8 cycloalkyl;
Here, each group may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups may optionally be substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), and (c) C _1-6 Alkoxy (wherein the radicals may be optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
The medicine according to claim 4. R ¹ in formula I is C _3-10 cycloalkyl; C _3-10 cycloalkyl-C _1-4 alkyl; phenyl-C _1-4 alkyl; 5 or 6-membered monocyclic heteroaryl-C _1-4 alkyl; Or 4-8 membered saturated or partially unsaturated monocyclic heterocycle-C _1-4 alkyl;
Here, each group may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) hydroxy,
(E) cyano,
(F) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (g) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy);
W is —O— or —N (R ⁵ ) —;
R ⁵ is hydrogen or C _1-6 alkyl;
R ² is C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 groups selected from:
(A) halogen,
(B) C _1-6 alkoxy (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens or hydroxy), and (c) hydroxy);
Alternatively, R ² and R ⁵ together with the nitrogen atom to which they are attached may form a 4-8 membered saturated or partially unsaturated monocyclic heterocycle; The ring may be optionally substituted with 1-4 identical or different groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(C) C _1-6 alkoxy (wherein the group may be optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy),
(D) phenyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, cyano, C _1-6 alkyl or C _1-6 alkoxy), and (e) 5- 6-membered monocyclic heteroaryl (wherein the group is optionally substituted with the same or different 1-4 halogen, cyano, C _1-6 alkyl or C _1-6 alkoxy),
The medicament according to claim 1. R ¹ in formula I is C _3-8 cycloalkyl-C _1-4 alkyl; or phenyl-C _1-4 alkyl;
Here, each group may be optionally substituted with the same or different 1-4 groups selected from:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens, C _1-6 alkoxy or hydroxy), and (c) C _1-6 Alkoxy (wherein the radicals may be optionally substituted with the same or different 1 to 3 halogens or hydroxy),
The medicine according to claim 6.   The medicament according to any one of claims 1 to 7, wherein X in formula I is O.   The pharmaceutical according to any one of claims 1 to 8, wherein W in the formula I is -O-. R ³ in Formula I is (i) C _1-6 alkyl (wherein the groups may be optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(Ii) C _3-8 cycloalkyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl, hydroxy or C _1-6 alkoxy), and (Iii) 4-8 membered saturated or partially unsaturated monocyclic heterocycle (wherein the groups are optionally the same or different 1-4 halogen, hydroxy, C _1-6 alkyl or C _1-6 May be substituted with alkoxy)
The medicament according to any one of claims 1 to 9, which is selected from: R ³ in formula I is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), tetrahydropyranyl (here Wherein the group is optionally substituted with the same or different 1-4 halogen, hydroxy or C _1-6 alkoxy), or dihydropyranyl. R ⁴ in formula I is (i) hydrogen,
(Ii) halogen, or (iii) C _1-6 alkyl (wherein the group may be optionally substituted with the same or different 1 to 3 halogens)
The medicament according to any one of claims 1 to 11, which is selected from: The medicament according to any one of claims 1 to 12, wherein R ⁴ in formula I is hydrogen. R ¹ in Formula I is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens or C _1-6 alkoxy);
R ² is C _3-8 cycloalkyl-C _1-4 alkyl or C _3-8 cycloalkyl; wherein each group is optionally substituted with the same or different 1-4 groups selected from: May be:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups may optionally be substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), and (c) C _1-6 Alkoxy (wherein the radicals are optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy);
X is O;
W is -O-
The medicine according to any one of claims 1 to 5. Formula Ia:

[Where:
R ¹ is C _1-6 alkyl (wherein the groups are optionally substituted with the same or different 1 to 3 halogens or C _1-6 alkoxy);
R ² is C _3-8 cycloalkyl-C _1-4 alkyl or C _3-8 cycloalkyl; wherein each group is optionally substituted with the same or different 1-4 groups selected from: May be:
(A) halogen,
(B) C _1-6 alkyl (wherein the groups may optionally be substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy), and (c) C _1-6 Alkoxy (wherein the radicals are optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy);
R ³ is (i) C _1-6 alkyl (wherein the group is optionally substituted with the same or different 1 to 3 halogens, hydroxy or C _1-6 alkoxy),
(Ii) C _3-8 cycloalkyl (wherein the groups are optionally substituted with the same or different 1-4 halogens, C _1-6 alkyl, hydroxy or C _1-6 alkoxy), and (Iii) 4-8 membered saturated or partially unsaturated monocyclic heterocycle (wherein the groups are optionally the same or different 1-4 halogen, hydroxy, C _1-6 alkyl or C _1-6 Optionally substituted with alkoxy);
R ⁴ is (i) hydrogen,
Selected from (ii) halogen, or (iii) C _1-6 alkyl, wherein the groups may be optionally substituted with 1 to 3 different halogens]
The pharmaceutical of Claim 1 which uses the compound shown by these, or its pharmaceutically acceptable salt as an active ingredient. R ³ is (here, said groups optionally substituted with hydroxy which may be optionally substituted) tetrahydropyranyl in Formula I be or dihydropyranyl; R ⁴ is hydrogen, according to any one of claims 1 to 15 Medicines. The group of compounds of formula I consisting of:
2-[(4,4-Difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On;
3- (4-chlorobenzyl) -2-methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one;
3-[(4,4-Difluorocyclohexyl) methyl] -2-methoxy-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On;
5-Chloro-2-[(4,4-difluorocyclohexyl) methoxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one;
2-{[(5-chloropyridin-2-yl) methyl] amino} -3-methyl-7- (propan-2-yl) imidazo [5,1-f] [1,2,4] triazine-4 (3H) -On;
3-Methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] methoxy} -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one;
2-[(trans-4-ethoxycyclohexyl) methoxy] -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On;
3-Methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[cis-4- (trifluoromethyl) cyclohexyl] methoxy} -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one;
2- (cyclohexyloxy) -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazin-4 (3H) -one;
2-{[trans-4- (Ethoxymethyl) cyclohexyl] oxy} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) -imidazo- [5,1-f] [1,2,4 ] Triazine-4 (3H) -one;
2-{[trans-4- (Ethoxymethyl) cyclohexyl] methoxy} -3-methyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine -4 (3H) -on;
3- ( ¹³ C, ² H ₃ ) methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1- f] [1,2,4] triazine-4 (3H) -one;
2-[(4,4-Difluorocyclohexyl) oxy] -3-ethyl-7- (tetrahydro-2H-pyran-4-yl) imidazo [5,1-f] [1,2,4] triazine-4 ( 3H) -On;
3-Methyl-7- (tetrahydro-2H-pyran-4-yl) -2-{[trans-4- (trifluoromethyl) cyclohexyl] oxy} -imidazo [5,1-f] [1,2,4 ] Triazine-4 (3H) -one;
3-ethyl-2-{[trans-4- (methoxymethyl) cyclohexyl] oxy} -7- (tetrahydro-2H-pyran-4-yl) -imidazo [5,1-f] [1,2,4] Triazine-4 (3H) -one;
7- (4-Hydroxytetrahydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] -methoxy} imidazo [5,1-f] [1, 2,4] triazin-4 (3H) -one; and
7- (3,6-Dihydro-2H-pyran-4-yl) -3-methyl-2-{[trans-4- (trifluoromethyl) cyclohexyl] methoxy} -imidazo [5,1-f] [1 , 2, 4] Triazin-4 (3H) -one.   The medicament according to any one of claims 1 to 17, which inhibits PDE1.   The medicament according to any one of claims 1 to 18, for treating a neurological disorder or a mental disorder.   The medicament according to claim 19, wherein the neurological disorder or psychiatric disorder is Alzheimer's disease, Parkinson's disease, depression, cognitive impairment, stroke, schizophrenia, Down's syndrome or fetal alcohol syndrome.   20. The medicament according to claim 19, wherein the neurological or psychiatric disorder is accompanied by a defect in one or more cognitive regions as defined by DSM-5.   Use of a compound of formula I or Ia according to claim 1 or 15 in the manufacture of a medicament for treating a neurological or psychiatric disorder.

Images